Details of Disease

General Information of Disease (ID: DISS7D1V)

• Disease Name: leukaemia
• Synonyms: leukemia; leukaemia; pediatric leukemia (disease); paediatric leukaemia (disease); leukemia (disease) of childhood; leukaemia (disease) of childhood; childhood leukemia (disease); childhood leukemia; childhood leukaemia (disease)
• Disease Class: 2A60-2B33: Leukaemia
• Definition: An acute or chronic leukemia that occurs during childhood.
• Disease Hierarchy:
  DISNAKFL: Leukemia
  DISS6SNG: Malignant neoplasm
  DISS7D1V: leukaemia
• ICD Code:
  ICD-11: ICD-11: 2A60-2B33
  ICD-10: ICD-10: C91-C95
  ICD-9: ICD-9: 204-208
  Expand ICD-9: 2.04E+14
• Disease Identifiers:
  MONDO ID: MONDO_0004355
  UMLS CUI: C1332977
  MedGen ID: 234132

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 9 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Acalabrutinib	DM7GCVW	Approved	NA	[1]
Bendamustine hydrochloride	DMFH15Z	Approved	Small molecular drug	[2]
Denileukin diftitox	DMMHR1U	Approved	NA	[3]
HUMAN CORTICOTROPIN-RELEASING HORMONE	DM4RKRI	Approved	NA	[4]
Lurbinectedin	DMEFRTZ	Approved	Small molecular drug	[5]
Methotrexate	DM2TEOL	Approved	Small molecular drug	[6]
Nelarabine	DMB6VEG	Approved	Small molecular drug	[7]
Quadracel	DMH832D	Approved	NA	[8]
Quizartinib	DM8Y4JS	Approved	Small molecular drug	[9]

This Disease is Treated as An Indication in 101 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABL 001	DMMF5K4	Phase 3	NA	[10]
HSV-Tk	DMD5P1C	Phase 3	NA	[11]
Lmprime P66	DMFMNZB	Phase 3	NA	[12]
MACI	DMS3SPV	Phase 3	NA	[13]
NVP-LAQ824	DM8JWNA	Phase 3	Small molecular drug	[14]
Radotinib	DMWA74Y	Phase 3	Small molecular drug	[15]
KamRAB	DM8ZWSF	Phase 2/3	NA	[16]
AG-858	DMNQ5T2	Phase 2	Vaccine	[17]
AVR118	DMLWRON	Phase 2	NA	[18]
CAR-T cells targeting CD22	DM6XN4C	Phase 2	CAR T Cell Therapy	[19]
CAR-T cells targeting CD30	DML0KWM	Phase 2	CAR T Cell Therapy	[19]
CART-19	DMHQKN6	Phase 2	CAR T Cell Therapy	[20]
CB-839	DM094UH	Phase 2	NA	[21]
CD19-targeting CAR T cells	DMQJBUK	Phase 2	CAR T Cell Therapy	[22]
Daporinad	DMCU74R	Phase 2	Small molecular drug	[23]
GSK2110183	DMZHB37	Phase 2	Small molecular drug	[24]
IRX-2	DMODLN7	Phase 2	NA	[25]
Itarnafloxin	DMCY9PO	Phase 2	Small molecular drug	[26]
JVRS-100	DMPMU38	Phase 2	Vaccine	[27]
LG-740	DM01OPD	Phase 2	NA	[28]
Lumiliximab	DMLTI39	Phase 2	Antibody	[29]
MDX-1342	DMKMSC4	Phase 2	Antibody	[30]
ONC201	DMM5SCF	Phase 2	NA	[11]
Plague vaccine	DMT3PJP	Phase 2	NA	[31]
TOL-3021	DMW17KS	Phase 2	NA	[32]
WT1 peptide vaccine	DMZ67Q0	Phase 2	Vaccine	[33]
[131I]-BC8	DMV86DY	Phase 2	Antibody	[34]
4SCAR19/22 T cells	DMI8TW3	Phase 1/2	CAR T Cell Therapy	[35]
AFX-9154	DM59ILU	Phase 1/2	NA	[36]
Anti-BCMA-CAR-transduced T cells	DMZ18IO	Phase 1/2	CAR T Cell Therapy	[37]
Anti-CD123-CAR-transduced T cells	DMFV6TY	Phase 1/2	CAR T Cell Therapy	[38]
Anti-CD19 CAR-T cells	DM1EH9D	Phase 1/2	CAR T Cell Therapy	[39]
Anti-CD19-CAR-T cells	DMNTP23	Phase 1/2	CAR T Cell Therapy	[40]
Anti-CD20-CAR-transduced T cells	DMXMK30	Phase 1/2	CAR T Cell Therapy	[41]
Anti-CD22 CAR-T cells	DMY6U8R	Phase 1/2	CAR T Cell Therapy	[39]
Anti-CD22-CAR-transduced T cells	DMTO9VF	Phase 1/2	CAR T Cell Therapy	[42]
Anti-CD30-CAR-transduced T cells	DMTZSPJ	Phase 1/2	CAR T Cell Therapy	[43]
AT9183	DM93VAC	Phase 1/2	NA	[44]
Autologous CD19-targeting CAR T cells	DMLOGI4	Phase 1/2	CAR T Cell Therapy	[45]
Beclanorsen	DMXVRI0	Phase 1/2	Antisense drug	[46]
BI 1206	DMTOMWB	Phase 1/2	Antibody	[47]
CAR-T cells targeting BCMA	DMENIQ7	Phase 1/2	CAR T Cell Therapy	[19]
CAR-T cells targeting CD19	DMIM9TZ	Phase 1/2	CAR T Cell Therapy	[19]
CAR-T cells targeting CLL1	DMCPM92	Phase 1/2	CAR T Cell Therapy	[19]
CART-19/22	DMX0R1E	Phase 1/2	CAR T Cell Therapy	[48]
CD19 and CD20 CAR-T Cells	DMRJ3ND	Phase 1/2	CAR T Cell Therapy	[49]
CD19 and CD22 CAR-T Cells	DM581CS	Phase 1/2	CAR T Cell Therapy	[49]
CD19-directed CAR-T cells	DMKQRUJ	Phase 1/2	CAR T Cell Therapy	[50]
CD22-Targeted CAR-T cells	DM61MBG	Phase 1/2	CAR T Cell Therapy	[51]
Chimeric Antigen Receptor Modified T cells Targeting CD19	DMHNFXR	Phase 1/2	CAR T Cell Therapy	[52]
IM19 CAR-T	DMKV5D6	Phase 1/2	CAR T Cell Therapy	[53]
JCAR017	DMJV2IF	Phase 1/2	CAR T Cell Therapy	[54]
MyVax	DMFIWUL	Phase 1/2	NA	[55]
SAR440234	DM6M8O4	Phase 1/2	Antibody	[56]
SCRI-huCAR19v1	DMS1NMO	Phase 1/2	CAR T Cell Therapy	[57]
UCART019	DMRJK26	Phase 1/2	CAR T Cell Therapy	[58]
WT-4869	DM3FIMD	Phase 1/2	NA	[59]
AC430	DMPS6U9	Phase 1	Small molecular drug	[60]
AFM11	DMIFJZD	Phase 1	Antibody	[61]
Allogeneic CART-19	DMCYV26	Phase 1	CAR T Cell Therapy	[62]
Anti-BCMA CAR-T cells	DMK25QD	Phase 1	CAR T Cell Therapy	[63]
Anti-CD123 CAR-T cells	DMYIZFW	Phase 1	CAR T Cell Therapy	[63]
Anti-CD19	DM0L6HL	Phase 1	NA	[11]
Anti-CD19 anti-CD20 Bispecific CAR-T	DMCABUR	Phase 1	CAR T Cell Therapy	[64]
Anti-CD19 CAR-T cells	DMUQ3C1	Phase 1	CAR T Cell Therapy	[63]
Anti-CD19-CAR	DMWKYSM	Phase 1	CAR T Cell Therapy	[65]
Anti-CD19-CAR T	DMMRANJ	Phase 1	CAR T Cell Therapy	[66]
Anti-CD30 CAR-T cells	DMTK78L	Phase 1	CAR T Cell Therapy	[63]
Anti-CD7 CAR-T cells	DMMFL2P	Phase 1	CAR T Cell Therapy	[63]
ARI-0001 cells	DMPLHBI	Phase 1	CAR T Cell Therapy	[67]
CC-90002	DMK0QDO	Phase 1	Antibody	[68]
CD10-CART	DM0XDYT	Phase 1	CAR T Cell Therapy	[69]
CD19+ CAR T Cells	DMGUQ8V	Phase 1	CAR T Cell Therapy	[70]
CD19-directed CAR-T cells	DMETGAQ	Phase 1	CAR T Cell Therapy	[71]
CD19-targeted CART cells	DMCZ3A2	Phase 1	CAR T Cell Therapy	[72]
CD19/CD22 CAR T-Cells	DMKA2FL	Phase 1	CAR T Cell Therapy	[73]
CD20-CART	DMSJBUZ	Phase 1	CAR T Cell Therapy	[69]
CD22-CART	DMHMPK1	Phase 1	CAR T Cell Therapy	[69]
CD22-specific CAR T-cells also expressing an EGFRt	DMP5V83	Phase 1	CAR T Cell Therapy	[74]
CDX-1127	DMPVUGE	Phase 1	NA	[75]
Combotox	DMA7PWX	Phase 1	NA	[76]
CSL-362-AML	DM7I39W	Phase 1	Antibody	[77]
Donor-derived CD19/22 bispecific CAR-T cells	DMZS350	Phase 1	CAR T Cell Therapy	[71]
HuCART19	DMNAR29	Phase 1	CAR T Cell Therapy	[78]
HuM195/rGel	DMDZBTY	Phase 1	Antibody	[79]
ICAR19 CAR-T cells	DMHG4Q9	Phase 1	CAR T Cell Therapy	[80]
IMMU-114	DMTFUM4	Phase 1	Antibody	[81]
INB-100	DM8PU34	Phase 1	Cell therapy	[82]
Lintuzumab Ac-226	DMMOTIT	Phase 1	Monoclonal antibody	[83]
mab-216	DMBVC1R	Phase 1	Monoclonal antibody	[84]
Oncoquest-CLL	DM1XWIJ	Phase 1	NA	[85]
Patient-derived CD19- and CD22 specific CAR	DMZSD3T	Phase 1	CAR T Cell Therapy	[86]
Ragweed allergy vaccine	DM5MMH7	Phase 1	NA	[87]
RGA-1512	DMWQHWF	Phase 1	NA	[88]
ROR1R-CAR-T Cell	DMIAK9P	Phase 1	CAR T Cell Therapy	[89]
Sleeping Beauty CAR-TCR	DMVUL1H	Phase 1	CAR T Cell Therapy	[90]
XL-228	DMW8N72	Phase 1	Small molecular drug	[91]
Anti-CD19 Chimeric Antigen Receptor T Cells	DM6NVPT	Clinical trial	CAR T Cell Therapy	[92]
CAR-CD19 T cell	DMXU2D1	Clinical trial	CAR T Cell Therapy	[93]
CD19-targeted CAR-T cells	DMLPAFG	Clinical trial	CAR T Cell Therapy	[94]
CD19CART	DMF936G	Clinical trial	CAR T Cell Therapy	[95]

This Disease is Treated as An Indication in 12 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aminopterin	DMQ9RBV	Withdrawn from market	Small molecular drug	[96]
LDI-200	DMKMTR7	Discontinued in Phase 3	NA	[97]
Lintuzumab	DMD39G4	Discontinued in Phase 2	Antibody	[98]
CB-001	DM3OTSJ	Discontinued in Phase 1/2	NA	[99]
IDM-4	DMJE3SB	Discontinued in Phase 1/2	NA	[100]
Oncolysin M	DM47ELH	Discontinued in Phase 1	NA	[101]
Ormaplatin	DMG3C2G	Discontinued in Phase 1	NA	[102]
BE-22179	DM39SEK	Terminated	NA	[105]
CMLVAX100	DMYJ2LO	Terminated	NA	[106]
FR-900482	DMPEJGR	Terminated	Small molecular drug	[107]
LN-040	DMZBTV8	Terminated	NA	[108]
Phosphonate	DMAJ9ZD	Terminated	Small molecular drug	[109]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
212Pb-labelled aCD37	DMLVADH	Preclinical	Radiopharmaceutical therapy agent	[103]
MC-2001	DMBT2RJ	Preclinical	NA	[104]

This Disease is Treated as An Indication in 13 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
111In-labeled LFA-1 targeted imaging agent (lymphoma/leukemia), NuView/University of New Mexico	DMBGQEH	Investigative	NA	[25]
AL-18	DMX72V3	Investigative	NA	[25]
CEP-37309	DMCQE1D	Investigative	NA	[25]
CTA-056	DMJ4EGI	Investigative	NA	[25]
EB-1,2,3 mab	DMYJDDA	Investigative	NA	[25]
ELP-10	DMWKDMM	Investigative	NA	[25]
EPZ-004777	DMLN4V5	Investigative	Small molecular drug	[110]
G-CSF	DMVFDYU	Investigative	NA	[111]
GenFusAb	DMP01XD	Investigative	NA	[25]
MDPTQ	DML8NUY	Investigative	NA	[25]
PV-327	DMVQ4WZ	Investigative	NA	[25]
PYZD-4409	DME0NO8	Investigative	Small molecular drug	[112]
SNG-8033	DM0W54R	Investigative	NA	[113]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 392 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AKR1C3	TT5ZWB6	Limited	Biomarker	[114]
ANG	TTURHFP	Limited	Altered Expression	[115]
ANXA8	TTSW16P	Limited	Altered Expression	[116]
APEX1	TTHGL48	Limited	Genetic Variation	[117]
BCL6	TTC9YX5	Limited	Biomarker	[118]
BRD4	TTSRAOU	Limited	Biomarker	[119]
CASP5	TTWR48J	Limited	Genetic Variation	[120]
CCL3	TT8I4WB	Limited	Biomarker	[121]
CCR7	TT2GIDQ	Limited	Biomarker	[122]
CD14	TT6I7DC	Limited	Biomarker	[123]
CD200	TT0BE68	Limited	Altered Expression	[124]
CD28	TTQ13FT	Limited	Biomarker	[125]
CD33	TTJVYO3	Limited	Biomarker	[126]
CD80	TT89Z17	Limited	Altered Expression	[127]
CEBPA	TT5LWG1	Limited	Genetic Variation	[128]
CES1	TTMF541	Limited	Biomarker	[129]
CHEK1	TTTU902	Limited	Biomarker	[130]
CNTF	TTGEM5Q	Limited	Biomarker	[131]
CRLF2	TTRMZ0N	Limited	Genetic Variation	[132]
CSF3R	TTC70AJ	Limited	Biomarker	[133]
CSPG4	TT7MYXI	Limited	Biomarker	[134]
CXCR4	TTBID49	Limited	Biomarker	[135]
CYBB	TT5T8MR	Limited	Biomarker	[136]
CYP1B1	TTI84H7	Limited	Altered Expression	[137]
DCK	TTJOCE4	Limited	Altered Expression	[138]
DDIT4	TTVEOY6	Limited	Biomarker	[139]
DGKA	TTGL8F0	Limited	Biomarker	[140]
DICER1	TTTEOPU	Limited	Altered Expression	[141]
DOT1L	TTSZ8T1	Limited	Altered Expression	[142]
EBI3	TTJF68X	Limited	Biomarker	[143]
EIF2AK2	TTXEZJ4	Limited	Biomarker	[144]
EP300	TTGH73N	Limited	Biomarker	[145]
EPOR	TTAUX24	Limited	Genetic Variation	[146]
EZH1	TTNJA0C	Limited	Posttranslational Modification	[147]
EZH2	TT9MZCQ	Limited	Genetic Variation	[148]
FCER2	TTCH6MU	Limited	Biomarker	[149]
FLT4	TTDCBX5	Limited	Biomarker	[150]
FUT4	TTNV1KZ	Limited	Biomarker	[151]
GEM	TTAZF9M	Limited	Genetic Variation	[152]
HDAC1	TT6R7JZ	Limited	Biomarker	[153]
HLA-G	TTLKFB3	Limited	Altered Expression	[154]
HNRNPA1	TTPJ9XK	Limited	Biomarker	[155]
IL3RA	TTENHJ0	Limited	Altered Expression	[156]
KIT	TTX41N9	Limited	Genetic Variation	[157]
LIFR	TTID542	Limited	Altered Expression	[158]
LYZ	TTAOZBW	Limited	Biomarker	[159]
MAP2K1	TTIDAPM	Limited	Biomarker	[160]
MERTK	TTO7LKR	Limited	Biomarker	[161]
MIA	TT5HNVS	Limited	Biomarker	[162]
MPO	TTVCZPI	Limited	Biomarker	[163]
MSLN	TT4RXME	Limited	Biomarker	[164]
MYCBP	TTVW4XU	Limited	Biomarker	[165]
MYCN	TT9JBY5	Limited	Altered Expression	[166]
NEDD8	TTNDC4K	Limited	Biomarker	[167]
NQO1	TT8XK6L	Limited	Genetic Variation	[168]
PIM1	TTTN5QW	Limited	Biomarker	[169]
PLK1	TTH4IP0	Limited	Biomarker	[170]
PMEL	TT8MK59	Limited	Biomarker	[171]
PML	TTLH9NY	Limited	Biomarker	[172]
PRMT5	TTR1D7X	Limited	Biomarker	[173]
PTK2B	TTTEFBV	Limited	Biomarker	[174]
PTK7	TTXH2ZN	Limited	Biomarker	[175]
PVRIG	TTOGCNT	Limited	Altered Expression	[176]
RARA	TTW38KT	Limited	Genetic Variation	[177]
RARG	TT1Q3IE	Limited	Genetic Variation	[177]
RNF6	TT4S09X	Limited	Biomarker	[178]
ROCK1	TTZN7RP	Limited	Biomarker	[179]
ROS1	TTSZ6Y3	Limited	Biomarker	[180]
RPS6KA3	TTUM2ZR	Limited	Biomarker	[181]
SELE	TT1PL7M	Limited	Biomarker	[182]
SF3B1	TTL2WUI	Limited	Genetic Variation	[183]
SPN	TTOZAX0	Limited	Biomarker	[149]
TCL1A	TTUKRDV	Limited	Genetic Variation	[184]
TERF1	TT1Y6J2	Limited	Altered Expression	[185]
THPO	TTCG5PE	Limited	Biomarker	[186]
TMBIM6	TT7QSMG	Limited	Biomarker	[187]
TRPM5	TT1N8F3	Limited	Genetic Variation	[188]
TSLP	TTHMW3T	Limited	Altered Expression	[189]
TYR	TTULVH8	Limited	Biomarker	[190]
VTCN1	TTCK85E	Limited	Biomarker	[191]
ZNF224	TT1CDXL	Limited	Biomarker	[192]
CDA	TTQ12RK	Disputed	Biomarker	[193]
CXCL12	TT4UGTF	Disputed	Biomarker	[135]
ID1	TTBXVDE	Disputed	Biomarker	[194]
ABL2	TT1A6HL	moderate	Biomarker	[195]
ACVRL1	TTGYPTC	moderate	Biomarker	[196]
AIMP2	TTXWHGF	moderate	Biomarker	[197]
BAK1	TTFM7V0	moderate	Biomarker	[198]
BCL2L2	TTQ79W8	moderate	Biomarker	[199]
CRK	TTFEUYR	moderate	Biomarker	[197]
CRTC2	TTFWETR	moderate	Biomarker	[200]
DCLK1	TTOHTCY	moderate	Biomarker	[201]
DHODH	TTLVP78	moderate	Altered Expression	[202]
EHMT2	TTS6RZT	moderate	Biomarker	[203]
FTO	TTFW3BT	moderate	Biomarker	[204]
GJB7	TTZ7POK	moderate	Biomarker	[205]
GPRC6A	TTI1PRE	moderate	Altered Expression	[206]
IL24	TT1EPXZ	moderate	Biomarker	[207]
ILK	TT7ALZG	moderate	Biomarker	[208]
ITGAM	TTB69FJ	moderate	Biomarker	[209]
KDM1A	TTNR0UQ	moderate	Biomarker	[210]
KMT5B	TTJGV7F	moderate	Biomarker	[211]
LTB4R	TTN53ZF	moderate	Altered Expression	[206]
LY9	TTZCL1U	moderate	Biomarker	[212]
MAP2K7	TT6QY3J	moderate	Biomarker	[213]
MAPK8	TT0K6EO	moderate	Biomarker	[214]
MCM7	TT1RM3F	moderate	Altered Expression	[215]
MPL	TTIHYA4	moderate	Biomarker	[216]
MRGPRX1	TTIX6PK	moderate	Altered Expression	[206]
MSI2	TTTXQF6	moderate	Biomarker	[217]
NRP1	TTIPJCB	moderate	Altered Expression	[218]
NSD1	TTTSJ3H	moderate	Biomarker	[219]
OXER1	TT7WBSV	moderate	Altered Expression	[206]
PGD	TTZ3IFB	moderate	Biomarker	[220]
PHGDH	TT8DRCK	moderate	Biomarker	[221]
PIM3	TTCGOIN	moderate	Altered Expression	[222]
PRTN3	TT5MLC4	moderate	Biomarker	[223]
RAB9A	TT958S6	moderate	Biomarker	[224]
ROR2	TTUDPCI	moderate	Biomarker	[225]
RPL15	TTQRVC9	moderate	Biomarker	[226]
RPSA	TTLUW5B	moderate	Altered Expression	[227]
RTN4R	TTVRZUO	moderate	Biomarker	[228]
SLC9A1	TTGSEFH	moderate	Biomarker	[229]
SMYD3	TTKLJYX	moderate	Biomarker	[230]
SSRP1	TTETDKQ	moderate	Biomarker	[231]
ST8SIA4	TTDP8YM	moderate	Altered Expression	[232]
TK1	TTP3QRF	moderate	Altered Expression	[233]
TNFRSF18	TTG6LA7	moderate	Biomarker	[234]
TRIM28	TTQ2BKV	moderate	Biomarker	[235]
USP10	TT5IH09	moderate	Biomarker	[236]
VDAC1	TTAMKGB	moderate	Biomarker	[237]
XIAP	TTK3WBU	moderate	Biomarker	[238]
ABCC3	TTVLG21	Strong	Biomarker	[239]
ABCC4	TTUEAFL	Strong	Genetic Variation	[240]
ADAM17	TT6AZXG	Strong	Biomarker	[241]
ADAMTS1	TTS2TEI	Strong	Biomarker	[242]
AICDA	TTKRTP6	Strong	Biomarker	[243]
AKR1B1	TTFBNVI	Strong	Biomarker	[244]
ALPI	TTHYMUV	Strong	Biomarker	[245]
ANK1	TTKFPMH	Strong	Genetic Variation	[146]
AOX1	TT3MOS2	Strong	Genetic Variation	[246]
APCS	TTB7VAT	Strong	Altered Expression	[247]
ASPA	TT6TLZP	Strong	Biomarker	[248]
ASRGL1	TT4WT91	Strong	Biomarker	[249]
ATIC	TT9NVXQ	Strong	Biomarker	[250]
ATR	TT8ZYBQ	Strong	Biomarker	[251]
AURKA	TTPS3C0	Strong	Biomarker	[252]
AURKB	TT9RTBL	Strong	Altered Expression	[253]
AXL	TTZPY6J	Strong	Biomarker	[254]
BCL11A	TTR61MW	Strong	Biomarker	[255]
BCL2A1	TTGT9C7	Strong	Biomarker	[256]
BPHL	TTTZ3EU	Strong	Biomarker	[257]
BRPF1	TTT46BN	Strong	Genetic Variation	[258]
BSG	TT5UJWD	Strong	Biomarker	[259]
BST2	TT90BJT	Strong	Biomarker	[260]
BTG1	TTL7N2W	Strong	Altered Expression	[261]
BTK	TTGM6VW	Strong	Biomarker	[262]
BUB1	TT78309	Strong	Biomarker	[263]
CALR	TTUZ7OA	Strong	Genetic Variation	[264]
CASP2	TT12VNG	Strong	Biomarker	[265]
CASP7	TTM7Y45	Strong	Genetic Variation	[266]
CASR	TTBUYHA	Strong	Biomarker	[267]
CBX7	TTBN3HC	Strong	Biomarker	[268]
CCNA2	TTAMQ62	Strong	Altered Expression	[269]
CCR5	TTJIH8Q	Strong	Biomarker	[135]
CCR6	TTFDB30	Strong	Biomarker	[270]
CD1A	TTBGTFN	Strong	Altered Expression	[271]
CD22	TTM6QSK	Strong	Biomarker	[272]
CD27	TTDO1MV	Strong	Genetic Variation	[273]
CD37	TTFCW29	Strong	Biomarker	[274]
CD3G	TTV3XPL	Strong	Genetic Variation	[275]
CD40LG	TTIJP3Q	Strong	Biomarker	[276]
CD5	TTEGYK1	Strong	Biomarker	[277]
CD70	TTNCIE0	Strong	Biomarker	[278]
CD79B	TTBN5I7	Strong	Biomarker	[279]
CD9	TTZEIBV	Strong	Biomarker	[280]
CDK1	TTH6V3D	Strong	Biomarker	[281]
CDK2	TT7HF4W	Strong	Biomarker	[282]
CDK6	TTO0FDJ	Strong	Biomarker	[283]
CDK8	TTBJR4L	Strong	Biomarker	[284]
CDK9	TT1LVF2	Strong	Biomarker	[285]
CEBPB	TTUI35N	Strong	Altered Expression	[286]
CLEC12A	TT70N8V	Strong	Altered Expression	[287]
CNTN2	TT2Z1WB	Strong	Genetic Variation	[288]
COPS5	TTSTNJR	Strong	Biomarker	[289]
CR1	TTEA8OW	Strong	Altered Expression	[290]
CR2	TT0HUN7	Strong	Altered Expression	[291]
CREBBP	TTFRCTK	Strong	Genetic Variation	[292]
CSE1L	TTTRULD	Strong	Biomarker	[293]
CSF1	TT0IQER	Strong	Biomarker	[294]
CSF1R	TT7MRDV	Strong	Altered Expression	[295]
CSF2RB	TTPYS82	Strong	Altered Expression	[296]
CSNK2A1	TTER6YH	Strong	Biomarker	[297]
CSNK2A2	TT7GR5W	Strong	Biomarker	[297]
CTF1	TTXGTZU	Strong	Biomarker	[298]
CTSG	TTQAJF1	Strong	Altered Expression	[299]
CYP3A5	TTHS0OK	Strong	Genetic Variation	[300]
DHFR	TTYZVDJ	Strong	Altered Expression	[301]
DLL1	TT9CFQD	Strong	Genetic Variation	[302]
DNASE1	TTYWGOJ	Strong	Biomarker	[303]
DNMT3A	TTJUALD	Strong	Biomarker	[304]
DNMT3B	TT6VZ78	Strong	Biomarker	[305]
EBP	TT4VQZX	Strong	Biomarker	[306]
EIF4E	TTZGCP6	Strong	Biomarker	[307]
ELANE	TTPLTSQ	Strong	Altered Expression	[308]
EPHA3	TTHS2LR	Strong	Biomarker	[309]
F2RL3	TTD0652	Strong	Altered Expression	[310]
F8	TT1290U	Strong	Biomarker	[311]
F9	TTFEZ5Q	Strong	Biomarker	[312]
FANCF	TTNZKFJ	Strong	Biomarker	[313]
FCGR2B	TT5RWKQ	Strong	Biomarker	[314]
FCGRT	TTKLPHO	Strong	Genetic Variation	[315]
FDXR	TT3W4IX	Strong	Biomarker	[244]
FES	TTLBY21	Strong	Altered Expression	[316]
FGF4	TTCEKVZ	Strong	Genetic Variation	[317]
FMNL1	TTW20PQ	Strong	Biomarker	[318]
FPR1	TT5Y4EM	Strong	Altered Expression	[319]
FUS	TTKGYZ9	Strong	Biomarker	[320]
FUT3	TTUPAD7	Strong	Altered Expression	[321]
GGH	TTZJRL0	Strong	Altered Expression	[322]
GPR137	TTATO6X	Strong	Altered Expression	[323]
GRB2	TTEYRJ9	Strong	Biomarker	[324]
GSTA1	TT4P8DE	Strong	Biomarker	[325]
HAX1	TT21BYA	Strong	Genetic Variation	[326]
HDAC7	TTMUEK1	Strong	Altered Expression	[327]
HDAC9	TT8M4E1	Strong	Biomarker	[328]
HDC	TTV9GOF	Strong	Biomarker	[329]
HMBS	TTT0HW3	Strong	Genetic Variation	[275]
HMGB2	TTA78JQ	Strong	Biomarker	[330]
HNF1A	TT01M3K	Strong	Biomarker	[331]
HOXA11	TTEX4ZA	Strong	Genetic Variation	[332]
HOXA13	TTN26OM	Strong	Genetic Variation	[332]
HOXA5	TTXSVQP	Strong	Biomarker	[333]
HOXA7	TTMRE4Q	Strong	Genetic Variation	[332]
HOXB13	TTZ6I58	Strong	Genetic Variation	[334]
HSF1	TTN6STZ	Strong	Biomarker	[335]
HSP90AA1	TT78R5H	Strong	Altered Expression	[336]
HSPB8	TTY0OJN	Strong	Altered Expression	[337]
IAPP	TTHN8EM	Strong	Biomarker	[245]
IDH1	TTV2A1R	Strong	Genetic Variation	[338]
IFNAR1	TTSYFMA	Strong	Genetic Variation	[339]
IGFBP7	TTUQ01B	Strong	Biomarker	[340]
IKZF3	TTCZVFZ	Strong	Genetic Variation	[341]
IL11	TTGUYTR	Strong	Biomarker	[131]
IL15	TTJFA35	Strong	Biomarker	[342]
IL15RA	TTGN89I	Strong	Altered Expression	[127]
IL1RL1	TT4GZA4	Strong	Genetic Variation	[343]
IL2	TTF89GD	Strong	Genetic Variation	[344]
IL7	TT8FRMO	Strong	Biomarker	[174]
IL7R	TTAWI51	Strong	Altered Expression	[345]
INPP5D	TTTP2Z1	Strong	Genetic Variation	[346]
IRAK1	TTXAJWN	Strong	Biomarker	[347]
IRF1	TT4TU3L	Strong	Biomarker	[348]
IRF8	TTHUBNK	Strong	Biomarker	[349]
ITGA6	TT165T3	Strong	Altered Expression	[350]
JMJD1C	TTBISK4	Strong	Biomarker	[351]
KAT6A	TT6O1J0	Strong	Genetic Variation	[352]
KAT6B	TTH4VJL	Strong	Genetic Variation	[353]
KCNH1	TT9XKUC	Strong	Altered Expression	[354]
KDM4C	TTV8CRH	Strong	Biomarker	[355]
KDM5A	TTIG67W	Strong	Biomarker	[356]
KDM5B	TTCLI75	Strong	Altered Expression	[357]
KIR2DS1	TTVWAGF	Strong	Biomarker	[358]
KIR3DL2	TTQH3N0	Strong	Biomarker	[358]
KLRK1	TTLRN4A	Strong	Biomarker	[164]
KSR1	TTHL1TV	Strong	Biomarker	[359]
LAMB3	TT2WOUQ	Strong	Altered Expression	[360]
LCK	TT860QF	Strong	Biomarker	[361]
LIN28A	TTO50LN	Strong	Biomarker	[362]
LONP1	TTM1VPZ	Strong	Biomarker	[169]
LRP6	TTSXOWE	Strong	Posttranslational Modification	[363]
LTB4R2	TTVJX54	Strong	Biomarker	[364]
LTF	TTSZDQU	Strong	Genetic Variation	[365]
LTK	TT1JZG6	Strong	Altered Expression	[366]
LYN	TT1RWNJ	Strong	Altered Expression	[367]
MAGEA1	TT63M7Q	Strong	Altered Expression	[368]
MAP2K5	TTV3O87	Strong	Biomarker	[369]
MAPK7	TTU6FSC	Strong	Biomarker	[369]
MAPK9	TT3IVG2	Strong	Biomarker	[370]
MARK2	TTAJ45Y	Strong	Biomarker	[371]
MBP	TT2RY5P	Strong	Genetic Variation	[372]
MDM2	TT9TE0O	Strong	Altered Expression	[373]
MLH1	TTISG27	Strong	Genetic Variation	[374]
MME	TT5TKPM	Strong	Altered Expression	[375]
MS4A1	TTUE541	Strong	Biomarker	[376]
MSH2	TTCAWRT	Strong	Altered Expression	[377]
MSR1	TT2TDH9	Strong	Biomarker	[378]
MTR	TTUTO39	Strong	Genetic Variation	[379]
MYB	TT8V13P	Strong	Biomarker	[380]
NAMPT	TTD1WIG	Strong	Biomarker	[381]
NCR1	TTQNRJM	Strong	Biomarker	[382]
NME1	TTDY8JH	Strong	Biomarker	[383]
NOTCH3	TTVX7IA	Strong	Biomarker	[384]
NOTCH4	TTXDIK2	Strong	Biomarker	[385]
NR0B2	TT25A9Q	Strong	Altered Expression	[386]
NR1I3	TTRANFM	Strong	Biomarker	[267]
NR4A3	TTJQB49	Strong	Biomarker	[387]
NR5A2	TTAU3SY	Strong	Altered Expression	[388]
P2RY1	TTA93TL	Strong	Biomarker	[389]
PARG	TT39J16	Strong	Biomarker	[257]
PAWR	TT3I4WV	Strong	Altered Expression	[310]
PAX5	TTA4REJ	Strong	Biomarker	[390]
PBK	TTMY6BZ	Strong	Altered Expression	[391]
PDGFB	TTQA6SX	Strong	Altered Expression	[392]
PECAM1	TT4EZB2	Strong	Genetic Variation	[393]
PF4	TTSG7Q5	Strong	Biomarker	[394]
PHB	TT6U071	Strong	Altered Expression	[395]
PHF8	TT81PFE	Strong	Biomarker	[396]
PIM2	TT69J2Z	Strong	Biomarker	[397]
PLA2R1	TTHKW7D	Strong	Posttranslational Modification	[398]
PLK4	TTGPNZQ	Strong	Biomarker	[399]
PPIB	TT6ZFQ4	Strong	Biomarker	[400]
PPP5C	TTTW7FJ	Strong	Biomarker	[401]
PRAME	TTPH7T0	Strong	Biomarker	[402]
PRG4	TTSKF4V	Strong	Biomarker	[403]
PRKAR1A	TTNAHEX	Strong	Biomarker	[267]
PRMT1	TTVOJAI	Strong	Biomarker	[404]
PSIP1	TTH9LDP	Strong	Biomarker	[405]
PSMB6	TT8EPLT	Strong	Genetic Variation	[302]
PTPN13	TT405FP	Strong	Altered Expression	[406]
PTPN2	TTY8PUS	Strong	Biomarker	[407]
PTPN6	TT369M5	Strong	Altered Expression	[386]
PTPRC	TTUS45N	Strong	Altered Expression	[209]
QPCT	TTJ7YTV	Strong	Biomarker	[408]
RALBP1	TTVSRUA	Strong	Biomarker	[409]
REG3A	TTL4H8N	Strong	Altered Expression	[410]
ROBO4	TT3S9TY	Strong	Altered Expression	[411]
ROR1	TTDEJAU	Strong	Biomarker	[225]
RUNX2	TTD6SZ8	Strong	Biomarker	[412]
RUNX3	TTKCVO7	Strong	Biomarker	[413]
S100A8	TT4AF6N	Strong	Biomarker	[414]
SCT	TTOBVIN	Strong	Biomarker	[415]
SELPLG	TTS5K8U	Strong	Biomarker	[416]
SEPTIN6	TTAGE7U	Strong	Biomarker	[417]
SH3GL1	TTTYNAM	Strong	Biomarker	[418]
SIRT6	TTUXYWF	Strong	Biomarker	[419]
SLC22A1	TTM5Q4V	Strong	Biomarker	[420]
SLC22A16	TTITAVR	Strong	Biomarker	[421]
SLC23A2	TTOP832	Strong	Biomarker	[422]
SLC29A1	TTLXAKE	Strong	Altered Expression	[423]
SLC46A1	TTY8Z2E	Strong	Altered Expression	[424]
SLCO1B1	TTFGXEB	Strong	Genetic Variation	[425]
SMPD2	TTE5VI6	Strong	Altered Expression	[426]
SMYD2	TT7YJFO	Strong	Biomarker	[427]
SNAP25	TTYQWA0	Strong	Genetic Variation	[428]
SOCS3	TTI0ME6	Strong	Altered Expression	[429]
SPTBN1	TTS9BDA	Strong	Biomarker	[430]
SRC	TT6PKBN	Strong	Biomarker	[431]
SRPK1	TTU3WV6	Strong	Biomarker	[432]
SRPK2	TTCZEJ9	Strong	Altered Expression	[433]
STC1	TTDLUER	Strong	Biomarker	[434]
STMN1	TT7W5OT	Strong	Altered Expression	[435]
SUV39H1	TTUWQTK	Strong	Biomarker	[436]
TERF2	TT5XSLT	Strong	Biomarker	[437]
TF	TT8WXAV	Strong	Altered Expression	[438]
TNFRSF10B	TTW20TU	Strong	Biomarker	[439]
TNFRSF13B	TTL9OD4	Strong	Biomarker	[440]
TNFRSF17	TTZ3P4W	Strong	Biomarker	[440]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[441]
TNFSF13	TTOI1RM	Strong	Biomarker	[442]
TNK1	TTWS7I3	Strong	Altered Expression	[443]
TNK2	TTIET93	Strong	Genetic Variation	[444]
TOP1	TTGTQHC	Strong	Altered Expression	[445]
TOP2A	TTCGY2K	Strong	Biomarker	[445]
TRB	TT84HCW	Strong	Biomarker	[446]
TRBC1	TT1DHW2	Strong	Biomarker	[447]
TRPV2	TTBECWA	Strong	Biomarker	[448]
TRPV6	TTBK14N	Strong	Biomarker	[449]
TUSC2	TTJ8O14	Strong	Altered Expression	[410]
UBE2E2	TTXJEOF	Strong	Altered Expression	[322]
UGCG	TTPHEX3	Strong	Altered Expression	[450]
USP7	TTXU3EQ	Strong	Biomarker	[451]
WDR5	TT7OFWB	Strong	Biomarker	[452]
WNT7A	TT8NARC	Strong	Altered Expression	[453]
WT1	TTZ8UT4	Strong	Biomarker	[454]
ZAP70	TTUMHT8	Strong	Biomarker	[455]
ABCB4	TTJUXV6	Definitive	Altered Expression	[456]
CD47	TT28S46	Definitive	Biomarker	[457]
DGKZ	TTSBBXL	Definitive	Biomarker	[458]
DLL4	TTV23LH	Definitive	Biomarker	[459]
GRIA3	TT82EZV	Definitive	Altered Expression	[460]
GRM3	TT8A9EF	Definitive	Altered Expression	[460]
HIPK2	TTOB49C	Definitive	Genetic Variation	[461]
JAK3	TTT7PJU	Definitive	Genetic Variation	[462]
KIR2DL1	TT4UXPE	Definitive	Biomarker	[463]
OPRK1	TTQW87Y	Definitive	Biomarker	[464]
PIN1	TTJNTSI	Definitive	Altered Expression	[465]
RIPK1	TTVJHX8	Definitive	Biomarker	[409]
SETD2	TTPC3H4	Definitive	Biomarker	[466]
SLC52A2	TT6TKEN	Definitive	Biomarker	[371]
SLC5A6	TT61XTV	Definitive	Altered Expression	[467]
USP1	TTG9MT5	Definitive	Biomarker	[468]

This Disease Is Related to 8 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC11	DTWN7FC	Limited	Biomarker	[469]
ATP7A	DT0LT17	moderate	Biomarker	[470]
ABCB5	DTKVEXO	Strong	Biomarker	[471]
SLC22A4	DT2EG60	Strong	Biomarker	[472]
SLC25A20	DTQOUM4	Strong	Genetic Variation	[473]
SLC29A2	DTW78DQ	Strong	Biomarker	[474]
SLC39A8	DTLPQGT	Strong	Biomarker	[475]
SLCO6A1	DTIFXNS	Strong	Genetic Variation	[476]

This Disease Is Related to 19 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
FPGS	DECWT2V	Limited	Genetic Variation	[477]
SCLY	DEH4TD6	Limited	Biomarker	[478]
ABO	DESIA7R	moderate	Genetic Variation	[479]
PARK7	DEPOVCH	moderate	Biomarker	[480]
PON2	DEHJU7E	moderate	Altered Expression	[481]
ACP3	DEDW5H6	Strong	Biomarker	[482]
AKR1C4	DEAJN47	Strong	Biomarker	[483]
ALDH1A1	DE2JP1Y	Strong	Altered Expression	[484]
ASNS	DEXISVQ	Strong	Genetic Variation	[485]
CMPK1	DEMPH4I	Strong	Biomarker	[486]
GSTM1	DEYZEJA	Strong	Genetic Variation	[487]
GSTT1	DE3PKUG	Strong	Biomarker	[487]
HK1	DEDMAGE	Strong	Biomarker	[488]
HPRT1	DEVXTP5	Strong	Genetic Variation	[489]
MTRR	DE6NIY9	Strong	Genetic Variation	[379]
NT5C2	DE1DOKJ	Strong	Genetic Variation	[490]
SULT2A1	DE0P6LK	Strong	Genetic Variation	[491]
THOP1	DE95LJC	Strong	Altered Expression	[492]
TPMT	DEFQ8VO	Strong	Altered Expression	[493]

This Disease Is Related to 563 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ABI1	OT5H4M62	Limited	Altered Expression	[494]
ADD1	OTTF68DC	Limited	Biomarker	[495]
ARID2	OTIRJXWM	Limited	Biomarker	[496]
ARSH	OTG0X9UQ	Limited	Biomarker	[324]
ASPG	OT5E2EKR	Limited	Biomarker	[497]
ATG5	OT4T5SMS	Limited	Biomarker	[248]
ATN1	OTNZFLKY	Limited	Biomarker	[498]
BLNK	OTSSPF6F	Limited	Altered Expression	[499]
CBFB	OTIAC6W4	Limited	Altered Expression	[500]
CBX2	OTOQ5WS4	Limited	Biomarker	[328]
CD226	OT4UG0KB	Limited	Altered Expression	[176]
CD48	OT83ZNPP	Limited	Biomarker	[501]
CEBPE	OTKZA25M	Limited	Biomarker	[502]
CEBPZ	OT11BATG	Limited	Biomarker	[503]
CIAPIN1	OTWS90F9	Limited	Biomarker	[504]
CIP2A	OTVS2GXA	Limited	Biomarker	[505]
COBL	OTTB4VFQ	Limited	Biomarker	[506]
CRKL	OTOYSD1R	Limited	Biomarker	[507]
DCTN6	OTI8PIN9	Limited	Biomarker	[508]
DDX4	OTQOV093	Limited	Altered Expression	[509]
DDX41	OT6KEIHP	Limited	Genetic Variation	[510]
DNTT	OTFSEF12	Limited	Posttranslational Modification	[511]
ELL	OTCBN5LF	Limited	Altered Expression	[512]
ERG	OTOTX9VU	Limited	Biomarker	[513]
ESM1	OT331Y8V	Limited	Biomarker	[514]
EXOSC5	OTADUQ7H	Limited	Altered Expression	[515]
FAM168A	OTDXQCS5	Limited	Biomarker	[516]
FBLIM1	OTFHXMON	Limited	Biomarker	[517]
FIP1L1	OTF91GTL	Limited	Biomarker	[518]
FLII	OT7G9JG6	Limited	Genetic Variation	[393]
GADD45GIP1	OT4IZ4TP	Limited	Biomarker	[519]
GDE1	OTU6FSBF	Limited	Biomarker	[520]
GINS2	OT974IYI	Limited	Altered Expression	[521]
GNB2	OT3JPRCQ	Limited	Genetic Variation	[522]
GOPC	OTRBGH71	Limited	Biomarker	[517]
GORASP1	OTQS91S7	Limited	Posttranslational Modification	[523]
HNRNPDL	OTB3BFCV	Limited	Biomarker	[524]
HOXB3	OT9UC5PE	Limited	Genetic Variation	[146]
IFI27	OTI2XGIT	Limited	Biomarker	[508]
IKZF1	OTCW1FKL	Limited	Genetic Variation	[525]
IL18R1	OT83XMPQ	Limited	Biomarker	[143]
INA	OT1D33T4	Limited	Biomarker	[526]
KAT2A	OTN0W2SW	Limited	Altered Expression	[527]
KDM6A	OTZM3MJJ	Limited	Biomarker	[528]
KIR3DL1	OTPOSXFX	Limited	Genetic Variation	[152]
KMT2B	OTMMAZQX	Limited	Altered Expression	[529]
KMT2D	OTTVHCLY	Limited	Altered Expression	[529]
KRT7	OTLT3JFN	Limited	Biomarker	[478]
LAMP5	OTC672RM	Limited	Biomarker	[530]
MEF2C	OTZGF1Y5	Limited	Biomarker	[531]
MEN1	OTN6U6V0	Limited	Biomarker	[532]
MLLT1	OT41UZU5	Limited	Biomarker	[533]
MNDA	OTCTKR47	Limited	Altered Expression	[534]
MRPL28	OT4LUTZU	Limited	Genetic Variation	[535]
MRPL58	OTPTWLZY	Limited	Biomarker	[536]
NBN	OT73B5MD	Limited	Biomarker	[537]
NCOA2	OTMQFPBB	Limited	Biomarker	[538]
NNAT	OTNRLO7G	Limited	Genetic Variation	[539]
NSD3	OT3677ZG	Limited	Biomarker	[540]
NUDC	OT073JKX	Limited	Altered Expression	[541]
NUDT21	OTZHKWAR	Limited	Biomarker	[542]
NUTM1	OTONYC08	Limited	Biomarker	[543]
NXT1	OT0VO6AY	Limited	Genetic Variation	[535]
OAZ1	OTPT0PKZ	Limited	Altered Expression	[544]
OSCP1	OTZ4IFGJ	Limited	Biomarker	[545]
PBX1	OTORABGO	Limited	Altered Expression	[546]
PDCD5	OT6T2DDL	Limited	Biomarker	[547]
PFDN5	OTTKPTUP	Limited	Biomarker	[165]
PLAGL2	OT6AP4V2	Limited	Altered Expression	[548]
PSMA7	OTPHI6ST	Limited	Biomarker	[549]
PSMD9	OT6Y5CC3	Limited	Biomarker	[508]
PVALB	OTZW1WVQ	Limited	Biomarker	[190]
RARS1	OTHPZ6JN	Limited	Biomarker	[550]
RERE	OT3G4GBZ	Limited	Biomarker	[551]
RRAS	OTBBF28C	Limited	Biomarker	[552]
SBDS	OTHDCCIB	Limited	Genetic Variation	[553]
SEPTIN11	OTX2O0ZX	Limited	Biomarker	[554]
SEPTIN9	OT1VMRFQ	Limited	Biomarker	[555]
SERINC3	OTQ1LAJ1	Limited	Biomarker	[556]
SERINC5	OT3COPVF	Limited	Biomarker	[556]
SH2B2	OTEDHHDH	Limited	Biomarker	[557]
SIGIRR	OTNC3XFD	Limited	Biomarker	[558]
SIGLEC1	OTNWSQA9	Limited	Altered Expression	[559]
SMARCA1	OT0Y6PTU	Limited	Biomarker	[560]
SSBP2	OTYG1G80	Limited	Biomarker	[561]
STAT5A	OTBSJGN3	Limited	Altered Expression	[562]
STAT5B	OTZVPEBT	Limited	Biomarker	[563]
STIL	OT9799VN	Limited	Biomarker	[171]
SUB1	OTK71JYU	Limited	Genetic Variation	[535]
TAF15	OTNE038N	Limited	Biomarker	[564]
TCF4	OTB9ASTK	Limited	Biomarker	[565]
TCHP	OTVDMHSY	Limited	Biomarker	[566]
TCL1B	OT4CSO39	Limited	Genetic Variation	[184]
TFIP11	OT7NVSWU	Limited	Biomarker	[567]
TICAM2	OTK7GIJ5	Limited	Biomarker	[508]
TLX3	OTBUHHK3	Limited	Altered Expression	[568]
TMED7	OTONO8E6	Limited	Biomarker	[508]
TNPO3	OTOT3HH0	Limited	Biomarker	[569]
TNR	OTVJGAFN	Limited	Genetic Variation	[570]
TP53BP2	OTOWJ2Y4	Limited	Altered Expression	[571]
TPD52	OTPKSK43	Limited	Altered Expression	[572]
FBXW11	OT2A6RLR	Disputed	Biomarker	[573]
GATA2	OTBP2QQ2	Disputed	Altered Expression	[574]
LIN28B	OTVWP0FN	Disputed	Biomarker	[575]
MRGPRF	OT74OZ2Z	Disputed	Biomarker	[576]
RBFOX2	OTXY1WVH	Disputed	Biomarker	[576]
TNFSF9	OTV9L89D	Disputed	Altered Expression	[577]
ACD	OTC54EPO	moderate	Biomarker	[578]
ADCY7	OTAWMGP3	moderate	Biomarker	[579]
AFF4	OTTL5Y8R	moderate	Biomarker	[580]
AHSA1	OTC7AFHT	moderate	Biomarker	[197]
AQP8	OT99JKME	moderate	Biomarker	[581]
ARHGEF1	OTXU4HBW	moderate	Biomarker	[582]
ASH1L	OTUT5NLJ	moderate	Biomarker	[583]
ASXL2	OTNG4E2M	moderate	Genetic Variation	[584]
ATXN1	OTQF0HNR	moderate	Biomarker	[585]
B3GAT1	OTXFP98E	moderate	Biomarker	[586]
CALM2	OTNYA92F	moderate	Biomarker	[587]
CCNG2	OTII38K2	moderate	Altered Expression	[588]
CD200R1	OT65Q9M6	moderate	Biomarker	[125]
CD244	OTSMR85N	moderate	Biomarker	[508]
CD99	OTPUZ5DE	moderate	Biomarker	[589]
CDC73	OT6JASZ1	moderate	Biomarker	[590]
CEMP1	OTUEH5X5	moderate	Altered Expression	[591]
CEP152	OTOKZR9B	moderate	Biomarker	[592]
CGAS	OTJYIXNB	moderate	Biomarker	[593]
CH25H	OT9S2BSW	moderate	Altered Expression	[594]
CIB1	OT4BVCRU	moderate	Altered Expression	[595]
CRISPLD2	OTVSFHTL	moderate	Biomarker	[596]
DACT1	OT19Z704	moderate	Biomarker	[597]
DCLRE1C	OTW3KB1I	moderate	Biomarker	[598]
DDX53	OTHK3EGZ	moderate	Biomarker	[599]
DEFB1	OT5SV0E4	moderate	Biomarker	[600]
DNER	OT2GH2E5	moderate	Biomarker	[601]
DOK1	OTGVRLW6	moderate	Altered Expression	[602]
DPY30	OTLHCJ6C	moderate	Biomarker	[603]
DYNLRB2	OT1G3HAF	moderate	Biomarker	[604]
EFNB2	OT0DCUOM	moderate	Biomarker	[605]
ERCC5	OTQAKFJM	moderate	Genetic Variation	[606]
EVPL	OTZIAFEK	moderate	Biomarker	[607]
FANCB	OTMZTXB5	moderate	Biomarker	[608]
FANCD2	OTVEB5LF	moderate	Biomarker	[313]
FH	OTEQWU6Q	moderate	Biomarker	[609]
GATA5	OTO81B63	moderate	Biomarker	[531]
GNB1	OTLL7L74	moderate	Genetic Variation	[610]
GOLGA6A	OTHU9MRX	moderate	Biomarker	[611]
GPR151	OT7EACU6	moderate	Altered Expression	[206]
GRAP2	OTS5NIZ3	moderate	Biomarker	[197]
GRB10	OTCKXGRC	moderate	Biomarker	[612]
HMGB3	OTCJ2EZY	moderate	Biomarker	[231]
HOXA10	OTB6GQ09	moderate	Altered Expression	[613]
IFIT3	OTPGHZB9	moderate	Altered Expression	[614]
IFNA1	OTPMKY0L	moderate	Biomarker	[563]
INPP4B	OTLROA7G	moderate	Biomarker	[615]
JAM3	OTX0F9QL	moderate	Biomarker	[616]
KLRF1	OTGHZ7FU	moderate	Biomarker	[617]
KNL1	OT4Q3LHV	moderate	Biomarker	[592]
LEF1	OTWS5I5H	moderate	Biomarker	[565]
LETMD1	OTZTZ4RD	moderate	Biomarker	[618]
LMO1	OTB59SKB	moderate	Biomarker	[619]
MARVELD2	OTKB96L5	moderate	Altered Expression	[620]
MKRN2	OTDD1V3O	moderate	Altered Expression	[621]
MLLT11	OTG5RVHC	moderate	Biomarker	[622]
MRGPRX3	OTRKCCDS	moderate	Altered Expression	[206]
MRGPRX4	OTOBHZVA	moderate	Altered Expression	[206]
MTHFD2	OT1LQSGX	moderate	Biomarker	[623]
MYCBP2	OTHODA1F	moderate	Biomarker	[624]
MZF1	OTMVZCPW	moderate	Biomarker	[625]
NDN	OTYBYJ82	moderate	Biomarker	[626]
NECTIN2	OTIE0W6O	moderate	Altered Expression	[627]
NKX2-3	OTF4IL5J	moderate	Biomarker	[228]
NT5C1A	OTS7UF36	moderate	Genetic Variation	[628]
NUDT15	OTX8SZOT	moderate	Genetic Variation	[629]
PAQR3	OTTKJ9Y4	moderate	Altered Expression	[630]
PCLAF	OTMVIOUU	moderate	Biomarker	[590]
PDP1	OT82RTMT	moderate	Posttranslational Modification	[631]
PICALM	OTQVRPMQ	moderate	Biomarker	[587]
PIK3R2	OTZSUQK5	moderate	Altered Expression	[632]
PKNOX1	OTUDMNHX	moderate	Biomarker	[633]
POLDIP2	OT8SZSJ6	moderate	Biomarker	[197]
PPM1K	OTNZ4N4E	moderate	Genetic Variation	[634]
PRF1	OTFVXD7H	moderate	Genetic Variation	[635]
PTPA	OTRGFOI7	moderate	Biomarker	[636]
RAB27A	OT9SQRWY	moderate	Biomarker	[637]
RAG2	OTG9UYTW	moderate	Biomarker	[638]
RALA	OT734R7X	moderate	Biomarker	[639]
RCBTB1	OTAYELI8	moderate	Biomarker	[611]
RNF19A	OTKWCV80	moderate	Biomarker	[197]
SETBP1	OTKGCOSR	moderate	Genetic Variation	[640]
SIGLEC10	OTD1WDQL	moderate	Altered Expression	[641]
SLFN11	OTJWFPMY	moderate	Altered Expression	[642]
SMARCA2	OTSGJ8SV	moderate	Genetic Variation	[560]
SNAP91	OTE3EXWZ	moderate	Biomarker	[587]
STUB1	OTSUYI9A	moderate	Biomarker	[643]
TCF7L1	OTTUTF0O	moderate	Biomarker	[644]
TJP2	OTQUY6BV	moderate	Biomarker	[645]
TMEM30A	OTR6N5J2	moderate	Biomarker	[646]
TRIM25	OT35SG1R	moderate	Biomarker	[647]
A1CF	OTJBKFA1	Strong	Biomarker	[248]
ABHD2	OTCRUOCS	Strong	Altered Expression	[648]
ABR	OTZQK8JF	Strong	Altered Expression	[649]
ACP1	OTJ9CKLU	Strong	Altered Expression	[650]
ADRM1	OTOU4EY6	Strong	Altered Expression	[651]
AFF1	OTT2C78E	Strong	Biomarker	[652]
AGFG2	OTXQZHCR	Strong	Genetic Variation	[653]
AHI1	OT8K2YWY	Strong	Biomarker	[654]
AKAP13	OTOZAR14	Strong	Biomarker	[655]
ANKRD26	OT2ENKKV	Strong	Genetic Variation	[656]
ANP32B	OT3SQMLU	Strong	Biomarker	[657]
ANXA7	OTLMD0TK	Strong	Biomarker	[658]
APCDD1	OTV9AD0L	Strong	Biomarker	[659]
APOBEC1	OTY8QX2R	Strong	Biomarker	[660]
APOBEC3A	OTYO6F5P	Strong	Biomarker	[661]
APOBEC3B	OTHLNI51	Strong	Genetic Variation	[662]
ARAP1	OTINOJJ7	Strong	Altered Expression	[319]
ARHGEF12	OTM2D3LT	Strong	Biomarker	[663]
ARID4A	OT1XKBZ0	Strong	Biomarker	[664]
ARID5B	OTUQ4CQY	Strong	Genetic Variation	[525]
ARIH2	OTJYJQJ8	Strong	Biomarker	[665]
ARR3	OTRZ00CH	Strong	Biomarker	[267]
ASAP1	OT4DLRYY	Strong	Altered Expression	[410]
ASAP2	OTGEXULW	Strong	Altered Expression	[410]
ASPM	OTKXQMNA	Strong	Biomarker	[248]
ASXL1	OTX931AW	Strong	Genetic Variation	[666]
ATF7IP	OTU6ZA7F	Strong	Biomarker	[667]
ATG3	OT28VBVK	Strong	Altered Expression	[668]
B4GALNT2	OT85V4QV	Strong	Biomarker	[669]
B4GALT1	OTBCXEK7	Strong	Biomarker	[670]
BAALC	OTUZSRVF	Strong	Altered Expression	[671]
BACH2	OT17GS18	Strong	Genetic Variation	[672]
BAG1	OTRQNIA4	Strong	Biomarker	[673]
BCAR1	OTKT2C2N	Strong	Biomarker	[293]
BCL10	OT47MCLI	Strong	Altered Expression	[674]
BCL3	OT1M5B95	Strong	Biomarker	[675]
BCOR	OTG013AX	Strong	Biomarker	[292]
BCORL1	OTPTFQN5	Strong	Biomarker	[676]
BRI3BP	OTWCFPRM	Strong	Altered Expression	[677]
C1QC	OTLE5U1P	Strong	Genetic Variation	[372]
C4BPA	OTHNH6Y8	Strong	Biomarker	[678]
CAB39L	OTQEBL0W	Strong	Genetic Variation	[679]
CAMK4	OT47RDGV	Strong	Altered Expression	[680]
CAMLG	OTTSRY39	Strong	Altered Expression	[681]
CAPS	OTC9GZ2M	Strong	Biomarker	[682]
CASP14	OTKY93H9	Strong	Genetic Variation	[266]
CBFA2T2	OTNOIB23	Strong	Altered Expression	[683]
CBX8	OT4U5V1T	Strong	Biomarker	[684]
CCDC51	OTOJNHNA	Strong	Biomarker	[685]
CCNA1	OTX4HD45	Strong	Altered Expression	[686]
CD247	OT45FGUX	Strong	Biomarker	[687]
CD79A	OTOJC8DV	Strong	Biomarker	[688]
CD82	OTH8MC64	Strong	Biomarker	[689]
CD8A	OTDWQJXK	Strong	Biomarker	[277]
CD8B	OTMZ1T7J	Strong	Biomarker	[277]
CDC34	OTNBK390	Strong	Altered Expression	[690]
CDKN2D	OT2TTZPZ	Strong	Biomarker	[312]
CDX4	OTD1SQKM	Strong	Altered Expression	[691]
CHAF1B	OTOMK4KH	Strong	Altered Expression	[692]
CHD1	OT9R9G0H	Strong	Genetic Variation	[693]
CHD5	OTS5EVHH	Strong	Altered Expression	[694]
CHGB	OT7SAQT2	Strong	Biomarker	[695]
CHMP5	OTQWZL6R	Strong	Altered Expression	[696]
CKB	OTUCKOTT	Strong	Altered Expression	[697]
CLEC11A	OT9KBH7C	Strong	Genetic Variation	[698]
CMTM5	OTMS7NDP	Strong	Biomarker	[699]
CNDP2	OTJR9436	Strong	Altered Expression	[138]
CNTNAP1	OT5Y03EU	Strong	Biomarker	[700]
CSHL1	OTQKU2F5	Strong	Altered Expression	[701]
CTBP2	OTGZGT87	Strong	Altered Expression	[269]
CTNNA1	OTFC725Z	Strong	Posttranslational Modification	[702]
CXADR	OT9ZP02A	Strong	Biomarker	[267]
CYTB	OTAHB98A	Strong	Genetic Variation	[703]
DACH1	OTMKNAGG	Strong	Biomarker	[704]
DCC	OT2C1SHW	Strong	Genetic Variation	[705]
DCDC2	OTSUFH1H	Strong	Biomarker	[706]
DLD	OT378CU9	Strong	Biomarker	[707]
DMBT1	OTVNU9D9	Strong	Genetic Variation	[708]
DNA2	OT4DJFFU	Strong	Altered Expression	[709]
DNAJC2	OT3JDA0R	Strong	Biomarker	[710]
DOK2	OTIJ38UF	Strong	Altered Expression	[711]
EAF1	OTN27MJW	Strong	Biomarker	[712]
ECD	OT3L3PCU	Strong	Altered Expression	[713]
EFNB1	OT7JJW8P	Strong	Biomarker	[714]
EGR3	OTGPJIRA	Strong	Biomarker	[715]
EIF3A	OTFABY9G	Strong	Biomarker	[716]
EIF3D	OTDOMP80	Strong	Biomarker	[717]
EIF6	OTEXMUED	Strong	Genetic Variation	[553]
EMB	OT67E3Q1	Strong	Biomarker	[718]
EMD	OTR8ZANE	Strong	Biomarker	[719]
ENOSF1	OT65D3ZK	Strong	Biomarker	[720]
EPC2	OTTG0W9R	Strong	Biomarker	[721]
ESAM	OTF518AI	Strong	Biomarker	[722]
ESPL1	OTMGEVOK	Strong	Altered Expression	[723]
ETV7	OTIAADPA	Strong	Altered Expression	[724]
EWSR1	OT7SRHV3	Strong	Biomarker	[725]
EXT1	OTRPALJK	Strong	Posttranslational Modification	[726]
FBXO9	OTW5P5JF	Strong	Biomarker	[727]
FCGR2C	OTNLMNYB	Strong	Biomarker	[314]
FCGR3B	OTSLSPZG	Strong	Altered Expression	[728]
FEN1	OT6QGG7O	Strong	Genetic Variation	[729]
FLI1	OT0EV3LX	Strong	Genetic Variation	[393]
FLNC	OT3F8J6Y	Strong	Biomarker	[730]
FLT3LG	OTU0YGC4	Strong	Biomarker	[731]
FUBP1	OT77SC9N	Strong	Biomarker	[732]
FUT1	OTODG57A	Strong	Biomarker	[733]
FZD9	OTTZ9MKK	Strong	Genetic Variation	[734]
GAB2	OTBFN705	Strong	Genetic Variation	[735]
GADD45A	OTDRV63V	Strong	Biomarker	[736]
GAS7	OT0M5TNY	Strong	Genetic Variation	[737]
GEN1	OT1XFQXF	Strong	Biomarker	[738]
GFI1	OT9HB9H8	Strong	Biomarker	[739]
GFI1B	OTRDW8YO	Strong	Genetic Variation	[740]
GIPC1	OTXLVCPJ	Strong	Altered Expression	[741]
GLIS2	OTOUUV1X	Strong	Altered Expression	[742]
GNL3	OTILGYO4	Strong	Biomarker	[743]
GPHN	OTAKK1SV	Strong	Biomarker	[744]
GPR180	OT2P0XNK	Strong	Biomarker	[745]
GPRC5A	OTPOCWR7	Strong	Posttranslational Modification	[746]
GSTK1	OTDNGWAF	Strong	Genetic Variation	[476]
GYPA	OTABU4YV	Strong	Genetic Variation	[747]
GYPB	OTESHUIX	Strong	Genetic Variation	[747]
GYPE	OTBHAG6A	Strong	Genetic Variation	[747]
H2AX	OT18UX57	Strong	Posttranslational Modification	[748]
H2AZ1	OT3KJJNQ	Strong	Biomarker	[387]
H4C1	OTB71W46	Strong	Altered Expression	[749]
HERPUD1	OT9EROL6	Strong	Genetic Variation	[428]
HFE	OTDD93KB	Strong	Genetic Variation	[750]
HIP1	OT7AKCFQ	Strong	Altered Expression	[751]
HLA-C	OTV38BUJ	Strong	Biomarker	[752]
HLA-DPB1	OTW8JHU2	Strong	Genetic Variation	[753]
HLF	OTTRK9XN	Strong	Biomarker	[754]
HMMR	OT4M0JTZ	Strong	Biomarker	[755]
HOXA1	OTMSOJ7D	Strong	Biomarker	[756]
HOXA3	OTIX5XFB	Strong	Genetic Variation	[332]
HOXA4	OTNVTQDT	Strong	Genetic Variation	[332]
HOXA6	OTHJP8M2	Strong	Genetic Variation	[332]
HOXB1	OTGC0EKI	Strong	Altered Expression	[757]
HOXB2	OTTD6HMV	Strong	Altered Expression	[757]
HOXB4	OTH1HRW5	Strong	Biomarker	[758]
HOXB5	OTU74TB8	Strong	Altered Expression	[757]
HOXB6	OT3TFQ0U	Strong	Altered Expression	[757]
HOXB7	OTC7WYU8	Strong	Altered Expression	[757]
HOXB8	OTKHOD17	Strong	Altered Expression	[757]
HOXB9	OTMVHQOU	Strong	Altered Expression	[757]
HOXC10	OT5WF17M	Strong	Biomarker	[759]
HOXD13	OTWSC8TF	Strong	Biomarker	[760]
HSPA4L	OT181WZB	Strong	Altered Expression	[761]
HTN3	OTEUXA81	Strong	Biomarker	[762]
IER3	OTZJI5FZ	Strong	Altered Expression	[763]
IGF2BP1	OT9G360P	Strong	Altered Expression	[764]
IGF2BP2	OT4ZSEEE	Strong	Biomarker	[765]
IGF2BP3	OTB97VIK	Strong	Biomarker	[765]
IGFBP4	OT2HZRBD	Strong	Biomarker	[766]
IL2RG	OTRZ3OMY	Strong	Altered Expression	[767]
IL3	OT0CQ35N	Strong	Biomarker	[768]
INTS3	OT7NX4CD	Strong	Biomarker	[385]
IRF4	OT1DHQ1P	Strong	Altered Expression	[769]
JARID2	OT14UM8H	Strong	Biomarker	[770]
KAT8	OT5LPQTR	Strong	Biomarker	[771]
KIR2DS4	OT00N6UJ	Strong	Biomarker	[772]
KIR2DS5	OTXLEN11	Strong	Biomarker	[773]
KLF1	OT1FK08U	Strong	Altered Expression	[774]
KLF2	OTIP1UFX	Strong	Biomarker	[298]
KMT2C	OTC59BCO	Strong	Genetic Variation	[775]
KRT20	OT4RB40L	Strong	Biomarker	[376]
KYAT3	OTO4U2QK	Strong	Biomarker	[776]
L3MBTL1	OT8M52QY	Strong	Genetic Variation	[777]
LDB1	OT20EAPR	Strong	Biomarker	[778]
LIG4	OT40DNXU	Strong	Altered Expression	[779]
LIMS1	OT729S0T	Strong	Biomarker	[780]
LLGL1	OTAIQSXZ	Strong	Biomarker	[781]
LPXN	OTUNV3CK	Strong	Biomarker	[782]
LRSAM1	OTOKWR6C	Strong	Genetic Variation	[783]
LXN	OTZQ2M6Y	Strong	Posttranslational Modification	[784]
MAGED4B	OTO37U7W	Strong	Altered Expression	[368]
MAGEF1	OTUU40U3	Strong	Altered Expression	[785]
MAGT1	OTQSAV5C	Strong	Biomarker	[245]
MARCHF8	OTH7PNN2	Strong	Genetic Variation	[786]
MARCKSL1	OT13J2FM	Strong	Altered Expression	[787]
MATK	OTVOJJLJ	Strong	Biomarker	[361]
MBD2	OTUQPP0R	Strong	Biomarker	[788]
MBD3	OTRL76H5	Strong	Biomarker	[528]
MCM3	OTOOHQPM	Strong	Altered Expression	[789]
ME2	OTO4LL76	Strong	Biomarker	[790]
MED15	OT0D0JVD	Strong	Posttranslational Modification	[746]
MEF2D	OT7CEIG0	Strong	Genetic Variation	[791]
MEIS2	OTG4ADLM	Strong	Biomarker	[792]
METTL14	OT6TPQMH	Strong	Biomarker	[582]
METTL3	OTSXP1M3	Strong	Biomarker	[793]
MLC1	OTCNZLSP	Strong	Posttranslational Modification	[794]
MLF1	OTC5BKHU	Strong	Biomarker	[795]
MLLT3	OTXH4DDG	Strong	Biomarker	[796]
MLXIP	OT30UNI7	Strong	Genetic Variation	[786]
MLXIPL	OTR9MLLW	Strong	Biomarker	[797]
MNAT1	OTXLOYCB	Strong	Biomarker	[798]
MNX1	OTXP9FH1	Strong	Biomarker	[799]
MOV10	OT0KAY9G	Strong	Biomarker	[800]
MRE11	OTGU8TZM	Strong	Biomarker	[537]
MRPS30	OTDXIAGG	Strong	Altered Expression	[410]
MRTFA	OTCVXASM	Strong	Biomarker	[531]
MS4A3	OT0CEJOO	Strong	Biomarker	[801]
MSX1	OT5U41ZP	Strong	Biomarker	[802]
MTPAP	OT6HQ02S	Strong	Altered Expression	[410]
MVP	OTJGHJRB	Strong	Biomarker	[803]
MYBL2	OTZ3JX8Q	Strong	Biomarker	[804]
MYLIP	OTL0PFGV	Strong	Genetic Variation	[786]
MYOD1	OTV2S79X	Strong	Biomarker	[531]
NANOG	OTUEY1FM	Strong	Genetic Variation	[805]
NCOR1	OT04XNOU	Strong	Genetic Variation	[806]
NCOR2	OTY917X0	Strong	Genetic Variation	[807]
NCR3	OT20M764	Strong	Biomarker	[808]
NFAT5	OTKIE59S	Strong	Biomarker	[809]
NFATC3	OTYOORME	Strong	Biomarker	[809]
NLRP2	OTJA81JU	Strong	Genetic Variation	[810]
NOG	OTGRHHPG	Strong	Biomarker	[811]
NOX5	OTHTH59G	Strong	Biomarker	[812]
NRARP	OTMYHUV2	Strong	Biomarker	[813]
NUDCD1	OT8DS3CX	Strong	Altered Expression	[515]
NUP98	OTNT12G2	Strong	Genetic Variation	[814]
OLIG2	OTMCN6D3	Strong	Altered Expression	[815]
P2RX5	OTLBR20R	Strong	Altered Expression	[388]
PACSIN2	OTC2R00C	Strong	Genetic Variation	[816]
PAFAH1B1	OT9T2TCJ	Strong	Biomarker	[817]
PAPOLA	OTPHD65D	Strong	Altered Expression	[410]
PARP4	OTXBK59G	Strong	Altered Expression	[818]
PBX3	OT8WMVM4	Strong	Genetic Variation	[819]
PCDH10	OT2GIT0E	Strong	Posttranslational Modification	[820]
PDAP1	OTJSWMOD	Strong	Altered Expression	[410]
PDIK1L	OTISF4KG	Strong	Genetic Variation	[821]
PGP	OT6QQ7OR	Strong	Biomarker	[822]
PHB2	OTCAX3AW	Strong	Altered Expression	[823]
PHC1	OT1JMX8U	Strong	Altered Expression	[824]
PHF6	OT8DXI40	Strong	Biomarker	[568]
PI4K2B	OT0D51QP	Strong	Biomarker	[825]
PIAS1	OTZVAHZI	Strong	Biomarker	[826]
PIP4K2A	OTO9JO9U	Strong	Biomarker	[827]
PKD2	OTIXBU8H	Strong	Biomarker	[828]
PLEKHB1	OTC7TNAX	Strong	Biomarker	[416]
PMAIP1	OTXEE550	Strong	Biomarker	[829]
PMEPA1	OTY8Z9UF	Strong	Altered Expression	[830]
POGLUT1	OTDX7GZD	Strong	Altered Expression	[831]
POU2F1	OTK7ELJ0	Strong	Biomarker	[420]
POU3F1	OTYARA94	Strong	Biomarker	[421]
POU4F1	OTMHYGWQ	Strong	Biomarker	[832]
PPBP	OT1FHGQS	Strong	Genetic Variation	[833]
PPP2R5C	OTF7CGO2	Strong	Biomarker	[834]
PRAM1	OTZN3DWD	Strong	Biomarker	[835]
PRDM1	OTQLSVBS	Strong	Biomarker	[836]
PRDM14	OTWZKY4L	Strong	Biomarker	[837]
PRDM2	OT8L7CGX	Strong	Genetic Variation	[838]
PRRX1	OTTZK5G8	Strong	Biomarker	[839]
PTPRA	OTZA82J1	Strong	Biomarker	[803]
PTPRO	OTFLKWOY	Strong	Genetic Variation	[840]
QRSL1	OTJDU2UG	Strong	Biomarker	[841]
RAB40B	OTCA9ZF5	Strong	Altered Expression	[842]
RAB8A	OTPB54Y3	Strong	Biomarker	[843]
RAC2	OTAOHFNH	Strong	Altered Expression	[844]
RAD50	OTYMU9G1	Strong	Biomarker	[537]
RAD52	OT0OTDHI	Strong	Altered Expression	[845]
RAG1	OTV131E4	Strong	Biomarker	[846]
RANGAP1	OTZGD3LJ	Strong	Altered Expression	[847]
RAP1GAP	OTC31ONQ	Strong	Biomarker	[848]
RARRES1	OTETUPP5	Strong	Posttranslational Modification	[746]
RASGRF1	OTNWJ7EN	Strong	Altered Expression	[849]
RBM15	OT8ZPGWF	Strong	Biomarker	[850]
RBMXL1	OTMGCWWB	Strong	Biomarker	[776]
RECQL4	OT59LSW7	Strong	Biomarker	[720]
RFC1	OT3L5PK3	Strong	Biomarker	[851]
RGCC	OTYJMLWM	Strong	Altered Expression	[852]
RGPD2	OTMUZ0HX	Strong	Genetic Variation	[653]
RHOXF2	OTKQWLKZ	Strong	Biomarker	[853]
RNASE3	OTVE2XD1	Strong	Biomarker	[854]
RNF20	OT9NK6ZT	Strong	Biomarker	[855]
ROPN1L	OTRWZJ68	Strong	Biomarker	[248]
RPN1	OTEG4KU9	Strong	Genetic Variation	[856]
RTEL1	OTI3PJCT	Strong	Biomarker	[857]
RUVBL2	OTGWJ4T4	Strong	Biomarker	[858]
S100A11	OTI57KDN	Strong	Altered Expression	[319]
SACM1L	OT6ORKTD	Strong	Biomarker	[859]
SALL4	OTC08PR5	Strong	Altered Expression	[860]
SAMHD1	OTBCIBC7	Strong	Biomarker	[861]
SEMG1	OT6Z4BPQ	Strong	Biomarker	[695]
SERP2	OT5GA6JZ	Strong	Genetic Variation	[862]
SERPINA4	OTBK0GG7	Strong	Biomarker	[863]
SET	OTGYYQJO	Strong	Biomarker	[505]
SETD1A	OTVVWRIC	Strong	Biomarker	[864]
SETX	OTG3JNOQ	Strong	Biomarker	[865]
SFRP5	OTLCVVSH	Strong	Biomarker	[866]
SGK3	OTQ6QO99	Strong	Biomarker	[615]
SH3BP4	OTVIRKW7	Strong	Biomarker	[867]
SHB	OTF2HSC0	Strong	Biomarker	[607]
SLC12A9	OTR7VRAK	Strong	Altered Expression	[868]
SMAD5	OTQNSVCQ	Strong	Biomarker	[869]
SMARCA5	OT5GR4Z2	Strong	Biomarker	[870]
SMARCD2	OTQTBWHW	Strong	Biomarker	[871]
SMC4	OTEJE6AG	Strong	Biomarker	[872]
SMCHD1	OTBV52DR	Strong	Altered Expression	[873]
SMPX	OTLSHGBF	Strong	Altered Expression	[701]
SMYD5	OTE5VET6	Strong	Altered Expression	[874]
SNF8	OTRQA2AI	Strong	Biomarker	[875]
SOAT1	OTB4Y5RJ	Strong	Biomarker	[876]
SOCS5	OTN1ABYR	Strong	Altered Expression	[877]
SON	OT9VWV18	Strong	Altered Expression	[878]
SOX6	OTT0W0LE	Strong	Biomarker	[879]
SOX7	OTOZOFAG	Strong	Altered Expression	[880]
SP100	OTN8SD5W	Strong	Biomarker	[881]
SPAG9	OT45AHMB	Strong	Genetic Variation	[882]
SPANXB1	OTLMGC9T	Strong	Genetic Variation	[883]
SPG7	OT8OY9ST	Strong	Biomarker	[267]
SPI1	OTVCA1D0	Strong	Altered Expression	[884]
SPIB	OTO4YKYI	Strong	Altered Expression	[885]
SPINK6	OTYKZANJ	Strong	Biomarker	[863]
SRI	OT4R3EAC	Strong	Altered Expression	[886]
STIM2	OTYNXAW0	Strong	Biomarker	[887]
SUV39H2	OTU0F4LL	Strong	Altered Expression	[888]
SWT1	OTY4AFM1	Strong	Biomarker	[889]
TAL1	OTX4K6QZ	Strong	Altered Expression	[890]
TALDO1	OTDKV2S2	Strong	Genetic Variation	[783]
TCF7	OT1ID822	Strong	Altered Expression	[891]
TCN2	OT41D0L3	Strong	Altered Expression	[892]
TEF	OTY3LAD9	Strong	Altered Expression	[893]
TELO2	OT2YQ9L8	Strong	Altered Expression	[724]
TES	OTL8PP6V	Strong	Biomarker	[894]
TESC	OTI8C76M	Strong	Altered Expression	[895]
TFCP2	OTA246TE	Strong	Altered Expression	[896]
TFPT	OTM70AK1	Strong	Altered Expression	[897]
TFR2	OTMYCCEO	Strong	Altered Expression	[898]
TGFBI	OTR443C5	Strong	Altered Expression	[899]
THUMPD1	OTKU8KWH	Strong	Genetic Variation	[900]
TIGAR	OTR7NMRJ	Strong	Biomarker	[901]
TLX1	OTVN0MNW	Strong	Biomarker	[902]
TMEM132D	OTV6I4Z0	Strong	Genetic Variation	[903]
TNFRSF10C	OTVHOL9B	Strong	Posttranslational Modification	[904]
TNFRSF10D	OTOSRDJT	Strong	Genetic Variation	[904]
TRAF1	OTTLM5RU	Strong	Biomarker	[905]
TRIM13	OTQIUACB	Strong	Biomarker	[267]
TRIM5	OTMZH7EJ	Strong	Biomarker	[906]
TRIM62	OT15YO6N	Strong	Altered Expression	[907]
TRPV5	OTWF4L0U	Strong	Biomarker	[449]
TSC22D3	OT03UM03	Strong	Biomarker	[908]
TSGA10	OTIF1O1T	Strong	Altered Expression	[909]
ARL6IP5	OTYZ6BEQ	Definitive	Genetic Variation	[910]
CBFA2T3	OTOJ10S1	Definitive	Biomarker	[837]
CSNK2A3	OTZP4KZK	Definitive	Altered Expression	[911]
DTX2	OT7QLDU4	Definitive	Genetic Variation	[912]
FCHSD2	OTKXLIJ6	Definitive	Altered Expression	[913]
FLVCR1	OT9XCFOC	Definitive	Genetic Variation	[914]
FMOD	OT9EJ5H8	Definitive	Biomarker	[915]
GPX3	OT6PK94R	Definitive	Posttranslational Modification	[916]
HEMGN	OTZPYUOY	Definitive	Altered Expression	[917]
KDM2B	OTDMCVW7	Definitive	Biomarker	[918]
KDM3B	OTZU5J5S	Definitive	Biomarker	[919]
LARP6	OTUQ9QS9	Definitive	Altered Expression	[920]
MACROD1	OTWFEVRW	Definitive	Biomarker	[921]
OPN1LW	OTFNUZ7O	Definitive	Genetic Variation	[922]
PAG1	OTFOJUIQ	Definitive	Genetic Variation	[922]
PCBP4	OTDLL4NB	Definitive	Genetic Variation	[922]
POLM	OT0SRIP4	Definitive	Altered Expression	[923]
PRDM16	OT0BGA27	Definitive	Biomarker	[924]
STAG2	OTR6X1Q7	Definitive	Genetic Variation	[925]
TEAD1	OTK6971C	Definitive	Biomarker	[926]
TFPI2	OTZCRWOR	Definitive	Biomarker	[926]
TLE1	OT50MRZ1	Definitive	Biomarker	[927]
TOX	OTE8BL5Z	Definitive	Biomarker	[928]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 210259
• [2] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7044).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 913).
• [5] ClinicalTrials.gov (NCT02421588) Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients. U.S. National Institutes of Health.
• [6] Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for ... Trials. 2015 Mar 4;16:77.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7090).
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [9] ClinicalTrials.gov (NCT02039726) An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects. U.S. National Institutes of Health.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040192)
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] ClinicalTrials.gov (NCT01309126) Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer. U.S. National Institutes of Health.
• [13] Clinical pipeline report, company report or official report of Sanofi.
• [14] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7814).
• [16] ClinicalTrials.gov (NCT02040090) Phase II/III Study of the Safety and Effectiveness of HRIG With Co-administration of Active Rabies Vaccine in Healthy Subjects. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT00058747) AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec . U.S. National Institutes of Health.
• [18] ClinicalTrials.gov (NCT01206335) Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [20] ClinicalTrials.gov (NCT01626495) Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
• [21] ClinicalTrials.gov (NCT02071862) Study of the Glutaminase Inhibitor CB-839 in Solid Tumors. U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT02132624) CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7745).
• [24] ClinicalTrials.gov (NCT01445587) A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [25] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [26] Targeting G-quadruplexes in gene promoters: a novel anticancer strategy . Nat Rev Drug Discov. 2011 April; 10(4): 261-275.
• [27] ClinicalTrials.gov (NCT00936468) Safety, Tolerability and Immunogenicity of Fluzone With and Without JVRS-100 in Elderly Subjects. U.S. National Institutes of Health.
• [28] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032981)
• [29] ClinicalTrials.gov (NCT00391066) Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL). U.S. National Institutes of Health.
• [30] ClinicalTrials.gov (NCT01974479) Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia. U.S. National Institutes of Health.
• [31] ClinicalTrials.gov (NCT01122784) Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant. U.S. National Institutes of Health.
• [32] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019680)
• [33] ClinicalTrials.gov (NCT01266083) Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL). U.S. National Institutes of Health.
• [34] Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995 Feb 15;85(4):1122-31.
• [35] ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
• [36] More Than 900 Medicines and Vaccines in Clinical Testing Offer New Hope in the Fight Against Cancer. Pharmaceutical Research and Manufacturers of America report. 2012.
• [37] ClinicalTrials.gov (NCT02954445) A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
• [38] ClinicalTrials.gov (NCT02937103) A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
• [39] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [40] ClinicalTrials.gov (NCT02672501) A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
• [41] ClinicalTrials.gov (NCT02710149) A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies
• [42] ClinicalTrials.gov (NCT03262298) Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
• [43] ClinicalTrials.gov (NCT02958410) A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
• [44] More Than 450 Medicines in Development for Rare Diseases. Pharmaceutical Research and Manufacturers of America report. 2013.
• [45] ClinicalTrials.gov (NCT02963038) CAR T Cells for Refractory B Cell Malignancy
• [46] ClinicalTrials.gov (NCT00285103) SPC2996 in Chronic Lymphocytic Leukaemia. U.S. National Institutes of Health.
• [47] ClinicalTrials.gov (NCT02933320) BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia. U.S. National Institutes of Health.
• [48] ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
• [49] ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
• [50] ClinicalTrials.gov (NCT02537977) CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy
• [51] ClinicalTrials.gov (NCT02935153) A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
• [52] ClinicalTrials.gov (NCT02349698) A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
• [53] ClinicalTrials.gov (NCT03142646) Safety and Efficacy Evaluation of IM19 CAR-T Cells
• [54] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041076)
• [55] ClinicalTrials.gov (NCT00302861) A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL). U.S. National Institutes of Health.
• [56] ClinicalTrials.gov (NCT03594955) First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome. U.S. National Institutes of Health.
• [57] ClinicalTrials.gov (NCT03684889) CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
• [58] ClinicalTrials.gov (NCT03166878) A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
• [59] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033385)
• [60] ClinicalTrials.gov (NCT01287858) Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects. U.S. National Institutes of Health.
• [61] ClinicalTrials.gov (NCT02848911) Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL. U.S. National Institutes of Health.
• [62] ClinicalTrials.gov (NCT02799550) Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL
• [63] ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [64] ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
• [65] ClinicalTrials.gov (NCT01593696) Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
• [66] ClinicalTrials.gov (NCT02546739) Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
• [67] ClinicalTrials.gov (NCT03144583) Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
• [68] ClinicalTrials.gov (NCT02641002) A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health.
• [69] ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
• [70] ClinicalTrials.gov (NCT02529813) CD19+ CAR T Cells for Lymphoid Malignancies
• [71] ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
• [72] ClinicalTrials.gov (NCT03599375) Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
• [73] ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
• [74] ClinicalTrials.gov (NCT03244306) A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma
• [75] ClinicalTrials.gov (NCT02284971) Pilot Study of SBRT and CDX-1127 in Prostate Cancer. U.S. National Institutes of Health.
• [76] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027936)
• [77] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031973)
• [78] ClinicalTrials.gov (NCT02374333) Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
• [79] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007636)
• [80] ClinicalTrials.gov (NCT03383952) A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
• [81] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039238)
• [82] Clinical pipeline report, company report or official report of IN8bio.
• [83] J Clin Oncol 29: 2011 (suppl, abstr 6516).
• [84] ClinicalTrials.gov (NCT00313053) Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia. U.S. National Institutes of Health.
• [85] ClinicalTrials.gov (NCT01976520) Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL). U.S. National Institutes of Health.
• [86] ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma
• [87] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033111)
• [88] ClinicalTrials.gov (NCT00009841) Gene Therapy in Treating Patients With Advanced Head and Neck Cancer. U.S. National Institutes of Health.
• [89] ClinicalTrials.gov (NCT02194374) Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
• [90] Clinical pipeline report, company report or official report of Ziopharm Oncology.
• [91] ClinicalTrials.gov (NCT00526838) Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies. U.S. National Institutes of Health.
• [92] ClinicalTrials.gov (NCT03624686) Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies
• [93] ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
• [94] ClinicalTrials.gov (NCT03564977) CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
• [95] ClinicalTrials.gov (NCT02813837) Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
• [96] Drug information of Aminopterin, Health Canada, 2007.
• [97] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006739)
• [98] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7983).
• [99] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020067)
• [100] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014824)
• [101] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003885)
• [102] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000791)
• [103] Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
• [104] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021088)
• [105] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004286)
• [106] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013916)
• [107] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003068)
• [108] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026172)
• [109] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004584)
• [110] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7377).
• [111] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4934).
• [112] The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood. 2010 Mar 18;115(11):2251-9.
• [113] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
• [114] The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.Mutat Res. 2009 Mar 9;662(1-2):67-74. doi: 10.1016/j.mrfmmm.2008.12.010. Epub 2008 Dec 31.
• [115] Plexin-B2 Mediates Physiologic and Pathologic Functions of Angiogenin.Cell. 2017 Nov 2;171(4):849-864.e25. doi: 10.1016/j.cell.2017.10.005.
• [116] Expression and modulation of annexin VIII in human leukemia-lymphoma cell lines.Leuk Res. 1993 Nov;17(11):949-57. doi: 10.1016/0145-2126(93)90042-j.
• [117] Effects of polymorphic DNA genes involved in BER and caspase pathways on the clinical outcome of myeloproliferative neoplasms under treatment with hydroxyurea.Mol Med Rep. 2018 Dec;18(6):5243-5255. doi: 10.3892/mmr.2018.9535. Epub 2018 Oct 8.
• [118] BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.J Exp Med. 2011 Oct 24;208(11):2163-74. doi: 10.1084/jem.20110304. Epub 2011 Sep 12.
• [119] BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment.J Clin Invest. 2019 Feb 21;129(5):1878-1894. doi: 10.1172/JCI120654. Print 2019 May 1.
• [120] Frameshift mutations in caspase-5 and other target genes in leukemia and lymphoma cell lines having microsatellite instability.Leuk Res. 2003 Apr;27(4):359-61. doi: 10.1016/s0145-2126(02)00215-1.
• [121] Osteolineage cells and regulation of the hematopoietic stem cell.Best Pract Res Clin Haematol. 2013 Sep;26(3):249-52. doi: 10.1016/j.beha.2013.10.004. Epub 2013 Oct 16.
• [122] Multiple myeloma secondary to acute lymphoblastic leukemia: A case report.Medicine (Baltimore). 2019 Jan;98(1):e14018. doi: 10.1097/MD.0000000000014018.
• [123] The outer membrane protein Tp92 of Treponema pallidum induces human mononuclear cell death and IL-8 secretion.J Cell Mol Med. 2018 Dec;22(12):6039-6054. doi: 10.1111/jcmm.13879. Epub 2018 Sep 14.
• [124] High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.Leuk Res. 2017 Jul;58:31-38. doi: 10.1016/j.leukres.2017.04.001. Epub 2017 Apr 4.
• [125] A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.Blood. 2017 Nov 30;130(22):2410-2419. doi: 10.1182/blood-2017-04-777052. Epub 2017 Oct 17.
• [126] Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy.Methods Mol Biol. 2019;1895:57-73. doi: 10.1007/978-1-4939-8922-5_5.
• [127] IL-15/IL-15R/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.Blood Adv. 2018 Nov 27;2(22):3177-3192. doi: 10.1182/bloodadvances.2018019026.
• [128] CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.Leukemia. 2019 Jul;33(7):1608-1619. doi: 10.1038/s41375-019-0382-3. Epub 2019 Jan 24.
• [129] Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.J Hematol Oncol. 2016 Feb 18;9:12. doi: 10.1186/s13045-016-0241-x.
• [130] Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells.Mol Cancer. 2014 Jun 10;13:147. doi: 10.1186/1476-4598-13-147.
• [131] Endoplasmic reticulum stress differentially modulates the IL-6 family of cytokines in murine astrocytes and macrophages.Sci Rep. 2019 Oct 17;9(1):14931. doi: 10.1038/s41598-019-51481-6.
• [132] Prognostic gene alterations and clonal changes in childhood B-ALL.Leuk Res. 2019 Aug;83:106159. doi: 10.1016/j.leukres.2019.05.009. Epub 2019 Jun 8.
• [133] A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.Cancer Res. 2018 Dec 15;78(24):6762-6770. doi: 10.1158/0008-5472.CAN-18-1638. Epub 2018 Oct 22.
• [134] CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.Int J Mol Sci. 2019 Jun 5;20(11):2764. doi: 10.3390/ijms20112764.
• [135] Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model.Cancer Lett. 2020 Jan 28;469:151-161. doi: 10.1016/j.canlet.2019.10.032. Epub 2019 Oct 24.
• [136] The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells.Cell Rep. 2019 Apr 2;27(1):238-254.e6. doi: 10.1016/j.celrep.2019.03.009.
• [137] Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 Are Associated with Early Age Acute Leukemia.PLoS One. 2015 May 18;10(5):e0127308. doi: 10.1371/journal.pone.0127308. eCollection 2015.
• [138] Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.Pharmacol Res. 2007 Apr;55(4):343-9. doi: 10.1016/j.phrs.2007.01.003. Epub 2007 Jan 16.
• [139] RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation.Exp Hematol. 2007 Apr;35(4):572-8. doi: 10.1016/j.exphem.2007.01.049.
• [140] Alternative splicing generates a diacylglycerol kinase transcript that acts as a dominant-negative modulator of superoxide production in localized aggressive periodontitis.J Periodontol. 2014 Jul;85(7):934-43. doi: 10.1902/jop.2013.130468. Epub 2013 Oct 30.
• [141] Overexpression of DICER1 induced by the upregulation of GATA1 contributes to the proliferation and apoptosis of leukemia cells.Int J Oncol. 2013 Apr;42(4):1317-24. doi: 10.3892/ijo.2013.1831. Epub 2013 Feb 19.
• [142] Structural Basis of Dot1L Stimulation by Histone H2B Lysine 120Ubiquitination.Mol Cell. 2019 Jun 6;74(5):1010-1019.e6. doi: 10.1016/j.molcel.2019.03.029. Epub 2019 Apr 10.
• [143] c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals.Blood. 2017 Dec 21;130(25):2739-2749. doi: 10.1182/blood-2017-02-769463. Epub 2017 Oct 27.
• [144] Nuclear, not cytoplasmic, PKR maneuvers in AML.Blood. 2015 Sep 24;126(13):1523-4. doi: 10.1182/blood-2015-08-661421.
• [145] CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.Epigenetics Chromatin. 2018 Jun 8;11(1):30. doi: 10.1186/s13072-018-0197-x.
• [146] FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Blood. 2010 Nov 4;116(18):3622-6. doi: 10.1182/blood-2010-05-283648. Epub 2010 Jul 23.
• [147] Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.Nat Commun. 2019 Nov 7;10(1):5051. doi: 10.1038/s41467-019-12960-6.
• [148] Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors.Cancer Cell. 2018 Feb 12;33(2):274-291.e8. doi: 10.1016/j.ccell.2018.01.006.
• [149] Intravascular Colonization of Kaposi Sarcoma: Expanding the Spectrum of Specific Infiltrates of B-Cell Chronic Lymphocytic Leukemia.Am J Dermatopathol. 2019 Dec;41(12):940-944. doi: 10.1097/DAD.0000000000001481.
• [150] DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4).BMC Cancer. 2012 Jan 17;12:19. doi: 10.1186/1471-2407-12-19.
• [151] MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/-catenin pathway in acute myeloid leukemia.J Exp Clin Cancer Res. 2019 May 16;38(1):200. doi: 10.1186/s13046-019-1179-y.
• [152] Natural Killer Cells Offer Differential Protection From Leukemia in Chinese Southern Han.Front Immunol. 2019 Jul 16;10:1646. doi: 10.3389/fimmu.2019.01646. eCollection 2019.
• [153] HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.Leukemia. 2018 Jan;32(1):49-60. doi: 10.1038/leu.2017.174. Epub 2017 Jun 5.
• [154] HLA-G peptide preferences change in transformed cells: impact on the binding motif.Immunogenetics. 2018 Aug;70(8):485-494. doi: 10.1007/s00251-018-1058-2. Epub 2018 Mar 30.
• [155] Chronic myelogenous leukemia cells remodel the bone marrow niche via exosome-mediated transfer of miR-320.Theranostics. 2019 Jul 28;9(19):5642-5656. doi: 10.7150/thno.34813. eCollection 2019.
• [156] Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias.Blood Adv. 2019 Dec 10;3(23):3962-3967. doi: 10.1182/bloodadvances.2019000731.
• [157] Gene mutation profile and risk stratification in AML1ETOpositive acute myeloid leukemia based on nextgeneration sequencing.Oncol Rep. 2019 Dec;42(6):2333-2344. doi: 10.3892/or.2019.7375. Epub 2019 Oct 15.
• [158] LIFR-CT3 induces differentiation of a human acute myelogenous leukemia cell line HL-60 by suppressing miR-155 expression through the JAK/STAT pathway.Leuk Res. 2014 Oct;38(10):1237-44. doi: 10.1016/j.leukres.2014.07.004. Epub 2014 Jul 22.
• [159] ORP4L Extracts and Presents PIP(2) from Plasma Membrane for PLC3 Catalysis: Targeting It Eradicates Leukemia Stem Cells.Cell Rep. 2019 Feb 19;26(8):2166-2177.e9. doi: 10.1016/j.celrep.2019.01.082.
• [160] Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):431-440.e13. doi: 10.1016/j.clml.2019.03.015. Epub 2019 Mar 26.
• [161] MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.JCI Insight. 2018 Nov 2;3(21):e97941. doi: 10.1172/jci.insight.97941.
• [162] Effect of a nutrient mixture on matrix metalloproteinase-9 dimers in various human cancer cell lines.Int J Oncol. 2014 Mar;44(3):986-92. doi: 10.3892/ijo.2013.2235. Epub 2013 Dec 30.
• [163] Flow cytometric false myeloperoxidase-positive childhood B-lineage acute lymphoblastic leukemia.Cytometry B Clin Cytom. 2018 May;94(3):477-483. doi: 10.1002/cyto.b.21613. Epub 2018 Jan 17.
• [164] CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy.J Hematol Oncol. 2019 Nov 8;12(1):113. doi: 10.1186/s13045-019-0819-1.
• [165] MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer.J Biol Chem. 2001 Nov 30;276(48):45137-44. doi: 10.1074/jbc.M106127200. Epub 2001 Sep 20.
• [166] L-myc and N-myc in hematopoietic malignancies.Leuk Lymphoma. 1993 Oct;11(3-4):197-205. doi: 10.3109/10428199309086996.
• [167] The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.Cell Cycle. 2019 Sep;18(18):2307-2322. doi: 10.1080/15384101.2019.1646068. Epub 2019 Jul 26.
• [168] Effects of the NQO1 609C>T polymorphism on leukemia susceptibility: evidence from a meta-analysis.Asian Pac J Cancer Prev. 2013;14(9):5311-6. doi: 10.7314/apjcp.2013.14.9.5311.
• [169] Understanding PIM-1 kinase inhibitor interactions with free energy simulation.Phys Chem Chem Phys. 2019 Apr 3;21(14):7544-7558. doi: 10.1039/c9cp00070d.
• [170] Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells.J Pediatr Hematol Oncol. 2019 Aug;41(6):e359-e370. doi: 10.1097/MPH.0000000000001416.
• [171] SIL-TAL1 rearrangement is related with poor outcome: a study from a Chinese institution.PLoS One. 2013 Sep 9;8(9):e73865. doi: 10.1371/journal.pone.0073865. eCollection 2013.
• [172] Promyelocytic leukemia protein in mesenchymal stem cells is essential for leukemia progression.Ann Hematol. 2018 Oct;97(10):1749-1755. doi: 10.1007/s00277-018-3463-x. Epub 2018 Aug 1.
• [173] Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation.Eur J Med Chem. 2019 Feb 15;164:317-333. doi: 10.1016/j.ejmech.2018.12.065. Epub 2018 Dec 26.
• [174] STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.Blood Adv. 2018 Sep 11;2(17):2199-2213. doi: 10.1182/bloodadvances.2018021063.
• [175] DNA Aptamers in the Detection of Leukemia Cells by the Thickness Shear Mode Acoustics Method.Chemphyschem. 2019 Feb 18;20(4):545-554. doi: 10.1002/cphc.201801126. Epub 2019 Feb 6.
• [176] DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.Cancers (Basel). 2019 Jun 23;11(6):877. doi: 10.3390/cancers11060877.
• [177] RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia.Hum Pathol. 2018 Oct;80:82-86. doi: 10.1016/j.humpath.2018.02.023. Epub 2018 Mar 10.
• [178] Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha.Oncotarget. 2017 Mar 21;8(12):20103-20112. doi: 10.18632/oncotarget.15384.
• [179] The cyclohexene derivative MC-3129 exhibits antileukemic activity via RhoA/ROCK1/PTEN/PI3K/Akt pathway-mediated mitochondrial translocation of cofilin.Cell Death Dis. 2018 May 29;9(6):656. doi: 10.1038/s41419-018-0689-4.
• [180] Tunicamycin promotes apoptosis in leukemia cells through ROS generation and downregulation of survivin expression.Apoptosis. 2015 Aug;20(8):1087-98. doi: 10.1007/s10495-015-1135-z.
• [181] p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.Blood. 2011 Jun 23;117(25):6885-94. doi: 10.1182/blood-2010-10-315721. Epub 2011 Apr 28.
• [182] p38 and JNK pathways control E-selectin-dependent extravasation of colon cancer cells by modulating miR-31 transcription.Oncotarget. 2017 Jan 3;8(1):1678-1687. doi: 10.18632/oncotarget.13779.
• [183] Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.Crit Rev Oncol Hematol. 2019 Jan;133:74-83. doi: 10.1016/j.critrevonc.2018.07.013. Epub 2018 Aug 3.
• [184] PI3K p110 inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.J Clin Invest. 2019 Jan 2;129(1):122-136. doi: 10.1172/JCI99386. Epub 2018 Nov 19.
• [185] Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia.Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24252-24258. doi: 10.1073/pnas.1913695116. Epub 2019 Nov 13.
• [186] Megakaryocyte and polyploidization.Exp Hematol. 2018 Jan;57:1-13. doi: 10.1016/j.exphem.2017.10.001. Epub 2017 Oct 27.
• [187] Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen.Leukemia. 2009 Oct;23(10):1818-24. doi: 10.1038/leu.2009.138. Epub 2009 Jul 16.
• [188] Expression and function of the transient receptor potential ion channel family in the hematologic malignancies.Curr Mol Pharmacol. 2013 Nov;6(3):137-48. doi: 10.2174/187446720603140415215431.
• [189] A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis.Haematologica. 2016 Apr;101(4):417-26. doi: 10.3324/haematol.2015.125336. Epub 2015 Nov 26.
• [190] Effect of tyrosinase and caffeic acid crosslinking of turbot parvalbumin on the digestibility, and release of mediators and cytokines from activated RBL-2H3 cells.Food Chem. 2019 Dec 1;300:125209. doi: 10.1016/j.foodchem.2019.125209. Epub 2019 Jul 20.
• [191] Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality.JCI Insight. 2019 Oct 3;4(19):e127716. doi: 10.1172/jci.insight.127716.
• [192] Role of ZNF224 in cell growth and chemoresistance of chronic lymphocitic leukemia.Hum Mol Genet. 2017 Jan 15;26(2):344-353. doi: 10.1093/hmg/ddw427.
• [193] CDA gene silencing regulated the proliferation and apoptosis of chronic myeloid leukemia K562 cells.Cancer Cell Int. 2018 Jul 9;18:96. doi: 10.1186/s12935-018-0587-y. eCollection 2018.
• [194] Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin.Blood. 2016 May 12;127(19):2322-6. doi: 10.1182/blood-2015-11-677708. Epub 2016 Mar 4.
• [195] High Expression of ABL2 Suppresses Apoptosis in Gastric Cancer.Dig Dis Sci. 2018 Sep;63(9):2294-2300. doi: 10.1007/s10620-018-5111-7. Epub 2018 May 16.
• [196] Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms. J Exp Clin Cancer Res. 2019 Jul 15;38(1):308. doi: 10.1186/s13046-019-1295-8.
• [197] Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK/c-Jun-mediated BCL2L1 expression.Toxicol Appl Pharmacol. 2015 Apr 1;284(1):33-41. doi: 10.1016/j.taap.2015.02.005. Epub 2015 Feb 12.
• [198] Cigarette smoke induces rat testicular injury via mitochondrial apoptotic pathway.Mol Reprod Dev. 2017 Oct;84(10):1053-1065. doi: 10.1002/mrd.22863.
• [199] Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.Clin Cancer Res. 2012 Feb 1;18(3):783-95. doi: 10.1158/1078-0432.CCR-11-1166. Epub 2011 Dec 15.
• [200] Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.Blood. 2017 Jan 12;129(2):177-187. doi: 10.1182/blood-2016-05-707653. Epub 2016 Oct 24.
• [201] Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.Cell Physiol Biochem. 2018;51(1):262-277. doi: 10.1159/000495228. Epub 2018 Nov 19.
• [202] Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.Cell. 2016 Sep 22;167(1):171-186.e15. doi: 10.1016/j.cell.2016.08.057. Epub 2016 Sep 15.
• [203] Transcriptional Selectivity of Epigenetic Therapy in Cancer.Cancer Res. 2017 Jan 15;77(2):470-481. doi: 10.1158/0008-5472.CAN-16-0834. Epub 2016 Nov 22.
• [204] The role of chlorine atom on the binding between 2-phenyl-1H-benzimidazole analogues and fat mass and obesity-associated protein.J Mol Recognit. 2019 Jun;32(6):e2774. doi: 10.1002/jmr.2774. Epub 2018 Dec 21.
• [205] Cx25 contributes to leukemia cell communication and chemosensitivity.Oncotarget. 2015 Oct 13;6(31):31508-21. doi: 10.18632/oncotarget.5226.
• [206] Visualization of ligand-induced G(i)-protein activation in chemotaxing cells.FASEB J. 2017 Mar;31(3):910-919. doi: 10.1096/fj.201601102R. Epub 2016 Nov 23.
• [207] Immunogenicity moderation effect of interleukin-24 on myelogenous leukemia cells.Anticancer Drugs. 2018 Apr;29(4):353-363. doi: 10.1097/CAD.0000000000000606.
• [208] Mechanisms and consequences of constitutive activation of integrin-linked kinase in acute myeloid leukemia.Cytokine Growth Factor Rev. 2018 Oct;43:1-7. doi: 10.1016/j.cytogfr.2018.06.001. Epub 2018 Jun 7.
• [209] Leukemia growth is inhibited by benzoxime without causing any harmful effect in rats bearing RBL-1 enotransplants.Oncol Lett. 2019 Feb;17(2):1934-1938. doi: 10.3892/ol.2018.9783. Epub 2018 Nov 30.
• [210] ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.Cancer Cell. 2018 Mar 12;33(3):495-511.e12. doi: 10.1016/j.ccell.2018.02.002. Epub 2018 Mar 1.
• [211] Suv4-20h1 promotes G1 to S phase transition by downregulating p21(WAF1/CIP1) expression in chronic myeloid leukemia K562 cells.Oncol Lett. 2018 May;15(5):6123-6130. doi: 10.3892/ol.2018.8092. Epub 2018 Feb 21.
• [212] CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.Hum Vaccin Immunother. 2015;11(7):1606-11. doi: 10.1080/21645515.2015.1046658.
• [213] Doubling Down on Mutant RAS Can MEK or Break Leukemia.Cell. 2017 Feb 23;168(5):749-750. doi: 10.1016/j.cell.2017.02.013.
• [214] HMGB1 regulates erastin-induced ferroptosis via RAS-JNK/p38 signaling in HL-60/NRAS(Q61L) cells.Am J Cancer Res. 2019 Apr 1;9(4):730-739. eCollection 2019.
• [215] RNAi-mediated knockdown of MCM7 gene on CML cells and its therapeutic potential for leukemia.Med Oncol. 2017 Feb;34(2):21. doi: 10.1007/s12032-016-0878-x. Epub 2017 Jan 5.
• [216] c-MPL Is a Candidate Surface Marker and Confers Self-Renewal, Quiescence, Chemotherapy Resistance, and Leukemia Initiation Potential in Leukemia Stem Cells.Stem Cells. 2018 Nov;36(11):1685-1696. doi: 10.1002/stem.2897. Epub 2018 Sep 5.
• [217] Transcriptome-wide analysis uncovers the targets of the RNA-binding protein MSI2 and effects of MSI2's RNA-binding activity on IL-6 signaling.J Biol Chem. 2018 Oct 5;293(40):15359-15369. doi: 10.1074/jbc.RA118.002243. Epub 2018 Aug 20.
• [218] Targeting neuropilin-1 in human leukemia and lymphoma.Blood. 2011 Jan 20;117(3):920-7. doi: 10.1182/blood-2010-05-282921. Epub 2010 Nov 9.
• [219] Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.Haematologica. 2014 Sep;99(9):1465-71. doi: 10.3324/haematol.2013.100917. Epub 2014 Jun 20.
• [220] Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin.Oncogene. 2017 Jan 12;36(2):254-262. doi: 10.1038/onc.2016.196. Epub 2016 Jun 6.
• [221] Reducing the serine availability complements the inhibition of the glutamine metabolism to block leukemia cell growth.Oncotarget. 2016 Jan 12;7(2):1765-76. doi: 10.18632/oncotarget.6426.
• [222] The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.J Pediatr Surg. 2019 Jun;54(6):1206-1213. doi: 10.1016/j.jpedsurg.2019.02.029. Epub 2019 Feb 28.
• [223] A novel specific cleavage of IB protein in acute myeloid leukemia cells involves protease PR3.Exp Cell Res. 2019 Sep 1;382(1):111441. doi: 10.1016/j.yexcr.2019.05.022. Epub 2019 May 22.
• [224] Erythroleukemia cells acquire an alternative mitophagy capability.Sci Rep. 2016 Apr 19;6:24641. doi: 10.1038/srep24641.
• [225] Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.J Clin Invest. 2016 Feb;126(2):585-98. doi: 10.1172/JCI83535.
• [226] Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells.Cancer Lett. 2016 Nov 28;382(2):215-230. doi: 10.1016/j.canlet.2016.08.016. Epub 2016 Sep 6.
• [227] Recent Advances in the Function of the 67 kDa Laminin Receptor and its Targeting for Personalized Therapy in Cancer.Curr Pharm Des. 2017;23(32):4745-4757. doi: 10.2174/1381612823666170710125332.
• [228] Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia.Oncotarget. 2016 Nov 8;7(45):73769-73780. doi: 10.18632/oncotarget.12063.
• [229] Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.J Biol Chem. 2015 May 15;290(20):12558-71. doi: 10.1074/jbc.M114.626960. Epub 2015 Mar 23.
• [230] SET and MYND domain containing protein 3 in cancer.Am J Transl Res. 2017 Jan 15;9(1):1-14. eCollection 2017.
• [231] Upregulation of miR-513b inhibits cell proliferation, migration, and promotes apoptosis by targeting high mobility group-box 3 protein in gastric cancer.Tumour Biol. 2014 Nov;35(11):11081-9. doi: 10.1007/s13277-014-2405-z. Epub 2014 Aug 6.
• [232] Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.Oncotarget. 2016 Sep 13;7(37):60074-60086. doi: 10.18632/oncotarget.11054.
• [233] Doxorubicin effects on leukemia and breast cancer cells in culture on the TK1 protein levels using AroCell TK 210 ELISA: a tool for drug development.Nucleosides Nucleotides Nucleic Acids. 2018;37(12):679-686. doi: 10.1080/15257770.2018.1478094. Epub 2018 Dec 6.
• [234] Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.Mol Ther. 2013 Apr;21(4):877-86. doi: 10.1038/mt.2013.11. Epub 2013 Feb 5.
• [235] Characterization of interaction between Trim28 and YY1 in silencing proviral DNA of Moloney murine leukemia virus.Virology. 2018 Mar;516:165-175. doi: 10.1016/j.virol.2018.01.012.
• [236] Inhibition of USP10 induces degradation of oncogenic FLT3.Nat Chem Biol. 2017 Dec;13(12):1207-1215. doi: 10.1038/nchembio.2486. Epub 2017 Oct 2.
• [237] Selective induction of cancer cell death by VDAC1-based peptides and their potential use in cancer therapy.Mol Oncol. 2018 Jun;12(7):1077-1103. doi: 10.1002/1878-0261.12313. Epub 2018 May 19.
• [238] Inhibition of X-linked inhibitor of apoptosis protein enhances anti-tumor potency of pure total flavonoids on the growth of leukemic cells.Exp Ther Med. 2018 Feb;15(2):2020-2026. doi: 10.3892/etm.2017.5627. Epub 2017 Dec 14.
• [239] Arsenic trioxide circumvents multidrug resistance based on different mechanisms in human leukemia cell lines.Anticancer Res. 2005 Mar-Apr;25(2A):991-8.
• [240] Lack of the multidrug transporter MRP4/ABCC4 defines the PEL-negative blood group and impairs platelet aggregation.Blood. 2020 Feb 6;135(6):441-448. doi: 10.1182/blood.2019002320.
• [241] Hydroquinone-induced FOXP3-ADAM17-Lyn-Akt-p21 signaling axis promotes malignant progression of human leukemia U937 cells.Arch Toxicol. 2017 Feb;91(2):983-997. doi: 10.1007/s00204-016-1753-4. Epub 2016 Jun 15.
• [242] Mapping transcription mechanisms from multimodal genomic data.BMC Bioinformatics. 2010 Oct 28;11 Suppl 9(Suppl 9):S2. doi: 10.1186/1471-2105-11-S9-S2.
• [243] Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells.J Exp Med. 2007 May 14;204(5):1157-66. doi: 10.1084/jem.20062662. Epub 2007 May 7.
• [244] Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells.Int J Biochem Cell Biol. 2005 Aug;37(8):1709-26. doi: 10.1016/j.biocel.2005.03.004. Epub 2005 Apr 26.
• [245] Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities.Leukemia. 2014 Jul;28(7):1414-22. doi: 10.1038/leu.2014.56. Epub 2014 Feb 3.
• [246] A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.Pharmacogenet Genomics.2014 Feb;24(2):129-32.
• [247] Pectenotoxin-2 represses telomerase activity in human leukemia cells through suppression of hTERT gene expression and Akt-dependent hTERT phosphorylation.FEBS Lett. 2008 Oct 15;582(23-24):3263-9. doi: 10.1016/j.febslet.2008.08.030. Epub 2008 Sep 5.
• [248] Growth inhibitory and proapoptotic effects of l-asparaginase from Fusarium culmorum ASP-87 on human leukemia cells (Jurkat).Fundam Clin Pharmacol. 2017 Jun;31(3):292-300. doi: 10.1111/fcp.12257. Epub 2016 Dec 30.
• [249] Effect of chemical modification with carboxymethyl dextran on kinetic and structural properties of L-asparaginase.Anal Biochem. 2020 Feb 15;591:113537. doi: 10.1016/j.ab.2019.113537. Epub 2019 Dec 9.
• [250] AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia.Mol Cancer Ther. 2011 Mar;10(3):437-47. doi: 10.1158/1535-7163.MCT-10-0777. Epub 2011 Jan 24.
• [251] Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase.Blood Adv. 2018 May 22;2(10):1157-1169. doi: 10.1182/bloodadvances.2017015214.
• [252] AURKA Suppresses Leukemic THP-1 Cell Differentiation through Inhibition of the KDM6B Pathway.Mol Cells. 2018 May 31;41(5):444-453. doi: 10.14348/molcells.2018.2311. Epub 2018 Feb 23.
• [253] The Deubiquitinating Enzyme USP14 Regulates Leukemic Chemotherapy Drugs-Induced Cell Apoptosis by Suppressing Ubiquitination of Aurora Kinase B.Cell Physiol Biochem. 2017;42(3):965-973. doi: 10.1159/000478679. Epub 2017 Jun 27.
• [254] ABL regulation by AXL promotes cisplatin resistance in esophageal cancer.Cancer Res. 2013 Jan 1;73(1):331-40. doi: 10.1158/0008-5472.CAN-12-3151. Epub 2012 Nov 1.
• [255] BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification.Mol Cancer. 2013 Jun 12;12:61. doi: 10.1186/1476-4598-12-61.
• [256] Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma.Blood. 2010 Apr 29;115(17):3559-69. doi: 10.1182/blood-2009-08-236760. Epub 2010 Feb 25.
• [257] Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.Oncotarget. 2016 Jan 19;7(3):2765-79. doi: 10.18632/oncotarget.6409.
• [258] MOZ and MORF acetyltransferases: Molecular interaction, animal development and human disease.Biochim Biophys Acta. 2015 Aug;1853(8):1818-26. doi: 10.1016/j.bbamcr.2015.04.014. Epub 2015 Apr 25.
• [259] shRNA-mediated EMMPRIN silencing inhibits human leukemic monocyte lymphoma U937 cell proliferation and increases chemosensitivity to adriamycin.Cell Biochem Biophys. 2015 Mar;71(2):827-35. doi: 10.1007/s12013-014-0270-4.
• [260] The role of the structural domains of human BST-2 in inhibiting the release of xenotropic murine leukemia virus-related virus.Biochem Biophys Res Commun. 2012 Nov 9;428(1):17-23. doi: 10.1016/j.bbrc.2012.10.001. Epub 2012 Oct 6.
• [261] Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.Exp Hematol. 2018 Apr;60:57-62.e3. doi: 10.1016/j.exphem.2018.01.006. Epub 2018 Feb 8.
• [262] Genetics in community-acquired pneumonia.Curr Opin Pulm Med. 2019 May;25(3):323-329. doi: 10.1097/MCP.0000000000000580.
• [263] hBUB1 defects in leukemia and lymphoma cells.Oncogene. 2002 Jul 11;21(30):4673-9. doi: 10.1038/sj.onc.1205585.
• [264] An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.Haematologica. 2017 Jan;102(1):79-84. doi: 10.3324/haematol.2016.149765. Epub 2016 Sep 29.
• [265] A caspase-2-RFXANK interaction and its implication for MHC class II expression.Cell Death Dis. 2018 Jan 23;9(2):80. doi: 10.1038/s41419-017-0144-y.
• [266] Association between CASP7 and CASP14 genetic polymorphisms and the risk of childhood leukemia.Hum Immunol. 2012 Jul;73(7):736-9. doi: 10.1016/j.humimm.2012.04.017. Epub 2012 Apr 28.
• [267] Allogeneic CAR T cell therapies for leukemia.Am J Hematol. 2019 May;94(S1):S50-S54. doi: 10.1002/ajh.25399. Epub 2019 Feb 1.
• [268] CBX7 Induces Self-Renewal of Human Normal and Malignant Hematopoietic Stem and Progenitor Cells by Canonical and Non-canonical Interactions.Cell Rep. 2019 Feb 12;26(7):1906-1918.e8. doi: 10.1016/j.celrep.2019.01.050.
• [269] NGF inhibits human leukemia proliferation by downregulating cyclin A1 expression through promoting acinus/CtBP2 association.Oncogene. 2009 Oct 29;28(43):3825-36. doi: 10.1038/onc.2009.236. Epub 2009 Aug 10.
• [270] Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia.J Leukoc Biol. 2016 Jun;99(6):1077-87. doi: 10.1189/jlb.5MA0915-394R. Epub 2016 Mar 1.
• [271] Phenotype, genotype and cytokine production in acute leukemia involving progenitors of dendritic Langerhans' cells.Leuk Res. 1994 Jul;18(7):499-511. doi: 10.1016/0145-2126(94)90088-4.
• [272] Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.Clin Cancer Res. 2019 Sep 1;25(17):5329-5341. doi: 10.1158/1078-0432.CCR-18-3784. Epub 2019 May 20.
• [273] ETV6/RUNX1-like acute lymphoblastic leukemia: A novel B-cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype.Genes Chromosomes Cancer. 2017 Aug;56(8):608-616. doi: 10.1002/gcc.22464. Epub 2017 May 5.
• [274] The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10.
• [275] Distinct breakpoints in band 11q23 of the t(4;11) and t(11;14) associated with leukocyte malignancy.Genes Chromosomes Cancer. 1992 Jul;5(1):50-6. doi: 10.1002/gcc.2870050108.
• [276] CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.Cancer Cell. 2019 Mar 18;35(3):473-488.e6. doi: 10.1016/j.ccell.2019.02.006.
• [277] Comparative sequence analysis of a region on human chromosome 13q14, frequently deleted in B-cell chronic lymphocytic leukemia, and its homologous region on mouse chromosome 14.Genomics. 2000 Dec 15;70(3):327-34. doi: 10.1006/geno.2000.6386.
• [278] CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.Blood. 2017 Jul 20;130(3):297-309. doi: 10.1182/blood-2016-12-756585. Epub 2017 May 11.
• [279] Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion.Blood. 2000 Apr 15;95(8):2725-7.
• [280] Knockdown of HOXA10 reverses the multidrug resistance of human chronic mylogenous leukemia K562/ADM cells by downregulating P-gp and MRP-1.Int J Mol Med. 2016 May;37(5):1405-11. doi: 10.3892/ijmm.2016.2539. Epub 2016 Mar 24.
• [281] Cis-trimethoxy resveratrol induces intrinsic apoptosis via prometaphase arrest and prolonged CDK1 activation pathway in human Jurkat T cells.Oncotarget. 2017 Dec 22;9(4):4969-4984. doi: 10.18632/oncotarget.23576. eCollection 2018 Jan 12.
• [282] miR-638 regulates differentiation and proliferation in leukemic cells by targeting cyclin-dependent kinase 2.J Biol Chem. 2015 Jan 16;290(3):1818-28. doi: 10.1074/jbc.M114.599191. Epub 2014 Dec 1.
• [283] Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.Eur J Med Chem. 2018 May 25;152:264-273. doi: 10.1016/j.ejmech.2018.04.048. Epub 2018 Apr 28.
• [284] A kinase-independent role for CDK8 in BCR-ABL1(+) leukemia.Nat Commun. 2019 Oct 18;10(1):4741. doi: 10.1038/s41467-019-12656-x.
• [285] Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.Eur J Med Chem. 2018 Oct 5;158:896-916. doi: 10.1016/j.ejmech.2018.09.025. Epub 2018 Sep 13.
• [286] The natural anti-tumor compound Celastrol targets a Myb-C/EBP-p300 transcriptional module implicated in myeloid gene expression.PLoS One. 2018 Feb 2;13(2):e0190934. doi: 10.1371/journal.pone.0190934. eCollection 2018.
• [287] The CLEC12A receptor marks human basophils: Potential implications for minimal residual disease detection in acute myeloid leukemia.Cytometry B Clin Cytom. 2018 May;94(3):520-526. doi: 10.1002/cyto.b.21540. Epub 2017 Aug 11.
• [288] L233P mutation in the bovine leukemia virus Tax protein depresses endothelial cell recruitment and tumorigenesis in athymic nude mice.Arch Virol. 2019 May;164(5):1343-1351. doi: 10.1007/s00705-019-04191-3. Epub 2019 Mar 8.
• [289] Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress.Clin Cancer Res. 2017 Aug 1;23(15):4450-4461. doi: 10.1158/1078-0432.CCR-16-2426. Epub 2017 Mar 7.
• [290] Intracellular storage and regulated plasma membrane expression of human complement receptor type 1 in rat basophil leukemia cell transfectants.Blood. 1998 Jul 1;92(1):300-9.
• [291] Quantitative comparison of Epstein-Barr virus receptor expression on sIgM and sIgG cell lines and B-cell lymphoma biopsies.Differentiation. 1982;22(2):113-9. doi: 10.1111/j.1432-0436.1982.tb01234.x.
• [292] Cytogenetic and molecular profile of endometrial stromal sarcoma.Genes Chromosomes Cancer. 2016 Nov;55(11):834-46. doi: 10.1002/gcc.22380. Epub 2016 Aug 9.
• [293] The human CAS (cellular apoptosis susceptibility) gene mapping on chromosome 20q13 is amplified in BT474 breast cancer cells and part of aberrant chromosomes in breast and colon cancer cell lines.Genome Res. 1996 Mar;6(3):187-94. doi: 10.1101/gr.6.3.187.
• [294] Colony stimulating factor-1 and leukemia inhibitor factor expression from current-cycle cannula isolated endometrial cells are associated with increased endometrial receptivity and pregnancy.BMC Womens Health. 2017 Aug 22;17(1):63. doi: 10.1186/s12905-017-0418-7.
• [295] Ets1 Plays a Critical Role in MLL/EB1-Mediated Leukemic Transformation in a Mouse Bone Marrow Transplantation Model.Neoplasia. 2019 May;21(5):469-481. doi: 10.1016/j.neo.2019.03.006. Epub 2019 Apr 8.
• [296] Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.Blood. 2010 Feb 18;115(7):1433-43. doi: 10.1182/blood-2009-06-227413. Epub 2009 Dec 9.
• [297] Lentivirus-mediated down-regulation of CK2 inhibits proliferation and induces apoptosis of malignant lymphoma and leukemia cells.Biochem Cell Biol. 2018 Dec;96(6):786-796. doi: 10.1139/bcb-2017-0345. Epub 2018 May 17.
• [298] Genomic and transcriptome analysis revealing an oncogenic functional module in meningiomas.Neurosurg Focus. 2013 Dec;35(6):E3. doi: 10.3171/2013.10.FOCUS13326.
• [299] All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia.Leukemia. 1996 Jan;10(1):95-101.
• [300] Genetic polymorphism of CYP3A5 in Indian chronic myeloid leukemia patients.Mol Cell Biochem. 2010 Mar;336(1-2):49-54. doi: 10.1007/s11010-009-0268-1. Epub 2009 Oct 13.
• [301] Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides.Anticancer Drugs. 2000 Apr;11(4):285-94. doi: 10.1097/00001813-200004000-00010.
• [302] T cell receptor delta gene rearrangements occur predominantly in immature myeloid leukemias exhibiting lineage promiscuity.Leukemia. 1990 Feb;4(2):100-5.
• [303] Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia.Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3070-5. doi: 10.1073/pnas.042702899. Epub 2002 Feb 26.
• [304] Loss of Dnmt3a and Dnmt3b does not affect epidermal homeostasis but promotes squamous transformation through PPAR-.Elife. 2017 Apr 20;6:e21697. doi: 10.7554/eLife.21697.
• [305] Methyltransferase DNMT3B in leukemia.Leuk Lymphoma. 2020 Feb;61(2):263-273. doi: 10.1080/10428194.2019.1666377. Epub 2019 Sep 24.
• [306] Sumoylation and the function of CCAAT enhancer binding protein alpha (C/EBP alpha).Blood Cells Mol Dis. 2008 Jul-Aug;41(1):77-81. doi: 10.1016/j.bcmd.2008.02.011. Epub 2008 Apr 10.
• [307] A blood pact: the significance and implications of eIF4E on lymphocytic leukemia.Physiol Res. 2018 Jul 17;67(3):363-382. doi: 10.33549/physiolres.933696. Epub 2018 Mar 12.
• [308] miR?5a?p affects the proliferation, migration and apoptosis of lens epithelial cells.Mol Med Rep. 2019 Feb;19(2):1110-1116. doi: 10.3892/mmr.2018.9738. Epub 2018 Dec 11.
• [309] Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide.Eur J Med Chem. 2019 Jan 1;161:594-606. doi: 10.1016/j.ejmech.2018.10.042. Epub 2018 Oct 23.
• [310] Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma. 2006 Aug;47(8):1629-38. doi: 10.1080/10428190600625398.
• [311] High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia.Int J Hematol. 2016 Feb;103(2):189-95. doi: 10.1007/s12185-015-1913-y. Epub 2015 Nov 26.
• [312] Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.Leukemia. 1998 Jun;12(6):845-59. doi: 10.1038/sj.leu.2401043.
• [313] Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.Mol Med Rep. 2015 Jun;11(6):4605-10. doi: 10.3892/mmr.2015.3288. Epub 2015 Jan 30.
• [314] Autoantigen inhibits apoptosis of a human B cell leukemia that produces pathogenic rheumatoid factor.J Immunol. 1993 Dec 15;151(12):7273-83.
• [315] T cell receptor alpha-chain gene rearrangements in B-precursor leukemia are in contrast to the findings in T cell acute lymphoblastic leukemia. Comparative study of T cell receptor gene rearrangement in childhood leukemia.J Clin Invest. 1987 Dec;80(6):1770-7. doi: 10.1172/JCI113270.
• [316] K562 leukemia cells transfected with the human c-fes gene acquire the ability to undergo myeloid differentiation.J Biol Chem. 1989 Jun 15;264(17):10276-81.
• [317] GRS, a novel member of the Bcl-2 gene family, is highly expressed in multiple cancer cell lines and in normal leukocytes.Oncogene. 1997 Feb 27;14(8):997-1001. doi: 10.1038/sj.onc.1200898.
• [318] FMNL1 promotes proliferation and migration of leukemia cells.J Leukoc Biol. 2013 Sep;94(3):503-12. doi: 10.1189/jlb.0113057. Epub 2013 Jun 25.
• [319] Expression profiles of signal transduction genes in ex vivo drug-resistant pediatric acute lymphoblastic leukemia.Anticancer Res. 2012 Feb;32(2):503-6.
• [320] Cryptic FUS-ERG fusion identified by RNA-sequencing in childhood acute myeloid leukemia.Oncol Rep. 2013 Dec;30(6):2587-92. doi: 10.3892/or.2013.2751. Epub 2013 Sep 25.
• [321] Involvement of alpha 1-2-fucosyltransferase I (FUT1) and surface-expressed Lewis(y) (CD174) in first endothelial cell-cell contacts during angiogenesis.J Cell Physiol. 2008 Apr;215(1):27-36. doi: 10.1002/jcp.21285.
• [322] Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia.Biochem Pharmacol. 2017 Mar 15;128:12-25. doi: 10.1016/j.bcp.2016.12.022. Epub 2016 Dec 30.
• [323] Down regulation of G protein-coupled receptor 137 expression inhibits proliferation and promotes apoptosis in leukemia cells.Cancer Cell Int. 2018 Jan 29;18:13. doi: 10.1186/s12935-018-0507-1. eCollection 2018.
• [324] Identification of Leukemia Subtypes from Microscopic Images Using Convolutional Neural Network.Diagnostics (Basel). 2019 Aug 25;9(3):104. doi: 10.3390/diagnostics9030104.
• [325] Role of alpha class glutathione transferases (GSTs) in chemoprevention: GSTA1 and A4 overexpressing human leukemia (HL60) cells resist sulforaphane and curcumin induced toxicity.Phytother Res. 2011 Apr;25(4):563-8. doi: 10.1002/ptr.3297. Epub 2010 Sep 20.
• [326] Genetic heterogeneity in severe congenital neutropenia: how many aberrant pathways can kill a neutrophil?.Curr Opin Allergy Clin Immunol. 2007 Dec;7(6):481-94. doi: 10.1097/ACI.0b013e3282f1d690.
• [327] The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.Cell Death Dis. 2015 Feb 12;6(2):e1635. doi: 10.1038/cddis.2014.594.
• [328] The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia.Oncogene. 2018 May;37(19):2559-2572. doi: 10.1038/s41388-018-0143-1. Epub 2018 Feb 22.
• [329] Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis.Hum Pathol. 2006 Apr;37(4):439-47. doi: 10.1016/j.humpath.2005.11.015. Epub 2006 Feb 7.
• [330] Coexpression of B-lymphoma Moloney murine leukemia virus insertion region-1 and sex-determining region of Y chromosome-related high mobility group box-2 in cervical carcinogenesis.Hum Pathol. 2013 Feb;44(2):208-17. doi: 10.1016/j.humpath.2012.02.020. Epub 2012 Aug 3.
• [331] Transcription factor expression in B-cell precursor-leukemia cell lines: preferential expression of T-bet.Leuk Res. 2005 Jul;29(7):841-8. doi: 10.1016/j.leukres.2004.12.010. Epub 2005 Feb 24.
• [332] Lineage and stage specific expression of HOX 1 genes in the human hematopoietic system.Biochem Biophys Res Commun. 1992 Mar 31;183(3):1124-30. doi: 10.1016/s0006-291x(05)80307-9.
• [333] Effect of silencing HOXA5 gene expression using RNA interference on cell cycle and apoptosis in Jurkat cells.Int J Mol Med. 2016 Mar;37(3):669-78. doi: 10.3892/ijmm.2016.2480. Epub 2016 Feb 4.
• [334] The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1366-72. doi: 10.1158/1055-9965.EPI-15-0247. Epub 2015 Jun 24.
• [335] Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia.Nat Med. 2018 Aug;24(8):1157-1166. doi: 10.1038/s41591-018-0105-8. Epub 2018 Jul 23.
• [336] Neferine in the LotusPlumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro.J Food Sci. 2019 Apr;84(4):904-910. doi: 10.1111/1750-3841.14484. Epub 2019 Mar 13.
• [337] HSPB8 is methylated in hematopoietic malignancies and overexpression of HSPB8 exhibits antileukemia effect.Exp Hematol. 2012 Jan;40(1):14-21. doi: 10.1016/j.exphem.2011.09.004. Epub 2011 Sep 10.
• [338] AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.Cancer Discov. 2017 May;7(5):478-493. doi: 10.1158/2159-8290.CD-16-1034. Epub 2017 Feb 13.
• [339] The PKR-Like Endoplasmic Reticulum Kinase Promotes the Dissemination of Myc-Induced Leukemic Cells.Mol Cancer Res. 2019 Jul;17(7):1450-1458. doi: 10.1158/1541-7786.MCR-19-0002. Epub 2019 Mar 22.
• [340] IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival.Cell Death Dis. 2014 Jun 26;5(6):e1300. doi: 10.1038/cddis.2014.268.
• [341] Runx1 is essential at two stages of early murine B-cell development.Blood. 2013 Jul 18;122(3):413-23. doi: 10.1182/blood-2013-01-480244. Epub 2013 May 23.
• [342] Cellular therapy: Adoptive immunotherapy with expanded natural killer cells.Immunol Rev. 2019 Jul;290(1):85-99. doi: 10.1111/imr.12793.
• [343] Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation.Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9802-7. doi: 10.1073/pnas.171309898. Epub 2001 Aug 7.
• [344] IFNG +874 A/T is associated with acute lymphoblastic leukemia in Mexican Mestizos.Cytokine. 2018 Nov;111:265-271. doi: 10.1016/j.cyto.2018.08.014. Epub 2018 Sep 11.
• [345] IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.Blood. 2019 Dec 12;134(24):2171-2182. doi: 10.1182/blood.2019000982.
• [346] Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling.Cell Signal. 2012 Nov;24(11):2095-101. doi: 10.1016/j.cellsig.2012.07.017. Epub 2012 Jul 20.
• [347] Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.Leukemia. 2018 Nov;32(11):2374-2387. doi: 10.1038/s41375-018-0112-2. Epub 2018 Mar 29.
• [348] Expression of interferon regulatory factor 1 and 2 in hematopoietic cells of children with juvenile myelomonocytic leukemia.Leuk Lymphoma. 1999 Nov;35(5-6):507-11. doi: 10.1080/10428199909169615.
• [349] Cross talk between Wnt/-catenin and Irf8 in leukemia progression and drug resistance.J Exp Med. 2013 Oct 21;210(11):2239-56. doi: 10.1084/jem.20130706. Epub 2013 Oct 7.
• [350] The increased expression of integrin 6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.PLoS One. 2012;7(1):e30706. doi: 10.1371/journal.pone.0030706. Epub 2012 Jan 25.
• [351] Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia.Blood Adv. 2019 May 14;3(9):1499-1511. doi: 10.1182/bloodadvances.2018026054.
• [352] Cytogenetic and Cytogenomic Microarray Characterization of Chromothripsis in Chromosome 8 Affecting MOZ/NCOA2 (TIF2), FGFR1, RUNX1T1, and RUNX1 in a Pediatric Acute Myeloid Leukemia.J Pediatr Hematol Oncol. 2017 May;39(4):e227-e232. doi: 10.1097/MPH.0000000000000770.
• [353] Expression, purification, and analysis of MOZ and MORF histone acetyltransferases.Methods. 2003 Sep;31(1):24-32. doi: 10.1016/s1046-2023(03)00084-7.
• [354] Eag1 channels as potential cancer biomarkers.Sensors (Basel). 2012;12(5):5986-95. doi: 10.3390/s120505986. Epub 2012 May 10.
• [355] Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia.Med Oncol. 2018 Nov 13;36(1):3. doi: 10.1007/s12032-018-1226-0.
• [356] Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities.Blood Adv. 2019 Nov 12;3(21):3307-3321. doi: 10.1182/bloodadvances.2019030981.
• [357] Down-regulation of JARID1B expression inhibits cell proliferation, induces apoptosis and blocks cell cycle in human acute lymphoblastic leukemia cells.Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1366-1373. doi: 10.26355/eurrev_201803_14480.
• [358] Novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia.Blood. 2011 Aug 4;118(5):1323-8. doi: 10.1182/blood-2010-10-313791. Epub 2011 May 25.
• [359] Induction of kinase suppressor of RAS-1(KSR-1) gene by 1, alpha25-dihydroxyvitamin D3 in human leukemia HL60 cells through a vitamin D response element in the 5'-flanking region.Oncogene. 2006 Nov 9;25(53):7078-85. doi: 10.1038/sj.onc.1209697. Epub 2006 May 29.
• [360] Self-inactivating MLV vectors have a reduced genotoxic profile in human epidermal keratinocytes.Gene Ther. 2013 Sep;20(9):949-57. doi: 10.1038/gt.2013.18. Epub 2013 Apr 25.
• [361] Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells.Cancer Cell. 2008 May;13(5):432-40. doi: 10.1016/j.ccr.2008.03.005.
• [362] Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia.Cancer Cell. 2012 Oct 16;22(4):524-35. doi: 10.1016/j.ccr.2012.08.028.
• [363] A physical, transcript, and deletion map of chromosome region 12p12.3 flanked by ETV6 and CDKN1B: hypermethylation of the LRP6 CpG island in two leukemia patients with hemizygous del(12p).Genomics. 1999 Feb 15;56(1):40-50. doi: 10.1006/geno.1998.5685.
• [364] Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.Biochem Biophys Res Commun. 2016 Apr 15;472(4):610-6. doi: 10.1016/j.bbrc.2016.03.018. Epub 2016 Mar 8.
• [365] Detection of exon polymorphisms in the human lactoferrin gene.Biochem Cell Biol. 2002;80(1):17-22. doi: 10.1139/o01-207.
• [366] ALK-activating homologous mutations in LTK induce cellular transformation.PLoS One. 2012;7(2):e31733. doi: 10.1371/journal.pone.0031733. Epub 2012 Feb 9.
• [367] Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.
• [368] Expression of the MAGE gene family in human lymphocytic leukemia.Cancer Immunol Immunother. 1995 Aug;41(2):90-103. doi: 10.1007/s002620050205.
• [369] Inhibition of MEK5 by BIX02188 induces apoptosis in cells expressing the oncogenic mutant FLT3-ITD.Biochem Biophys Res Commun. 2011 Aug 26;412(2):307-12. doi: 10.1016/j.bbrc.2011.07.089. Epub 2011 Jul 28.
• [370] The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11746-50. doi: 10.1073/pnas.92.25.11746.
• [371] Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia.Oncogene. 2017 May 4;36(18):2589-2598. doi: 10.1038/onc.2016.416. Epub 2016 Nov 7.
• [372] Polymorphisms in innate immunity genes and risk of childhood leukemia.Hum Immunol. 2010 Jul;71(7):727-30. doi: 10.1016/j.humimm.2010.04.004. Epub 2010 May 16.
• [373] Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia.Cancers (Basel). 2019 Nov 12;11(11):1779. doi: 10.3390/cancers11111779.
• [374] Mutational landscape of T-cell lymphoma in mice lacking the DNA mismatch repair gene Mlh1: no synergism with ionizing radiation.Carcinogenesis. 2019 Apr 29;40(2):216-224. doi: 10.1093/carcin/bgz013.
• [375] Preparation and identification of a novel immunomodulator composed of muramyl dipeptide and anti-CD10 monoclonal antibody for treatment of minimal residual disease in acute leukemia children.Int Immunopharmacol. 2011 Sep;11(9):1211-9. doi: 10.1016/j.intimp.2011.03.022. Epub 2011 Apr 12.
• [376] 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.J Immunother Cancer. 2019 Jan 29;7(1):22. doi: 10.1186/s40425-019-0509-0.
• [377] Aberrant DNA methylation and epigenetic inactivation of hMSH2 decrease overall survival of acute lymphoblastic leukemia patients via modulating cell cycle and apoptosis.Asian Pac J Cancer Prev. 2014;15(1):355-62. doi: 10.7314/apjcp.2014.15.1.355.
• [378] A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia.Blood. 2011 Jul 14;118(2):390-400. doi: 10.1182/blood-2010-11-316760. Epub 2011 May 19.
• [379] Methionine synthase reductase A66G polymorphism and leukemia risk: evidence from published studies.Leuk Lymphoma. 2014 Aug;55(8):1910-4. doi: 10.3109/10428194.2013.867492. Epub 2014 Jan 24.
• [380] MYB - A regulatory factor in hematopoiesis.Gene. 2018 Jul 30;665:6-17. doi: 10.1016/j.gene.2018.04.065. Epub 2018 Apr 25.
• [381] Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.Leuk Res. 2018 Jun;69:39-46. doi: 10.1016/j.leukres.2018.04.004. Epub 2018 Apr 5.
• [382] NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human.J Clin Invest. 2011 Apr;121(4):1456-70. doi: 10.1172/JCI43242.
• [383] Extracellular NM23-H1 protein inhibits the survival of primary cultured normal human peripheral blood mononuclear cells and activates the cytokine production.Int J Hematol. 2009 Sep;90(2):143-152. doi: 10.1007/s12185-009-0384-4. Epub 2009 Aug 5.
• [384] Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.Oncogene. 2018 Jul;37(28):3839-3851. doi: 10.1038/s41388-018-0234-z. Epub 2018 Apr 12.
• [385] Identification of a gene element essential for leukemia-specific expression of transgenes.Leukemia. 2004 Mar;18(3):415-9. doi: 10.1038/sj.leu.2403260.
• [386] Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm.Asian Pac J Cancer Prev. 2015;16(6):2219-25. doi: 10.7314/apjcp.2015.16.6.2219.
• [387] Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.Leuk Res. 2016 Nov;50:85-94. doi: 10.1016/j.leukres.2016.09.018. Epub 2016 Sep 26.
• [388] Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells.J Immunother. 2009 Jul-Aug;32(6):539-51. doi: 10.1097/CJI.0b013e3181987c22.
• [389] Cloning and chromosomal localization of the human P2Y1 purinoceptor.Biochem Biophys Res Commun. 1996 Jan 26;218(3):783-8. doi: 10.1006/bbrc.1996.0139.
• [390] PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.PLoS Genet. 2019 Aug 5;15(8):e1008280. doi: 10.1371/journal.pgen.1008280. eCollection 2019 Aug.
• [391] PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells.Blood Cells Mol Dis. 2001 Sep-Oct;27(5):825-9. doi: 10.1006/bcmd.2001.0452.
• [392] Detection of minimal residual disease in acute myelogenous leukemia by RNA-in situ hybridization.Bone Marrow Transplant. 1989 Jan;4 Suppl 1:13-5.
• [393] The poor prognosis of the primary gastric epithelioid angiosarcoma: A case report.Medicine (Baltimore). 2018 Apr;97(15):e0287. doi: 10.1097/MD.0000000000010287.
• [394] Platelet factor 4 enhances the adhesion of normal and leukemic hematopoietic stem/progenitor cells to endothelial cells.Leuk Res. 2004 Jun;28(6):631-8. doi: 10.1016/j.leukres.2003.10.028.
• [395] -catenin induces expression of prohibitin gene in acute leukemic cells.Oncol Rep. 2017 Jun;37(6):3201-3208. doi: 10.3892/or.2017.5599. Epub 2017 Apr 25.
• [396] The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer.Biochem Biophys Res Commun. 2014 Aug 15;451(1):119-25. doi: 10.1016/j.bbrc.2014.07.076. Epub 2014 Jul 24.
• [397] Role of PIM2 in allergic asthma.Mol Med Rep. 2017 Nov;16(5):7504-7512. doi: 10.3892/mmr.2017.7499. Epub 2017 Sep 18.
• [398] PLA2R1: expression and function in cancer.Biochim Biophys Acta. 2014 Aug;1846(1):40-4. doi: 10.1016/j.bbcan.2014.03.003. Epub 2014 Mar 22.
• [399] The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.Leuk Lymphoma. 2015 Jul;56(7):2123-33. doi: 10.3109/10428194.2014.971407. Epub 2015 Jan 24.
• [400] A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs.J Immunol. 1999 Nov 1;163(9):4994-5004.
• [401] Knockdown of protein phosphatase 5 (PPP5C) suppresses the growth of leukemic cell line U937.Cell Mol Biol (Noisy-le-grand). 2016 Sep 30;62(11):27-31.
• [402] PRAME peptide-specific CD8(+) Tcells represent the predominant response against leukemia-associated antigens in healthy individuals.Eur J Immunol. 2018 Aug;48(8):1400-1411. doi: 10.1002/eji.201747399. Epub 2018 Jul 8.
• [403] Hemangiopoietin inhibits apoptosis of MO7e leukemia cells through phosphatidylinositol 3-kinase-AKT pathway.Biochem Biophys Res Commun. 2004 Apr 23;317(1):198-204. doi: 10.1016/j.bbrc.2004.03.034.
• [404] PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD(+) acute myeloid leukemia.Blood. 2019 Aug 8;134(6):548-560. doi: 10.1182/blood.2019001282. Epub 2019 Jun 19.
• [405] LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis. Blood. 2018 Jan 4;131(1):95-107.
• [406] The leukemia-associated fusion protein Tel-platelet-derived growth factor receptor (Tel-PdgfR) inhibits transcriptional repression of PTPN13 gene by interferon consensus sequence binding protein (Icsbp).J Biol Chem. 2012 Mar 9;287(11):8110-25. doi: 10.1074/jbc.M111.294884. Epub 2012 Jan 18.
• [407] Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.J Biol Chem. 2019 Aug 16;294(33):12483-12494. doi: 10.1074/jbc.RA119.008666. Epub 2019 Jun 27.
• [408] Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors.Cancer. 1993 Jun 15;71(12):3873-81. doi: 10.1002/1097-0142(19930615)71:12<3873::aid-cncr2820711214>3.0.co;2-1.
• [409] Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway.Leukemia. 2017 May;31(5):1154-1165. doi: 10.1038/leu.2016.287. Epub 2016 Oct 17.
• [410] Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.Leukemia. 1993 Feb;7(2):290-7.
• [411] Clinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia.PLoS One. 2015 Mar 20;10(3):e0119831. doi: 10.1371/journal.pone.0119831. eCollection 2015.
• [412] Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.Haematologica. 2020 Mar;105(3):697-707. doi: 10.3324/haematol.2018.205534. Epub 2019 May 23.
• [413] Expression and Prognosis Analyses of Runt-Related Transcription Factor Family in Human Leukemia.Mol Ther Oncolytics. 2018 Dec 18;12:103-111. doi: 10.1016/j.omto.2018.12.008. eCollection 2019 Mar 29.
• [414] S100A9 induces differentiation of acute myeloid leukemia cells through TLR4.Blood. 2017 Apr 6;129(14):1980-1990. doi: 10.1182/blood-2016-09-738005. Epub 2017 Jan 30.
• [415] Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia.J Natl Compr Canc Netw. 2014 Jul;12(7):963-8. doi: 10.6004/jnccn.2014.0092.
• [416] Functional characterization of L-selectin ligands on human neutrophils and leukemia cell lines: evidence for mucinlike ligand activity distinct from P-selectin glycoprotein ligand-1.Blood. 1998 Feb 1;91(3):1067-75.
• [417] Expression pattern of the septin gene family in acute myeloid leukemias with and without MLL-SEPT fusion genes.Leuk Res. 2010 May;34(5):615-21. doi: 10.1016/j.leukres.2009.08.018. Epub 2009 Sep 12.
• [418] EEN encodes for a member of a new family of proteins containing an Src homology 3 domain and is the third gene located on chromosome 19p13 that fuses to MLL in human leukemia.Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2563-8. doi: 10.1073/pnas.94.6.2563.
• [419] Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.Haematologica. 2018 Jan;103(1):80-90. doi: 10.3324/haematol.2017.176248. Epub 2017 Oct 12.
• [420] Transcription factor Oct1 protects against hematopoietic stress and promotes acute myeloid leukemia.Exp Hematol. 2019 Aug;76:38-48.e2. doi: 10.1016/j.exphem.2019.07.002. Epub 2019 Jul 8.
• [421] Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp Hematol. 2002 Oct;30(10):1162-9.
• [422] Association of Leukemia Target Genes Tet2, Bcl2, and Slc23a2 in Vitamin C Pathways.Cancer Genomics Proteomics. 2019 Sep-Oct;16(5):333-344. doi: 10.21873/cgp.20138.
• [423] Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome.Oncotarget. 2017 Apr 4;8(14):23073-23086. doi: 10.18632/oncotarget.14981.
• [424] PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells. Biochem Biophys Res Commun. 2008 Nov 28;376(4):787-92.
• [425] SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy. J Pediatr Hematol Oncol. 2018 Jul;40(5):e289-e294.
• [426] Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase.Mol Cancer. 2010 Sep 13;9:239. doi: 10.1186/1476-4598-9-239.
• [427] SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress.Oncotarget. 2017 Mar 7;8(10):16712-16727. doi: 10.18632/oncotarget.15147.
• [428] Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.Eur J Med Chem. 2019 Feb 15;164:391-398. doi: 10.1016/j.ejmech.2018.12.059. Epub 2018 Dec 24.
• [429] SOCS3 overexpression enhances ADM resistance in bladder cancer T24 cells.Eur Rev Med Pharmacol Sci. 2017 Jul;21(13):3005-3011.
• [430] Comparative analyses of studies of childhood leukemia and magnetic fields, radon and gamma radiation.J Radiol Prot. 2017 Jun 26;37(2):459-491. doi: 10.1088/1361-6498/aa5fc7. Epub 2017 Jun 6.
• [431] Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
• [432] SRPK1siRNA suppresses K562 cell growth and induces apoptosis via the PARPcaspase3 pathway.Mol Med Rep. 2018 Jan;17(1):2070-2076. doi: 10.3892/mmr.2017.8032. Epub 2017 Nov 13.
• [433] Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340).PLoS One. 2015 Aug 5;10(8):e0134882. doi: 10.1371/journal.pone.0134882. eCollection 2015.
• [434] Stanniocalcin-1 as a novel marker to detect minimal residual disease of human leukemia.Tohoku J Exp Med. 2004 Oct;204(2):125-33. doi: 10.1620/tjem.204.125.
• [435] Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.Mutat Res. 2011 Jun 17;722(2):154-64. doi: 10.1016/j.mrgentox.2010.08.019. Epub 2010 Sep 9.
• [436] Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A.J Korean Med Sci. 2013 Feb;28(2):237-46. doi: 10.3346/jkms.2013.28.2.237. Epub 2013 Jan 29.
• [437] Telomere attrition and chromosome instability via downregulation of TRF2 contributes to arsenic trioxide-induced apoptosis of human T-Cell leukemia cell line molt-4 cells.Cancer Biol Ther. 2007 Aug;6(8):1186-92. doi: 10.4161/cbt.6.8.4381. Epub 2007 May 4.
• [438] Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis.Life Sci. 1992;50(26):2059-65. doi: 10.1016/0024-3205(92)90572-7.
• [439] Expression of TRAIL and its receptor DR5 and their significance in acute leukemia cells.Genet Mol Res. 2015 Dec 28;14(4):18562-8.
• [440] Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival.PLoS One. 2011;6(6):e20787. doi: 10.1371/journal.pone.0020787. Epub 2011 Jun 8.
• [441] Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity.Leukemia. 2015 Feb;29(2):387-95. doi: 10.1038/leu.2014.174. Epub 2014 Jun 3.
• [442] Arrayed molecular barcoding identifies TNFSF13 as a positive regulator of acute myeloid leukemia-initiating cells.Haematologica. 2019 Oct;104(10):2006-2016. doi: 10.3324/haematol.2018.192062. Epub 2019 Feb 28.
• [443] Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38- stem/progenitor cells.Oncogene. 1996 Feb 15;12(4):903-13.
• [444] Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.Sci Signal. 2018 Jul 17;11(539):eaao5617. doi: 10.1126/scisignal.aao5617.
• [445] Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.DNA Repair (Amst). 2020 Jan;85:102747. doi: 10.1016/j.dnarep.2019.102747. Epub 2019 Nov 6.
• [446] Molecular analysis of TCRB and ABL in a t(7;9)-containing cell line (SUP-T3) from a human T-cell leukemia.Proc Natl Acad Sci U S A. 1987 Jan;84(1):251-5. doi: 10.1073/pnas.84.1.251.
• [447] Targeting the T cell receptor -chain constant region for immunotherapy of T cell malignancies.Nat Med. 2017 Dec;23(12):1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13.
• [448] Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation.Sci Rep. 2019 Feb 7;9(1):1554. doi: 10.1038/s41598-018-37469-8.
• [449] Endogenous expression of TRPV5 and TRPV6 calcium channels in human leukemia K562 cells.Am J Physiol Cell Physiol. 2009 May;296(5):C1098-104. doi: 10.1152/ajpcell.00435.2008. Epub 2009 Mar 18.
• [450] Glucosylceramide synthase promotes Bcl-2 expression via the ERK signaling pathway in the K562/A02 leukemia drug-resistant cell line.Int J Hematol. 2014 Dec;100(6):559-66. doi: 10.1007/s12185-014-1679-7. Epub 2014 Oct 4.
• [451] USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia.Clin Cancer Res. 2019 Jan 1;25(1):222-239. doi: 10.1158/1078-0432.CCR-18-1740. Epub 2018 Sep 17.
• [452] The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening.Bioorg Med Chem Lett. 2019 Feb 15;29(4):638-645. doi: 10.1016/j.bmcl.2018.12.035. Epub 2018 Dec 17.
• [453] Peripheral T-lymphocytes express WNT7A and its restoration in leukemia-derived lymphoblasts inhibits cell proliferation.BMC Cancer. 2012 Feb 7;12:60. doi: 10.1186/1471-2407-12-60.
• [454] Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine.Hum Vaccin Immunother. 2018 Jan 2;14(1):159-162. doi: 10.1080/21645515.2017.1382787. Epub 2017 Oct 30.
• [455] ZAP-70 upregulation in transformed B cells after early pre-BI cell transplant into NOD/SCID mice.Oncogene. 2005 Jul 28;24(32):5119-24. doi: 10.1038/sj.onc.1208706.
• [456] Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.J Natl Cancer Inst. 1990 Jul 4;82(13):1133-40. doi: 10.1093/jnci/82.13.1133.
• [457] CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells.Cancer Sci. 2019 Jan;110(1):256-268. doi: 10.1111/cas.13885. Epub 2018 Dec 14.
• [458] T Cells Deficient in Diacylglycerol Kinase Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia.Cancer Res. 2017 Oct 15;77(20):5676-5686. doi: 10.1158/0008-5472.CAN-17-1309. Epub 2017 Sep 15.
• [459] Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.Carcinogenesis. 2013 Mar;34(3):667-77. doi: 10.1093/carcin/bgs386. Epub 2012 Dec 13.
• [460] Human T-leukemia and T-lymphoma express glutamate receptor AMPA GluR3, and the neurotransmitter glutamate elevates the cancer-related matrix-metalloproteinases inducer CD147/EMMPRIN, MMP-9 secretion and engraftment of T-leukemia in vivo.Leuk Lymphoma. 2009 Jun;50(6):985-97. doi: 10.1080/10428190902878448.
• [461] Functional impairment of the HIPK2 small ubiquitin-like modifier (SUMO)-interacting motif in acute myeloid leukemia.Am J Cancer Res. 2019 Jan 1;9(1):94-107. eCollection 2019.
• [462] HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.Cancer Discov. 2018 May;8(5):616-631. doi: 10.1158/2159-8290.CD-17-0583. Epub 2018 Mar 1.
• [463] Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation.J Clin Oncol. 2013 Oct 20;31(30):3782-90. doi: 10.1200/JCO.2012.47.4007. Epub 2013 Sep 16.
• [464] A novel monoclonal antibody, KOR-SA3544 which reacts to Philadelphia chromosome-positive acute lymphoblastic leukemia cells with high sensitivity.Leukemia. 1995 Jul;9(7):1233-9.
• [465] Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.J Hematol Oncol. 2018 May 30;11(1):73. doi: 10.1186/s13045-018-0611-7.
• [466] Roles of SETD2 in Leukemia-Transcription, DNA-Damage, and Beyond.Int J Mol Sci. 2019 Feb 27;20(5):1029. doi: 10.3390/ijms20051029.
• [467] Biotin conjugated organic molecules and proteins for cancer therapy: A review.Eur J Med Chem. 2018 Feb 10;145:206-223. doi: 10.1016/j.ejmech.2018.01.001. Epub 2018 Jan 2.
• [468] Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.Mol Cancer Ther. 2013 Dec;12(12):2651-62. doi: 10.1158/1535-7163.MCT-13-0103-T. Epub 2013 Oct 15.
• [469] AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403. doi: 10.1073/pnas.171321298.
• [470] Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.Cytokine. 2017 Jan;89:116-121. doi: 10.1016/j.cyto.2016.01.024. Epub 2016 Apr 16.
• [471] Expression of ABCB5 gene in hematological malignances and its significance.Leuk Lymphoma. 2012 Jun;53(6):1211-5. doi: 10.3109/10428194.2011.637214. Epub 2011 Dec 7.
• [472] SLC22A4 and RUNX1: identification of RA susceptible genes.J Mol Med (Berl). 2004 Sep;82(9):558-64. doi: 10.1007/s00109-004-0547-y. Epub 2004 Jun 4.
• [473] Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers.Clin Cancer Res. 2001 Nov;7(11):3416-22.
• [474] Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H.Leuk Res. 2008 Aug;32(8):1268-78. doi: 10.1016/j.leukres.2007.12.015. Epub 2008 Feb 14.
• [475] Role of ZIP8 in regulation of cisplatin sensitivity through Bcl-2. Toxicol Appl Pharmacol. 2019 Jan 1;362:52-58. doi: 10.1016/j.taap.2018.10.016. Epub 2018 Oct 17.
• [476] Polymorphic variants of GSTM1, GSTT1, and GSTP1 genes in childhood acute leukemias: A preliminary study in Argentina.Hematology. 2015 Oct;20(9):511-6. doi: 10.1179/1607845415Y.0000000007. Epub 2015 Mar 23.
• [477] Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia.Oncotarget. 2014 Oct 15;5(19):9183-98. doi: 10.18632/oncotarget.2399.
• [478] Specification of hematopoietic and vascular development by the bHLH transcription factor SCL without direct DNA binding.Development. 1999 Oct;126(20):4603-15. doi: 10.1242/dev.126.20.4603.
• [479] ABO genotyping of various hematopoietic cell lines to select model cells for research purposes.Hum Immunol. 2019 Nov;80(11):917-922. doi: 10.1016/j.humimm.2019.08.002. Epub 2019 Aug 17.
• [480] Subcellular localization of DJ-1 in human HL-60 leukemia cells in response to diallyl disulfide treatment.Mol Med Rep. 2016 Nov;14(5):4666-4672. doi: 10.3892/mmr.2016.5831. Epub 2016 Oct 12.
• [481] The anti-apoptotic PON2 protein is Wnt/-catenin-regulated and correlates with radiotherapy resistance in OSCC patients.Oncotarget. 2016 Aug 9;7(32):51082-51095. doi: 10.18632/oncotarget.9013.
• [482] 5'-nucleotidase activity in lymphocytes from patients affected by B-cell chronic lymphocytic leukemia.Clin Biochem. 1998 Jun;31(4):269-72. doi: 10.1016/s0009-9120(98)00017-4.
• [483] Association of MTG8 (ETO/CDR), a leukemia-related protein, with serine/threonine protein kinases and heat shock protein HSP90 in human hematopoietic cell lines.Jpn J Cancer Res. 1999 Jan;90(1):60-8. doi: 10.1111/j.1349-7006.1999.tb00666.x.
• [484] Identification of cancer-type specific expression patterns for active aldehyde dehydrogenase (ALDH) isoforms in ALDEFLUOR assay.Cell Biol Toxicol. 2019 Apr;35(2):161-177. doi: 10.1007/s10565-018-9444-y. Epub 2018 Sep 15.
• [485] Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.Mol Cancer Ther. 2019 Sep;18(9):1587-1592. doi: 10.1158/1535-7163.MCT-18-1329. Epub 2019 Jun 17.
• [486] Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells.Int J Mol Med. 2001 Sep;8(3):273-8.
• [487] Effects of GST null genotypes on individual susceptibility to leukemia: A meta-analysis.Exp Mol Pathol. 2019 Jun;108:137-142. doi: 10.1016/j.yexmp.2019.01.004. Epub 2019 Jan 17.
• [488] Glycolytic Enzyme PKM2 Mediates Autophagic Activation to Promote Cell Survival in NPM1-Mutated Leukemia.Int J Biol Sci. 2019 Mar 1;15(4):882-894. doi: 10.7150/ijbs.30290. eCollection 2019.
• [489] Analysis of mutagenic V(D)J recombinase mediated mutations at the HPRT locus as an in vivo model for studying rearrangements with leukemogenic potential in children.DNA Repair (Amst). 2006 Sep 8;5(9-10):1049-64. doi: 10.1016/j.dnarep.2006.05.023. Epub 2006 Jun 27.
• [490] Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.Leukemia. 2018 Jun;32(6):1393-1403. doi: 10.1038/s41375-018-0073-5. Epub 2018 Feb 25.
• [491] Cloned hst gene from normal human leukocyte DNA transforms NIH3T3 cells.Biochem Biophys Res Commun. 1988 Mar 30;151(3):965-72. doi: 10.1016/s0006-291x(88)80460-1.
• [492] Retroviral integration site analysis identifies ICSBP as a collaborating tumor suppressor gene in NUP98-TOP1-induced leukemia.Exp Hematol. 2006 Sep;34(9):1192-201. doi: 10.1016/j.exphem.2006.04.020.
• [493] Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.Clin Pharmacol Ther. 2017 Mar;101(3):373-381. doi: 10.1002/cpt.463. Epub 2016 Nov 18.
• [494] Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia.Leukemia. 2014 Nov;28(11):2165-77. doi: 10.1038/leu.2014.120. Epub 2014 Apr 4.
• [495] T-cell acute lymphoblastic leukemia with add(1)(p36) and del(12)(p11) following acute myelocytic leukemia with partial deletion of 9p.Cancer Genet Cytogenet. 2004 Apr 1;150(1):62-5. doi: 10.1016/j.cancergencyto.2003.08.003.
• [496] The chromatin remodeling subunit Baf200 promotes normal hematopoiesis and inhibits leukemogenesis.J Hematol Oncol. 2018 Feb 26;11(1):27. doi: 10.1186/s13045-018-0567-7.
• [497] Acquired Hypofibrinogenemia Before Asparaginase Exposure During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report of 2 Cases and Review of the Literature.J Pediatr Hematol Oncol. 2018 Oct;40(7):e470-e472. doi: 10.1097/MPH.0000000000001114.
• [498] An ARC-Regulated IL1/Cox-2/PGE2/-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML.Cancer Res. 2019 Mar 15;79(6):1165-1177. doi: 10.1158/0008-5472.CAN-18-0921. Epub 2019 Jan 23.
• [499] SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells.Oncogene. 2006 Aug 24;25(37):5180-6. doi: 10.1038/sj.onc.1209520. Epub 2006 Apr 24.
• [500] CBF-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.Cell. 2018 Jun 28;174(1):172-186.e21. doi: 10.1016/j.cell.2018.05.048.
• [501] TGF- regulated leukemia cell susceptibility against NK targeting through the down-regulation of the CD48 expression.Immunobiology. 2019 Sep;224(5):649-658. doi: 10.1016/j.imbio.2019.07.002. Epub 2019 Aug 9.
• [502] Association of genetic variation in IKZF1, ARID5B, CDKN2A, and CEBPE with the risk of acute lymphoblastic leukemia in Tunisian children and their contribution to racial differences in leukemia incidence.Pediatr Hematol Oncol. 2016 Apr;33(3):157-67. doi: 10.3109/08880018.2016.1161685.
• [503] A tool compound targeting the core binding factor Runt domain to disrupt binding to CBF in leukemic cells.Leuk Lymphoma. 2018 Sep;59(9):2188-2200. doi: 10.1080/10428194.2017.1410882. Epub 2017 Dec 18.
• [504] Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-B and ERK5 signaling pathway.Biochem Pharmacol. 2016 Jan 1;99:132-45. doi: 10.1016/j.bcp.2015.12.002. Epub 2015 Dec 8.
• [505] The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.J Cancer Res Clin Oncol. 2018 Dec;144(12):2339-2349. doi: 10.1007/s00432-018-2765-7. Epub 2018 Oct 20.
• [506] IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia.Transl Oncol. 2019 May;12(5):726-732. doi: 10.1016/j.tranon.2019.02.002. Epub 2019 Mar 13.
• [507] CRKL regulates alternative splicing of cancer-related genes in cervical cancer samples and HeLa cell.BMC Cancer. 2019 May 27;19(1):499. doi: 10.1186/s12885-019-5671-8.
• [508] CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27(kip1) signaling.Haematologica. 2017 Apr;102(4):707-718. doi: 10.3324/haematol.2016.151555. Epub 2017 Jan 25.
• [509] Germline factor DDX4 functions in blood-derived cancer cell phenotypes.Cancer Sci. 2017 Aug;108(8):1612-1619. doi: 10.1111/cas.13299. Epub 2017 Jul 11.
• [510] Novel DDX41 variants in Thai patients with myeloid neoplasms.Int J Hematol. 2020 Feb;111(2):241-246. doi: 10.1007/s12185-019-02770-3. Epub 2019 Nov 11.
• [511] Protein phosphatase 1 (PP1) and Casein Kinase II (CK2) regulate Ikaros-mediated repression of TdT in thymocytes and T-cell leukemia.Pediatr Blood Cancer. 2014 Dec;61(12):2230-5. doi: 10.1002/pbc.25221. Epub 2014 Sep 11.
• [512] AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia.Mol Cell. 2010 Feb 12;37(3):429-37. doi: 10.1016/j.molcel.2010.01.026.
• [513] An ERG Enhancer-Based Reporter Identifies Leukemia Cells with Elevated Leukemogenic Potential Driven by ERG-USP9X Feed-Forward Regulation.Cancer Res. 2019 Aug 1;79(15):3862-3876. doi: 10.1158/0008-5472.CAN-18-3215. Epub 2019 Jun 7.
• [514] Downregulation of ENDOCAN in myeloid leukemia cells inhibits proliferation and promotes apoptosis by suppressing nuclear factorB activity.Mol Med Rep. 2019 Apr;19(4):3247-3254. doi: 10.3892/mmr.2019.9969. Epub 2019 Feb 19.
• [515] Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.Clin Cancer Res. 2005 Jun 15;11(12):4504-11. doi: 10.1158/1078-0432.CCR-05-0036.
• [516] FAM168A participates in the development of chronic myeloid leukemia via BCR-ABL1/AKT1/NFB pathway.BMC Cancer. 2019 Jul 10;19(1):679. doi: 10.1186/s12885-019-5898-4.
• [517] Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K- Inhibitor CAL-101.Cancer Invest. 2019;37(7):311-324. doi: 10.1080/07357907.2019.1651328. Epub 2019 Aug 14.
• [518] FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia.Ann Hematol. 2014 Sep;93(9):1473-81. doi: 10.1007/s00277-014-2085-1. Epub 2014 Apr 25.
• [519] CRIF1 interacting with CDK2 regulates bone marrow microenvironment-induced G0/G1 arrest of leukemia cells.PLoS One. 2014 Feb 10;9(2):e85328. doi: 10.1371/journal.pone.0085328. eCollection 2014.
• [520] MicroRNA in leukemia: Tumor suppressors and oncogenes with prognostic potential.J Cell Physiol. 2019 Jun;234(6):8465-8486. doi: 10.1002/jcp.27776. Epub 2018 Dec 4.
• [521] GINS2 regulates matrix metallopeptidase 9 expression and cancer stem cell property in human triple negative Breast cancer.Biomed Pharmacother. 2016 Dec;84:1568-1574. doi: 10.1016/j.biopha.2016.10.032. Epub 2016 Nov 6.
• [522] Molecular pathogenesis of disease progression in MLL-rearranged AML.Leukemia. 2019 Mar;33(3):612-624. doi: 10.1038/s41375-018-0253-3. Epub 2018 Sep 12.
• [523] The Marine Natural Product Pseudopterosin Blocks Cytokine Release of Triple-Negative Breast Cancer and Monocytic Leukemia Cells by Inhibiting NF-B Signaling.Mar Drugs. 2017 Aug 23;15(9):262. doi: 10.3390/md15090262.
• [524] Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34(+) cells via pre-B-cell leukemia homeobox 1.Oncogene. 2020 Jan;39(2):443-453. doi: 10.1038/s41388-019-0998-9. Epub 2019 Sep 5.
• [525] Association of ARID5B and IKZF1 Variants with Leukemia from Northern India.Genet Test Mol Biomarkers. 2019 Mar;23(3):176-179. doi: 10.1089/gtmb.2018.0283. Epub 2019 Feb 27.
• [526] Dioncophyllines C(2), D(2), and F and Related Naphthylisoquinoline Alkaloids from the Congolese Liana Ancistrocladus ileboensis with Potent Activities against Plasmodium falciparum and against Multiple Myeloma and Leukemia Cell Lines.J Nat Prod. 2017 Feb 24;80(2):443-458. doi: 10.1021/acs.jnatprod.6b00967. Epub 2017 Jan 25.
• [527] The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.Leukemia. 2019 Nov;33(11):2628-2639. doi: 10.1038/s41375-019-0581-y. Epub 2019 Oct 1.
• [528] MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.FASEB J. 2019 Apr;33(4):5268-5286. doi: 10.1096/fj.201801035R. Epub 2019 Jan 22.
• [529] The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer.Front Oncol. 2018 Nov 14;8:502. doi: 10.3389/fonc.2018.00502. eCollection 2018.
• [530] Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia.Clin Cancer Res. 2019 May 1;25(9):2795-2808. doi: 10.1158/1078-0432.CCR-18-1474. Epub 2019 Jan 16.
• [531] Direct Reprogramming of Fibroblasts Into Smooth Muscle-Like Cells With Defined Transcription Factors-Brief Report.Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):2191-2197. doi: 10.1161/ATVBAHA.118.310870.
• [532] Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.Exp Hematol. 2019 Jan;69:37-42. doi: 10.1016/j.exphem.2018.10.001. Epub 2018 Oct 10.
• [533] The efficiency of murine MLL-ENL-driven leukemia initiation changes with age and peaks during neonatal development.Blood Adv. 2019 Aug 13;3(15):2388-2399. doi: 10.1182/bloodadvances.2019000554.
• [534] Regulation and specificity of MNDA expression in monocytes, macrophages, and leukemia/B lymphoma cell lines.J Cell Biochem. 1994 Dec;56(4):559-67. doi: 10.1002/jcb.240560417.
• [535] Regulation of DNA methylation and tumor suppression gene expression by miR-29b in leukemia patients and related mechanisms.Eur Rev Med Pharmacol Sci. 2018 Jan;22(1):158-165. doi: 10.26355/eurrev_201801_14113.
• [536] Knockdown of immature colon carcinoma transcript1 induces suppression of proliferation, S-phase arrest and apoptosis in leukemia cells.Oncol Rep. 2018 Mar;39(3):1269-1275. doi: 10.3892/or.2018.6185. Epub 2018 Jan 3.
• [537] Germline variants in MRE11/RAD50/NBN complex genes in childhood leukemia.BMC Cancer. 2013 Oct 5;13:457. doi: 10.1186/1471-2407-13-457.
• [538] Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.Int J Hematol. 2014 Jan;99(1):21-31. doi: 10.1007/s12185-013-1466-x. Epub 2013 Nov 21.
• [539] Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia.Carcinogenesis. 2002 Apr;23(4):559-64. doi: 10.1093/carcin/23.4.559.
• [540] NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler.Mol Cell. 2015 Dec 17;60(6):847-59. doi: 10.1016/j.molcel.2015.10.033. Epub 2015 Nov 25.
• [541] The nuclear migration gene NudC and human hematopoiesis.Leuk Lymphoma. 2000 Nov;39(5-6):447-54. doi: 10.3109/10428190009113375.
• [542] Knockdown of NUDT21 inhibits proliferation and promotes apoptosis of human K562 leukemia cells through ERK pathway.Cancer Manag Res. 2018 Oct 8;10:4311-4323. doi: 10.2147/CMAR.S173496. eCollection 2018.
• [543] Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.Genes Chromosomes Cancer. 2020 Feb;59(2):125-130. doi: 10.1002/gcc.22808. Epub 2019 Oct 4.
• [544] Assay of OAZ1 mRNA levels in chronic myeloid leukemia combined with application of leukemia PCR array identified relevant gene changes affected by antizyme.Acta Haematol. 2014;131(3):141-7. doi: 10.1159/000353406. Epub 2013 Oct 26.
• [545] HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML.Leukemia. 2013 Jun;27(6):1358-68. doi: 10.1038/leu.2012.366. Epub 2012 Dec 18.
• [546] Emerging Roles of MTG16 in Cell-Fate Control of Hematopoietic Stem Cells and Cancer.Stem Cells Int. 2017;2017:6301385. doi: 10.1155/2017/6301385. Epub 2017 Nov 22.
• [547] Synergistic antitumoral efficacy of a novel replicative adenovirus SG611-PDCD5 and daunorubicin in human leukemic cells.Onco Targets Ther. 2018 Aug 23;11:5121-5132. doi: 10.2147/OTT.S167868. eCollection 2018.
• [548] The transcription factor PlagL2 activates Mpl transcription and signaling in hematopoietic progenitor and leukemia cells.Leukemia. 2011 Apr;25(4):655-62. doi: 10.1038/leu.2010.301. Epub 2011 Jan 25.
• [549] Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia.J Vis Exp. 2019 Sep 5;(151):10.3791/59593. doi: 10.3791/59593.
• [550] A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.Haematologica. 2007 Jun;92(6):744-52. doi: 10.3324/haematol.10869.
• [551] ETV6/ARG oncoprotein confers autonomous cell growth by enhancing c-Myc expression via signal transducer and activator of transcription 5 activation in the acute promyelocytic leukemia cell line HT93A.Leuk Lymphoma. 2015;56(8):2416-23. doi: 10.3109/10428194.2014.982643. Epub 2014 Dec 4.
• [552] FAS and RAS related Apoptosis defects: From autoimmunity to leukemia.Immunol Rev. 2019 Jan;287(1):50-61. doi: 10.1111/imr.12720.
• [553] Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome.Genes Dev. 2011 May 1;25(9):917-29. doi: 10.1101/gad.623011.
• [554] FLJ10849, a septin family gene, fuses MLL in a novel leukemia cell line CNLBC1 derived from chronic neutrophilic leukemia in transformation with t(4;11)(q21;q23).Leukemia. 2004 May;18(5):998-1005. doi: 10.1038/sj.leu.2403334.
• [555] Steps solidifying a role for SEPT9 in breast cancer suggest that greater strides are needed.Breast Cancer Res. 2012 Jan 9;14(1):101. doi: 10.1186/bcr3056.
• [556] Potent Enhancement of HIV-1 Replication by Nef in the Absence of SERINC3 and SERINC5.mBio. 2019 Jun 11;10(3):e01071-19. doi: 10.1128/mBio.01071-19.
• [557] Structure characterization and anti-leukemia activity of a novel polysaccharide from Angelica sinensis (Oliv.) Diels.Int J Biol Macromol. 2019 Jan;121:161-172. doi: 10.1016/j.ijbiomac.2018.09.213. Epub 2018 Oct 2.
• [558] The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia.Leuk Lymphoma. 2017 Oct;58(10):2419-2425. doi: 10.1080/10428194.2017.1295142. Epub 2017 Feb 28.
• [559] CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway.J Immunol Res. 2019 Apr 15;2019:6032141. doi: 10.1155/2019/6032141. eCollection 2019.
• [560] The roles of SNF2/SWI2 nucleosome remodeling enzymes in blood cell differentiation and leukemia.Biomed Res Int. 2015;2015:347571. doi: 10.1155/2015/347571. Epub 2015 Feb 19.
• [561] Adenoviral E1B55K oncoprotein sequesters candidate leukemia suppressor sequence-specific single-stranded DNA-binding protein 2 into aggresomes.Oncogene. 2007 Jul 19;26(33):4797-805. doi: 10.1038/sj.onc.1210281. Epub 2007 Feb 19.
• [562] High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.Haematologica. 2020 Jan 31;105(2):435-447. doi: 10.3324/haematol.2019.216986. Print 2020.
• [563] Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.Leukemia. 2019 Jul;33(7):1583-1597. doi: 10.1038/s41375-018-0369-5. Epub 2019 Jan 24.
• [564] Mixed Phenotype Acute Leukemia with t(12;17)(p13;q21)/TAF15-ZNF384 and Other Chromosome Abnormalities.Cytogenet Genome Res. 2016;149(3):165-170. doi: 10.1159/000448447. Epub 2016 Sep 9.
• [565] MicroRNA-124 represses wound healing by targeting SERP1 and inhibiting the Wnt/-catenin pathway.Adv Clin Exp Med. 2019 Jun;28(6):711-718. doi: 10.17219/acem/94163.
• [566] Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix-Loop-Helix Peptides with Cell Penetrating and Tumor Suppressor Properties.ACS Chem Biol. 2019 Sep 20;14(9):2071-2087. doi: 10.1021/acschembio.9b00593. Epub 2019 Aug 21.
• [567] STIP Regulates ERK1/2 Signaling Pathway Involved in Interaction with PP1 in Lymphoblastic Leukemia.Curr Mol Med. 2016;16(8):767-775. doi: 10.2174/1566524016666161018154401.
• [568] PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia.Blood. 2019 Apr 18;133(16):1729-1741. doi: 10.1182/blood-2018-07-860726. Epub 2019 Feb 12.
• [569] Interferon-Inducible MicroRNA miR-128 Modulates HIV-1 Replication by Targeting TNPO3 mRNA.J Virol. 2019 Sep 30;93(20):e00364-19. doi: 10.1128/JVI.00364-19. Print 2019 Oct 15.
• [570] TNR/11q#1 trinucleotide (GCC)n repeat alleles and predisposition to acute and chronic leukemia.Ann Hum Genet. 2004 Jul;68(Pt 4):362-6. doi: 10.1046/j.1529-8817.2004.00101.x.
• [571] Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure.PLoS One. 2013 Nov 27;8(11):e80193. doi: 10.1371/journal.pone.0080193. eCollection 2013.
• [572] Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: clinical and sample considerations.Leuk Res. 2006 Nov;30(11):1355-63. doi: 10.1016/j.leukres.2006.03.009. Epub 2006 Apr 18.
• [573] Fbxw11 promotes the proliferation of lymphocytic leukemia cells through the concomitant activation of NF-B and -catenin/TCF signaling pathways.Cell Death Dis. 2018 Apr 1;9(4):427. doi: 10.1038/s41419-018-0440-1.
• [574] Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice.Leukemia. 2020 Mar;34(3):759-770. doi: 10.1038/s41375-019-0605-7. Epub 2019 Oct 17.
• [575] Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.J Hematol Oncol. 2017 Jul 11;10(1):138. doi: 10.1186/s13045-017-0507-y.
• [576] Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia.Cancer Res. 2010 Jun 15;70(12):4949-60. doi: 10.1158/0008-5472.CAN-09-1962. Epub 2010 May 25.
• [577] Analysis of CD137 and CD137L expression in human primary tumor tissues.Croat Med J. 2008 Apr;49(2):192-200. doi: 10.3325/cmj.2008.2.192.
• [578] A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cells.BMC Cancer. 2015 Sep 7;15:621. doi: 10.1186/s12885-015-1639-5.
• [579] ADCY7 supports development of acute myeloid leukemia.Biochem Biophys Res Commun. 2015 Sep 11;465(1):47-52. doi: 10.1016/j.bbrc.2015.07.123. Epub 2015 Jul 26.
• [580] The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output.Mol Cell Biol. 2012 Jul;32(13):2608-17. doi: 10.1128/MCB.00182-12. Epub 2012 Apr 30.
• [581] Sulforaphane Modulates AQP8-Linked Redox Signalling in Leukemia Cells.Oxid Med Cell Longev. 2018 Nov 18;2018:4125297. doi: 10.1155/2018/4125297. eCollection 2018.
• [582] METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification.Cell Stem Cell. 2018 Feb 1;22(2):191-205.e9. doi: 10.1016/j.stem.2017.11.016. Epub 2017 Dec 28.
• [583] ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.Cancer Discov. 2016 Jul;6(7):770-83. doi: 10.1158/2159-8290.CD-16-0058. Epub 2016 May 6.
• [584] ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.Nat Commun. 2017 May 18;8:15429. doi: 10.1038/ncomms15429.
• [585] Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML.Blood. 2012 Aug 16;120(7):1473-84. doi: 10.1182/blood-2011-12-395335. Epub 2012 Jun 26.
• [586] Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.Int J Hematol. 2018 Dec;108(6):588-597. doi: 10.1007/s12185-018-2517-0. Epub 2018 Aug 27.
• [587] A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.Oncogene. 2019 May;38(20):3824-3842. doi: 10.1038/s41388-018-0666-5. Epub 2019 Jan 22.
• [588] Vitamin K2 and cotylenin A synergistically induce monocytic differentiation and growth arrest along with the suppression of c-MYC expression and induction of cyclin G2 expression in human leukemia HL-60 cells.Int J Oncol. 2015 Aug;47(2):473-80. doi: 10.3892/ijo.2015.3028. Epub 2015 Jun 4.
• [589] Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia.Haematologica. 2020 Apr;105(4):999-1012. doi: 10.3324/haematol.2018.207001. Epub 2019 Aug 1.
• [590] The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.Oncogene. 2018 Jan 25;37(4):450-460. doi: 10.1038/onc.2017.337. Epub 2017 Sep 25.
• [591] CEMP1 Induces Transformation in Human Gingival Fibroblasts.PLoS One. 2015 May 26;10(5):e0127286. doi: 10.1371/journal.pone.0127286. eCollection 2015.
• [592] D40/KNL1/CASC5 and autosomal recessive primary microcephaly.Congenit Anom (Kyoto). 2017 Nov;57(6):191-196. doi: 10.1111/cga.12252. Epub 2017 Nov 1.
• [593] DDX41 Recognizes RNA/DNA Retroviral Reverse Transcripts and Is Critical for In Vivo Control of Murine Leukemia Virus Infection.mBio. 2018 Jun 5;9(3):e00923-18. doi: 10.1128/mBio.00923-18.
• [594] Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.Sci Rep. 2015 Nov 18;5:16709. doi: 10.1038/srep16709.
• [595] Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.Exp Hematol. 2014 Sep;42(9):783-92.e1. doi: 10.1016/j.exphem.2014.05.007. Epub 2014 May 23.
• [596] Isolation and Characterization of a Phaseolus vulgaris Trypsin Inhibitor with Antiproliferative Activity on Leukemia and Lymphoma Cells.Molecules. 2017 Jan 23;22(1):187. doi: 10.3390/molecules22010187.
• [597] DACT1 overexpression inhibits proliferation, enhances apoptosis, and increases daunorubicin chemosensitivity in KG-1 cells.Tumour Biol. 2017 Oct;39(10):1010428317711089. doi: 10.1177/1010428317711089.
• [598] Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.Blood. 2007 Oct 1;110(7):2569-77. doi: 10.1182/blood-2006-12-062927. Epub 2007 Apr 17.
• [599] Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models.Metallomics. 2017 Mar 22;9(3):309-322. doi: 10.1039/c6mt00226a.
• [600] Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.J Med Chem. 2018 Jul 26;61(14):6110-6120. doi: 10.1021/acs.jmedchem.8b00483. Epub 2018 Jul 17.
• [601] Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.J Clin Invest. 2018 Dec 3;128(12):5383-5398. doi: 10.1172/JCI121366. Epub 2018 Oct 29.
• [602] Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia.J Cell Physiol. 2018 Sep;233(9):6604-6614. doi: 10.1002/jcp.26271. Epub 2018 Mar 14.
• [603] Specific inhibition of DPY30 activity by ASH2L-derived peptides suppresses blood cancer cell growth.Exp Cell Res. 2019 Sep 15;382(2):111485. doi: 10.1016/j.yexcr.2019.06.030. Epub 2019 Jun 26.
• [604] Functional Evidence of the Involvement of the Dynein Light Chain DYNLRB2 in Murine Leukemia Virus Infection.J Virol. 2017 Apr 28;91(10):e00129-17. doi: 10.1128/JVI.00129-17. Print 2017 May 15.
• [605] Effect of EPH-ephrin signaling on the growth of human leukemia cells.Anticancer Res. 2014 Jun;34(6):2913-8.
• [606] Polymorphisms in XPC, XPD and XPG DNA repair genes and leukemia risk in a Tunisian population.Leuk Lymphoma. 2015 Jun;56(6):1856-62. doi: 10.3109/10428194.2014.974045. Epub 2014 Nov 14.
• [607] Disparate effects of Shb gene deficiency on disease characteristics in murine models of myeloid, B-cell, and T-cell leukemia.Tumour Biol. 2018 Apr;40(4):1010428318771472. doi: 10.1177/1010428318771472.
• [608] The Role of Regulatory B Cells in Patients with Acute Myeloid Leukemia.Med Sci Monit. 2019 Apr 24;25:3026-3031. doi: 10.12659/MSM.915556.
• [609] Fumarate hydratase is a critical metabolic regulator of hematopoietic stem cell functions.J Exp Med. 2017 Mar 6;214(3):719-735. doi: 10.1084/jem.20161087. Epub 2017 Feb 15.
• [610] An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.Oncogene. 2017 Oct 26;36(43):5985-5994. doi: 10.1038/onc.2017.210. Epub 2017 Jun 26.
• [611] The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.PLoS One. 2015 Jul 6;10(7):e0131716. doi: 10.1371/journal.pone.0131716. eCollection 2015.
• [612] Grb10 is involved in BCR-ABL-positive leukemia in mice.Leukemia. 2015 Apr;29(4):858-68. doi: 10.1038/leu.2014.283. Epub 2014 Sep 24.
• [613] Downregulation of miR?35a predicts poor prognosis in acute myeloid leukemia and regulates leukemia progression via modulating HOXA10 expression.Mol Med Rep. 2018 Jul;18(1):1134-1140. doi: 10.3892/mmr.2018.9066. Epub 2018 May 23.
• [614] Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells.Cell Death Dis. 2017 May 4;8(5):e2765. doi: 10.1038/cddis.2017.159.
• [615] INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.J Exp Clin Cancer Res. 2018 Jan 17;37(1):8. doi: 10.1186/s13046-018-0675-9.
• [616] JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia.Cancer Res. 2017 Dec 1;77(23):6627-6640. doi: 10.1158/0008-5472.CAN-17-1223. Epub 2017 Sep 28.
• [617] Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.J Biol Chem. 2015 Sep 11;290(37):22474-84. doi: 10.1074/jbc.M115.678912. Epub 2015 Jul 21.
• [618] Quantitative detection of the human cervical cancer oncogene for monitoring the minimal residual disease in acute leukemia.Exp Biol Med (Maywood). 2015 Jan;240(1):128-34. doi: 10.1177/1535370214543067. Epub 2014 Jul 17.
• [619] Clinical significance of LMO1 in gastric cancer tissue and its association with apoptosis of cancer cells.Oncol Lett. 2017 Dec;14(6):6511-6518. doi: 10.3892/ol.2017.7102. Epub 2017 Sep 28.
• [620] Chemoinformatic Approach to Assess Toxicity of Ionic Liquids.Methods Mol Biol. 2018;1800:559-571. doi: 10.1007/978-1-4939-7899-1_26.
• [621] Ubiquitous expression of MAKORIN-2 in normal and malignant hematopoietic cells and its growth promoting activity.PLoS One. 2014 Mar 27;9(3):e92706. doi: 10.1371/journal.pone.0092706. eCollection 2014.
• [622] Activation of Wnt signaling pathway by AF1q enriches stem-like population and enhance mammosphere formation of breast cells.Biochem Biophys Res Commun. 2017 Mar 18;484(4):884-889. doi: 10.1016/j.bbrc.2017.02.018. Epub 2017 Feb 8.
• [623] Targeting MTHFD2 in acute myeloid leukemia.J Exp Med. 2016 Jun 27;213(7):1285-306. doi: 10.1084/jem.20151574. Epub 2016 Jun 20.
• [624] Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia.Oncotarget. 2015 Dec 8;6(39):42300-11. doi: 10.18632/oncotarget.5982.
• [625] Role and Regulation of Myeloid Zinc Finger Protein 1 in Cancer.J Cell Biochem. 2015 Oct;116(10):2146-54. doi: 10.1002/jcb.25203.
• [626] Necdin modulates leukemia-initiating cell quiescence and chemotherapy response.Oncotarget. 2017 Sep 18;8(50):87607-87622. doi: 10.18632/oncotarget.20999. eCollection 2017 Oct 20.
• [627] DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma.Cancer Immunol Immunother. 2015 Apr;64(4):409-18. doi: 10.1007/s00262-014-1648-2. Epub 2014 Dec 31.
• [628] Pharmacogenetic characterization of naturally occurring germline NT5C1A variants to chemotherapeutic nucleoside analogs.Pharmacogenet Genomics. 2016 Jun;26(6):271-9. doi: 10.1097/FPC.0000000000000208.
• [629] Thiopurine-mediated impairment of hematopoietic stem and leukemia cells in Nudt15(R138C) knock-in mice.Leukemia. 2020 Mar;34(3):882-894. doi: 10.1038/s41375-019-0583-9. Epub 2019 Oct 24.
• [630] RKTG overexpression inhibits proliferation and induces apoptosis of human leukemia cells via suppression of the ERK and PI3K/AKT signaling pathways.Oncol Lett. 2017 Jul;14(1):965-970. doi: 10.3892/ol.2017.6182. Epub 2017 May 17.
• [631] Tyr-94 phosphorylation inhibits pyruvate dehydrogenase phosphatase 1 and promotes tumor growth.J Biol Chem. 2014 Aug 1;289(31):21413-22. doi: 10.1074/jbc.M114.581124. Epub 2014 Jun 24.
• [632] The regulation of tumor-suppressive microRNA, miR-126, inchronic lymphocytic leukemia.Cancer Med. 2017 Apr;6(4):778-787. doi: 10.1002/cam4.996. Epub 2017 Mar 15.
• [633] The miR-17?2 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.Leuk Res. 2016 Jul;46:51-60. doi: 10.1016/j.leukres.2016.04.006. Epub 2016 Apr 16.
• [634] PPM1K Regulates Hematopoiesis and Leukemogenesis through CDC20-Mediated Ubiquitination of MEIS1 and p21.Cell Rep. 2018 May 1;23(5):1461-1475. doi: 10.1016/j.celrep.2018.03.140.
• [635] High Level of Perforin Expression Is Required for Effective Correction of Hemophagocytic Lymphohistiocytosis.Hum Gene Ther. 2016 Oct;27(10):847-859. doi: 10.1089/hum.2016.065. Epub 2016 Jul 29.
• [636] TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.Int J Oncol. 2019 May;54(5):1785-1796. doi: 10.3892/ijo.2019.4740. Epub 2019 Mar 5.
• [637] Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.Leukemia. 2018 Mar;32(3):575-587. doi: 10.1038/leu.2017.259. Epub 2017 Aug 17.
• [638] In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity.Leukemia. 2014 Jun;28(6):1316-25. doi: 10.1038/leu.2013.374. Epub 2013 Nov 13.
• [639] Modulating the Growth and Imatinib Sensitivity of Chronic Myeloid Leukemia Stem/Progenitor Cells with Pullulan/MicroRNA Nanoparticles In Vitro.J Biomed Nanotechnol. 2015 Nov;11(11):1961-74. doi: 10.1166/jbn.2015.2147.
• [640] Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies.PLoS Genet. 2017 Mar 27;13(3):e1006683. doi: 10.1371/journal.pgen.1006683. eCollection 2017 Mar.
• [641] SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders.Haematologica. 2014 Aug;99(8):1356-64. doi: 10.3324/haematol.2013.100230. Epub 2014 May 23.
• [642] SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.Clin Cancer Res. 2015 Sep 15;21(18):4184-93. doi: 10.1158/1078-0432.CCR-14-2112. Epub 2015 Mar 16.
• [643] The ubiquitin ligase STUB1 regulates stability and activity of RUNX1 and RUNX1-RUNX1T1.J Biol Chem. 2017 Jul 28;292(30):12528-12541. doi: 10.1074/jbc.M117.785675. Epub 2017 May 23.
• [644] Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.Cancer Lett. 2017 Feb 1;386:131-140. doi: 10.1016/j.canlet.2016.11.021. Epub 2016 Nov 25.
• [645] Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia.PLoS One. 2016 Oct 20;11(10):e0165210. doi: 10.1371/journal.pone.0165210. eCollection 2016.
• [646] Tmem30a Plays Critical Roles in Ensuring the Survival of Hematopoietic Cells and Leukemia Cells in Mice.Am J Pathol. 2018 Jun;188(6):1457-1468. doi: 10.1016/j.ajpath.2018.02.015. Epub 2018 Mar 21.
• [647] Overexpression of feline tripartite motif-containing 25 interferes with the late stage of feline leukemia virus replication.Virus Res. 2015 Jun 2;204:88-94. doi: 10.1016/j.virusres.2015.04.017. Epub 2015 Apr 24.
• [648] O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia.J Exp Med. 2013 Apr 8;210(4):805-19. doi: 10.1084/jem.20121482. Epub 2013 Mar 11.
• [649] ABR, a novel inducer of transcription factor C/EBP, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia.Oncotarget. 2017 Oct 26;8(61):103626-103639. doi: 10.18632/oncotarget.22093. eCollection 2017 Nov 28.
• [650] Differential expression of protein tyrosine phosphatase genes during phorbol ester-induced differentiation of human leukemia U937 cells.Cell Growth Differ. 1993 Dec;4(12):1033-9.
• [651] Knockdown of Adhesion-Regulating Molecule 1 Inhibits Proliferation in HL60 Cells.Acta Haematol. 2015;134(2):88-100. doi: 10.1159/000369916. Epub 2015 Apr 21.
• [652] AF4 encodes a ubiquitous protein that in both native and MLL-AF4 fusion types localizes to subnuclear compartments.Blood. 1998 Nov 15;92(10):3841-7.
• [653] Candidate genes for expansion and transformation of hematopoietic stem cells by NUP98-HOX fusion genes.PLoS One. 2007 Aug 22;2(8):e768. doi: 10.1371/journal.pone.0000768.
• [654] AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.Oncotarget. 2011 Dec;2(12):918-34. doi: 10.18632/oncotarget.405.
• [655] Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10years and future perspectives.Wien Klin Wochenschr. 2018 Sep;130(17-18):517-529. doi: 10.1007/s00508-018-1355-7. Epub 2018 Jul 13.
• [656] Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation.J Clin Invest. 2014 Feb;124(2):580-91. doi: 10.1172/JCI71861. Epub 2014 Jan 16.
• [657] Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.Blood. 2013 Dec 5;122(24):3960-3. doi: 10.1182/blood-2013-04-497693. Epub 2013 Oct 7.
• [658] Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice.FEBS Lett. 2009 Jun 18;583(12):1859-66. doi: 10.1016/j.febslet.2009.04.046. Epub 2009 May 8.
• [659] Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation.Nat Genet. 2004 Mar;36(3):257-63. doi: 10.1038/ng1305. Epub 2004 Feb 8.
• [660] Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo.J Mol Biol. 2009 Jan 9;385(1):65-78. doi: 10.1016/j.jmb.2008.10.043. Epub 2008 Nov 1.
• [661] Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.Cancer Res. 2017 Sep 1;77(17):4579-4588. doi: 10.1158/0008-5472.CAN-16-3394. Epub 2017 Jun 27.
• [662] The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res. 2004 Jan 15;64(2):728-35.
• [663] Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells.J Biol Chem. 2004 Jul 9;279(28):28831-4. doi: 10.1074/jbc.C400105200. Epub 2004 May 13.
• [664] Structural insight into recognition of methylated histone tails by retinoblastoma-binding protein 1.J Biol Chem. 2012 Mar 9;287(11):8531-40. doi: 10.1074/jbc.M111.299149. Epub 2012 Jan 12.
• [665] The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia.Oncogene. 2018 May;37(19):2532-2544. doi: 10.1038/s41388-018-0131-5. Epub 2018 Feb 20.
• [666] RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.J Hematol Oncol. 2019 Oct 22;12(1):104. doi: 10.1186/s13045-019-0789-3.
• [667] In situ hybridization detection of HTLV-I RNA in peripheral blood mononuclear cells of TSP/HAM patients and their spouses.J Med Virol. 1991 Jan;33(1):64-71. doi: 10.1002/jmv.1890330113.
• [668] Atg3 Overexpression Enhances Bortezomib-Induced Cell Death in SKM-1 Cell.PLoS One. 2016 Jul 8;11(7):e0158761. doi: 10.1371/journal.pone.0158761. eCollection 2016.
• [669] B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1.Cell Death Dis. 2013 Jun 6;4(6):e654. doi: 10.1038/cddis.2013.186.
• [670] B4GALT1 gene knockdown inhibits the hedgehog pathway and reverses multidrug resistance in the human leukemia K562/adriamycin-resistant cell line.IUBMB Life. 2012 Nov;64(11):889-900. doi: 10.1002/iub.1080. Epub 2012 Sep 29.
• [671] Histone post-translational modifications associated to BAALC expression in leukemic cells.Biochem Biophys Res Commun. 2012 Jan 13;417(2):721-5. doi: 10.1016/j.bbrc.2011.12.013. Epub 2011 Dec 14.
• [672] Identification of IGHC-BACH2 fusion transcripts resulting from cryptic chromosomal rearrangements of 14q32 with 6q15 in aggressive B-cell lymphoma/leukemia.Genes Chromosomes Cancer. 2011 Apr;50(4):207-16. doi: 10.1002/gcc.20845. Epub 2011 Jan 13.
• [673] BAG1: the guardian of anti-apoptotic proteins in acute myeloid leukemia.PLoS One. 2011;6(10):e26097. doi: 10.1371/journal.pone.0026097. Epub 2011 Oct 10.
• [674] Diversity of the apoptotic response to chemotherapy in childhood leukemia.Leukemia. 2002 Feb;16(2):223-32. doi: 10.1038/sj.leu.2402360.
• [675] Molecular analysis of the BCL-3 locus at chromosome 17q22 in B-cell neoplasms.Blood. 1993 Sep 15;82(6):1813-9.
• [676] Tumor SHB gene expression affects disease characteristics in human acute myeloid leukemia.Tumour Biol. 2017 Oct;39(10):1010428317720643. doi: 10.1177/1010428317720643.
• [677] Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization.Oncogene. 2003 Jul 24;22(30):4679-89. doi: 10.1038/sj.onc.1206624.
• [678] MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13.Oncogene. 1993 Nov;8(11):3085-92.
• [679] Leukemia-associated gene MLAA-34 reduces arsenic trioxide-induced apoptosis in HeLa cells via activation of the Wnt/-catenin signaling pathway.PLoS One. 2017 Oct 23;12(10):e0186868. doi: 10.1371/journal.pone.0186868. eCollection 2017.
• [680] A novel crosstalk between calcium/calmodulin kinases II and IV regulates cell proliferation in myeloid leukemia cells.Cell Signal. 2015 Feb;27(2):204-14. doi: 10.1016/j.cellsig.2014.11.007. Epub 2014 Nov 15.
• [681] CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.Breast Cancer Res Treat. 2011 Nov;130(1):19-27. doi: 10.1007/s10549-010-1274-4. Epub 2010 Dec 3.
• [682] The sensitivity of reported effects of EMF on childhood leukemia to uncontrolled confounding by residential mobility: a hybrid simulation study and an empirical analysis using CAPS data.Cancer Causes Control. 2019 Aug;30(8):901-908. doi: 10.1007/s10552-019-01189-9. Epub 2019 May 29.
• [683] The leukemia associated nuclear corepressor ETO homologue genes MTG16 and MTGR1 are regulated differently in hematopoietic cells.BMC Mol Biol. 2012 Mar 23;13:11. doi: 10.1186/1471-2199-13-11.
• [684] The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3.Oncogene. 2001 Jan 25;20(4):411-9. doi: 10.1038/sj.onc.1204108.
• [685] Targeting a mitochondrial potassium channel to fight cancer.Cell Calcium. 2015 Jul;58(1):131-8. doi: 10.1016/j.ceca.2014.09.006. Epub 2014 Oct 18.
• [686] WT1 regulates cyclinA1 expression in K562cells.Oncol Rep. 2019 Nov;42(5):2016-2028. doi: 10.3892/or.2019.7287. Epub 2019 Aug 21.
• [687] Upregulated TCR enhances interleukin-2 production in T-cells from patients with CML.DNA Cell Biol. 2012 Nov;31(11):1628-35. doi: 10.1089/dna.2012.1798. Epub 2012 Oct 11.
• [688] CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity.Cancer Genet Cytogenet. 2005 Nov;163(1):62-7. doi: 10.1016/j.cancergencyto.2005.06.002.
• [689] CD82 supports survival of childhood acute myeloid leukemia cells via activation of Wnt/-catenin signaling pathway.Pediatr Res. 2019 Jun;85(7):1024-1031. doi: 10.1038/s41390-019-0370-3. Epub 2019 Mar 12.
• [690] Expression and localization of the CDC34 ubiquitin-conjugating enzyme in pediatric acute lymphoblastic leukemia.Cell Growth Differ. 2001 Aug;12(8):427-33.
• [691] Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model.Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16924-9. doi: 10.1073/pnas.0604579103. Epub 2006 Oct 26.
• [692] A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia Pathogenesis.Cancer Cell. 2018 Nov 12;34(5):707-723.e7. doi: 10.1016/j.ccell.2018.10.004.
• [693] Congenital heart disease complexity and childhood cancer risk.Birth Defects Res. 2018 Oct 16;110(17):1314-1321. doi: 10.1002/bdr2.1390. Epub 2018 Oct 16.
• [694] Silencing of CHD5 gene by promoter methylation in leukemia.PLoS One. 2014 Jan 13;9(1):e85172. doi: 10.1371/journal.pone.0085172. eCollection 2014.
• [695] Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.Blood. 2012 Oct 25;120(17):3491-500. doi: 10.1182/blood-2012-02-412643. Epub 2012 Sep 6.
• [696] PNAS-2: a novel gene probably participating in leukemogenesis.Oncology. 2006;71(5-6):423-9. doi: 10.1159/000108576. Epub 2007 Sep 14.
• [697] Increased creatine kinase BB activity and CKB mRNA expression in patients with hematologic disorders: relation to methylation status of the CKB promoter.Clin Chim Acta. 2005 Nov;361(1-2):135-40. doi: 10.1016/j.cccn.2005.05.028.
• [698] Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.J Allergy Clin Immunol. 2010 Mar;125(3):719-26, 726.e1-726.e4. doi: 10.1016/j.jaci.2009.10.020. Epub 2010 Jan 12.
• [699] Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia.Leuk Res. 2011 Jun;35(6):771-6. doi: 10.1016/j.leukres.2010.11.023. Epub 2010 Dec 18.
• [700] BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.Oncogene. 2002 May 9;21(20):3225-31. doi: 10.1038/sj.onc.1205452.
• [701] CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia.J Exp Med. 2009 Apr 13;206(4):779-91. doi: 10.1084/jem.20081922. Epub 2009 Apr 6.
• [702] Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.Cancer Res. 2009 Nov 1;69(21):8482-90. doi: 10.1158/0008-5472.CAN-09-1153. Epub 2009 Oct 13.
• [703] Tumor necrosis factor and immune interferon synergistically induce cytochrome b-245 heavy-chain gene expression and nicotinamide-adenine dinucleotide phosphate hydrogenase oxidase in human leukemic myeloid cells.J Clin Invest. 1989 May;83(5):1570-9. doi: 10.1172/JCI114054.
• [704] Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH study.Clin Chem. 2008 Oct;54(10):1705-15. doi: 10.1373/clinchem.2008.108506. Epub 2008 Aug 21.
• [705] Expression of the DCC gene in human hematological malignancies.Leuk Lymphoma. 1994 Dec;16(1-2):13-8. doi: 10.3109/10428199409114135.
• [706] Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities.Oncotarget. 2017 Nov 1;8(60):102150-102160. doi: 10.18632/oncotarget.22235. eCollection 2017 Nov 24.
• [707] Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A. 1999 Nov23;96(24):13989-94.
• [708] Silencing of DMBT1 in neuroblastoma cell lines is not due to methylation of CCWGG motifs on its promoter.Neoplasma. 2006;53(1):15-8.
• [709] The effect of paclitaxel on gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cells.Food Chem Toxicol. 2002 May;40(5):705-13. doi: 10.1016/s0278-6915(01)00129-6.
• [710] ZRF1 controls the retinoic acid pathway and regulates leukemogenic potential in acute myeloid leukemia.Oncogene. 2014 Nov 27;33(48):5501-10. doi: 10.1038/onc.2013.501. Epub 2013 Dec 2.
• [711] All-trans retinoic acid induces p62DOK1 and p56DOK2 expression which enhances induced differentiation and G0 arrest of HL-60 leukemia cells.Am J Hematol. 2006 Aug;81(8):603-15. doi: 10.1002/ajh.20667.
• [712] ELL and EAF1 are Cajal body components that are disrupted in MLL-ELL leukemia.Mol Biol Cell. 2003 Apr;14(4):1517-28. doi: 10.1091/mbc.e02-07-0394.
• [713] Increased oxidative DNA damage, inducible nitric oxide synthase, nuclear factor kappaB expression and enhanced antiapoptosis-related proteins in Helicobacter pylori-infected non-cardiac gastric adenocarcinoma.World J Gastroenterol. 2004 Aug 1;10(15):2232-40. doi: 10.3748/wjg.v10.i15.2232.
• [714] Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.Blood. 2010 Mar 25;115(12):2412-9. doi: 10.1182/blood-2009-05-222208. Epub 2010 Jan 8.
• [715] Megakaryocyte-derived excessive transforming growth factor 1 inhibits proliferation of normal hematopoietic stem cells in acute myeloid leukemia.Exp Hematol. 2018 Apr;60:40-46.e2. doi: 10.1016/j.exphem.2017.12.010. Epub 2018 Jan 4.
• [716] Electrochemical branched-DNA assay for polymerase chain reaction-free detection and quantification of oncogenes in messenger RNA.Anal Chem. 2008 Dec 15;80(24):9402-10. doi: 10.1021/ac801263r.
• [717] Knockdown of eukaryotic translation initiation factor 3 subunit D (eIF3D) inhibits proliferation of acute myeloid leukemia cells.Mol Cell Biochem. 2018 Jan;438(1-2):191-198. doi: 10.1007/s11010-017-3127-5. Epub 2017 Aug 12.
• [718] Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals.Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1201-6. doi: 10.1073/pnas.95.3.1201.
• [719] The LEM domain proteins emerin and LAP2alpha are dispensable for human immunodeficiency virus type 1 and murine leukemia virus infections.J Virol. 2008 Jun;82(12):5860-8. doi: 10.1128/JVI.00076-08. Epub 2008 Apr 9.
• [720] Realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicity.J Pharmacol Sci. 2019 Jun;140(2):162-170. doi: 10.1016/j.jphs.2019.06.003. Epub 2019 Jun 15.
• [721] Enhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cells.Leukemia. 2014 May;28(5):1081-91. doi: 10.1038/leu.2013.316. Epub 2013 Oct 29.
• [722] ESAM is a novel human hematopoietic stem cell marker associated with a subset of human leukemias.Exp Hematol. 2016 Apr;44(4):269-81.e1. doi: 10.1016/j.exphem.2015.12.010. Epub 2016 Jan 14.
• [723] Measurement of separase proteolytic activity in single living cells by a fluorogenic flow cytometry assay.PLoS One. 2015 Aug 12;10(8):e0133769. doi: 10.1371/journal.pone.0133769. eCollection 2015.
• [724] The ETS factor TEL2 is a hematopoietic oncoprotein.Blood. 2006 Feb 1;107(3):1124-32. doi: 10.1182/blood-2005-03-1196. Epub 2005 Oct 18.
• [725] EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway.Cancer Sci. 2016 Dec;107(12):1745-1754. doi: 10.1111/cas.13080. Epub 2016 Nov 25.
• [726] Epigenetic loss of the familial tumor-suppressor gene exostosin-1 (EXT1) disrupts heparan sulfate synthesis in cancer cells.Hum Mol Genet. 2004 Nov 15;13(22):2753-65. doi: 10.1093/hmg/ddh298. Epub 2004 Sep 22.
• [727] Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia.Cancers (Basel). 2019 Nov 3;11(11):1717. doi: 10.3390/cancers11111717.
• [728] Bufalin Enhances Immune Responses in Leukemic Mice Through Enhancing Phagocytosis of Macrophage In Vivo.In Vivo. 2018 Sep-Oct;32(5):1129-1136. doi: 10.21873/invivo.11355.
• [729] The Association of Flap Endonuclease 1 Genotypes with the Risk of Childhood Leukemia.Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):69-74.
• [730] LncRNA expression profile of Np63 in cervical squamous cancers and its suppressive effects on LIF expression.Cytokine. 2017 Aug;96:114-122. doi: 10.1016/j.cyto.2017.04.001. Epub 2017 Apr 7.
• [731] Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.Cancer Cell. 2010 Oct 19;18(4):341-52. doi: 10.1016/j.ccr.2010.09.008.
• [732] The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.Leukemia. 2019 Jul;33(7):1700-1712. doi: 10.1038/s41375-018-0358-8. Epub 2019 Jan 11.
• [733] Genotoxicity of retroviral hematopoietic stem cell gene therapy.Expert Opin Biol Ther. 2011 May;11(5):581-93. doi: 10.1517/14712598.2011.562496. Epub 2011 Mar 7.
• [734] Methylation status of the promoter region of the human frizzled 9 gene in acute myeloid leukemia.Mol Med Rep. 2016 Aug;14(2):1339-44. doi: 10.3892/mmr.2016.5387. Epub 2016 Jun 10.
• [735] Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.Leukemia. 2017 Jun;31(6):1415-1422. doi: 10.1038/leu.2016.326. Epub 2016 Nov 14.
• [736] Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.Oncotarget. 2017 Feb 14;8(7):10809-10821. doi: 10.18632/oncotarget.14580.
• [737] Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2814-9. doi: 10.1073/pnas.050397097.
• [738] Whole-exome sequencing of a rare case of familial childhood acute lymphoblastic leukemia reveals putative predisposing mutations in Fanconi anemia genes.BMC Cancer. 2015 Jul 23;15:539. doi: 10.1186/s12885-015-1549-6.
• [739] Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in mice.Leukemia. 2019 Jan;33(1):110-121. doi: 10.1038/s41375-018-0166-1. Epub 2018 Jun 20.
• [740] A somatic mutation of GFI1B identified in leukemia alters cell fate via a SPI1 (PU.1) centered genetic regulatory network.Dev Biol. 2016 Mar 15;411(2):277-286. doi: 10.1016/j.ydbio.2016.02.002. Epub 2016 Feb 3.
• [741] Expression of human GIPC1 in normal tissues, cancer cell lines, and primary tumors.Int J Mol Med. 2002 May;9(5):509-13.
• [742] hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.J Cancer Res Clin Oncol. 2018 Jul;144(7):1279-1288. doi: 10.1007/s00432-018-2654-0. Epub 2018 May 8.
• [743] Nucleostemin silencing induces differentiation and potentiates all-trans-retinoic acid effects in human acute promyelocytic leukemia NB4 cells via autophagy.Leuk Res. 2017 Dec;63:15-21. doi: 10.1016/j.leukres.2017.10.007. Epub 2017 Oct 26.
• [744] The small oligomerization domain of gephyrin converts MLL to an oncogene.Blood. 2004 May 15;103(10):3876-82. doi: 10.1182/blood-2003-11-3817. Epub 2004 Jan 29.
• [745] ITR?84 modulates cell differentiation in human chronic myelogenous leukemia K562 cells.Oncol Rep. 2018 Jan;39(1):383-391. doi: 10.3892/or.2017.6090. Epub 2017 Nov 9.
• [746] Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers.Cancer Res. 2004 Apr 1;64(7):2411-7. doi: 10.1158/0008-5472.can-03-0164.
• [747] Somatic mutations at T-cell antigen receptor and glycophorin A loci in pediatric leukemia patients following chemotherapy: comparison with HPRT locus mutation.Mutat Res. 1994 Sep;315(2):95-103. doi: 10.1016/0921-8777(94)90010-8.
• [748] Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.Mol Cancer Ther. 2018 Aug;17(8):1694-1704. doi: 10.1158/1535-7163.MCT-18-0028. Epub 2018 May 10.
• [749] Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.Eur J Pharmacol. 2017 Mar 15;799:143-153. doi: 10.1016/j.ejphar.2017.02.014. Epub 2017 Feb 10.
• [750] Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.Cancer. 2013 Oct 1;119(19):3555-62. doi: 10.1002/cncr.28256. Epub 2013 Jul 16.
• [751] Prognostic significance of huntingtin interacting protein 1 expression on patients with acute myeloid leukemia.Sci Rep. 2017 Apr 28;7:45960. doi: 10.1038/srep45960.
• [752] Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Better Outcome after Umbilical Cord Blood Transplantation.Front Immunol. 2017 Jul 13;8:810. doi: 10.3389/fimmu.2017.00810. eCollection 2017.
• [753] Identification of the new HLA-DPB1 allele, DPB1*647:01, in an Italian patient with leukemia.HLA. 2018 Apr;91(4):311-312. doi: 10.1111/tan.13235. Epub 2018 Feb 26.
• [754] The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability.Cancer Cell. 2019 Dec 9;36(6):630-644.e9. doi: 10.1016/j.ccell.2019.10.004. Epub 2019 Nov 14.
• [755] TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.Blood. 2012 Apr 12;119(15):3440-9. doi: 10.1182/blood-2011-06-357939. Epub 2012 Feb 27.
• [756] The homeodomain region controls the phenotype of HOX-induced murine leukemia.Blood. 2012 Nov 8;120(19):4018-27. doi: 10.1182/blood-2011-10-384685. Epub 2012 Sep 18.
• [757] Expression of selected human HOX-2 genes in B/T acute lymphoid leukemia and interleukin-2/interleukin-1 beta-stimulated natural killer lymphocytes.Blood. 1992 Jul 1;80(1):185-93.
• [758] Downregulation of Prdm16 mRNA is a specific antileukemic mechanism during HOXB4-mediated HSC expansion in vivo.Blood. 2014 Sep 11;124(11):1737-47. doi: 10.1182/blood-2013-10-534735. Epub 2014 Jul 31.
• [759] HOXC10 is overexpressed in breast cancer and transcriptionally regulated by estrogen via involvement of histone methylases MLL3 and MLL4.J Mol Endocrinol. 2012 Jan 25;48(1):61-75. doi: 10.1530/JME-11-0078. Print 2012 Feb.
• [760] Heterogenous fusion transcripts involving the NUP98 gene and HOXD13 gene activation in a case of acute myeloid leukemia with the t(2;11)(q31;p15) translocation.Leukemia. 2000 Sep;14(9):1621-9. doi: 10.1038/sj.leu.2401881.
• [761] Identification of an overexpressed gene, HSPA4L, the product of which can provoke prevalent humoral immune responses in leukemia patients.Exp Hematol. 2007 Jul;35(7):1091-9. doi: 10.1016/j.exphem.2007.03.015.
• [762] Molecular cloning of six novel Krppel-like zinc finger genes from hematopoietic cells and identification of a novel transregulatory domain KRNB.J Biol Chem. 1999 Dec 10;274(50):35741-8. doi: 10.1074/jbc.274.50.35741.
• [763] Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes.Cancer Res. 2009 Oct 1;69(19):7518-23. doi: 10.1158/0008-5472.CAN-09-1428. Epub 2009 Sep 22.
• [764] RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1.Leukemia. 2020 May;34(5):1354-1363. doi: 10.1038/s41375-019-0656-9. Epub 2019 Nov 25.
• [765] Identification of characteristic IGF2BP expression patterns in distinct B-ALL entities.Blood Cells Mol Dis. 2011 Apr 15;46(4):321-6. doi: 10.1016/j.bcmd.2011.02.005. Epub 2011 Mar 17.
• [766] Insulin-like growth factor-binding protein 4 in children with acute lymphoblastic leukemia.Int J Hematol. 2005 Aug;82(2):137-42. doi: 10.1532/IJH97.E0429.
• [767] CD8?innate-type lymphocytes in the intestinal epithelium mediate mucosal immunity.Immunity. 2014 Sep 18;41(3):451-464. doi: 10.1016/j.immuni.2014.08.010. Epub 2014 Sep 11.
• [768] IL-3 and GM-CSF modulate functions of splenic macrophages in ENU induced leukemia.Cytokine. 2017 Mar;91:89-95. doi: 10.1016/j.cyto.2016.12.009. Epub 2016 Dec 28.
• [769] Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies.PLoS One. 2014 Sep 10;9(9):e106788. doi: 10.1371/journal.pone.0106788. eCollection 2014.
• [770] JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.Int J Hematol. 2015 Jul;102(1):76-85. doi: 10.1007/s12185-015-1797-x. Epub 2015 May 5.
• [771] Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis.Cancer Res. 2017 Apr 1;77(7):1753-1762. doi: 10.1158/0008-5472.CAN-16-2374. Epub 2017 Feb 15.
• [772] Killer cell immunoglobulin-like receptor gene polymorphisms in patients with leukemia: possible association with susceptibility to the disease.Leuk Res. 2010 Jan;34(1):55-8. doi: 10.1016/j.leukres.2009.04.022. Epub 2009 May 18.
• [773] KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.Mol Immunol. 2008 Aug;45(13):3631-8. doi: 10.1016/j.molimm.2008.04.016. Epub 2008 Jun 16.
• [774] Survey and evaluation of mutations in the human KLF1 transcription unit.Sci Rep. 2018 Apr 26;8(1):6587. doi: 10.1038/s41598-018-24962-3.
• [775] High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations.Blood. 2012 Mar 8;119(10):e67-75. doi: 10.1182/blood-2011-09-380444. Epub 2012 Jan 10.
• [776] Hypoxia selects for a quiescent, CML stem/leukemia initiating-like population dependent on CBP/catenin transcription.Curr Mol Pharmacol. 2013 Nov;6(3):204-10. doi: 10.2174/1874467207666140219121219.
• [777] The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6).J Biol Chem. 2003 Apr 25;278(17):15412-20. doi: 10.1074/jbc.M300592200. Epub 2003 Feb 14.
• [778] LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.Mol Cell Biol. 2015 Nov 23;36(3):488-506. doi: 10.1128/MCB.00901-15. Print 2016 Feb 1.
• [779] Phosphorylated Sp1 is the regulator of DNA-PKcs and DNA ligase IV transcription of daunorubicin-resistant leukemia cell lines.Biochim Biophys Acta. 2014;1839(4):265-74. doi: 10.1016/j.bbagrm.2014.02.004. Epub 2014 Feb 13.
• [780] Pinch-1 was up-regulated in leukemia BMSC and its possible effect.Clin Exp Med. 2013 Feb;13(1):21-7. doi: 10.1007/s10238-012-0176-7. Epub 2012 Feb 5.
• [781] The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML.J Exp Med. 2013 Jan 14;210(1):15-22. doi: 10.1084/jem.20120596. Epub 2012 Dec 31.
• [782] ETV6-LPXN fusion transcript generated by t(11;12)(q12.1;p13) in a patient with relapsing acute myeloid leukemia with NUP98-HOXA9.Genes Chromosomes Cancer. 2016 Mar;55(3):242-50. doi: 10.1002/gcc.22327. Epub 2015 Nov 6.
• [783] The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.Haematologica. 2012 Sep;97(9):1405-13. doi: 10.3324/haematol.2011.059030. Epub 2012 Apr 4.
• [784] Latexin is down-regulated in hematopoietic malignancies and restoration of expression inhibits lymphoma growth.PLoS One. 2012;7(9):e44979. doi: 10.1371/journal.pone.0044979. Epub 2012 Sep 27.
• [785] MAGE-F1, a novel ubiquitously expressed member of the MAGE superfamily.Gene. 2001 Apr 18;267(2):173-82. doi: 10.1016/s0378-1119(01)00406-1.
• [786] MicroRNA 146a Polymorphisms and Expression in Indian Children with Acute Lymphoblastic Leukemia.Lab Med. 2019 Jul 16;50(3):249-253. doi: 10.1093/labmed/lmy074.
• [787] Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.Blood. 1998 Jun 15;91(12):4480-8.
• [788] Role of N(6)-methyladenosine modification in cancer.Curr Opin Genet Dev. 2018 Feb;48:1-7. doi: 10.1016/j.gde.2017.10.005. Epub 2017 Oct 14.
• [789] Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis.Clin Cancer Res. 2004 Dec 15;10(24):8386-95. doi: 10.1158/1078-0432.CCR-04-1029.
• [790] Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2.PLoS One. 2010 Sep 2;5(9):e12520. doi: 10.1371/journal.pone.0012520.
• [791] Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia.EBioMedicine. 2016 Jun;8:173-183. doi: 10.1016/j.ebiom.2016.04.038. Epub 2016 May 13.
• [792] Meis2 as a critical player in MN1-induced leukemia.Blood Cancer J. 2017 Sep 29;7(9):e613. doi: 10.1038/bcj.2017.86.
• [793] The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.Nat Med. 2017 Nov;23(11):1369-1376. doi: 10.1038/nm.4416. Epub 2017 Sep 18.
• [794] Triptolide induces apoptosis in human leukemia cells through caspase-3-mediated ROCK1 activation and MLC phosphorylation.Cell Death Dis. 2013 Dec 5;4(12):e941. doi: 10.1038/cddis.2013.469.
• [795] NPM and NPM-MLF1 interact with chromatin remodeling complexes and influence their recruitment to specific genes.PLoS Genet. 2019 Nov 1;15(11):e1008463. doi: 10.1371/journal.pgen.1008463. eCollection 2019 Nov.
• [796] De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.Nat Commun. 2018 May 2;9(1):1770. doi: 10.1038/s41467-018-04180-1.
• [797] ChREBP promotes the differentiation of leukemia-initiating cells to inhibit leukemogenesis through the TXNIP/RUNX1 pathways.Oncotarget. 2016 Jun 21;7(25):38347-38358. doi: 10.18632/oncotarget.9520.
• [798] A MENage Trois in leukemia.Cancer Cell. 2008 Jul 8;14(1):3-5. doi: 10.1016/j.ccr.2008.06.009.
• [799] The dual role of HLXB9 in leukemia.Pediatr Blood Cancer. 2011 Mar;56(3):349-52. doi: 10.1002/pbc.22679.
• [800] Moloney leukemia virus 10 (MOV10) protein inhibits retrovirus replication.J Biol Chem. 2010 May 7;285(19):14346-55. doi: 10.1074/jbc.M110.109314. Epub 2010 Mar 9.
• [801] Ecotropic viral integration site 1 regulates the progression of acute myeloid leukemia via MS4A3-mediated TGF/EMT signaling pathway.Oncol Lett. 2018 Aug;16(2):2701-2708. doi: 10.3892/ol.2018.8890. Epub 2018 Jun 4.
• [802] Epigenetic analysis of childhood acute lymphoblastic leukemia.Epigenetics. 2009 Apr 1;4(3):185-93. doi: 10.4161/epi.4.3.8752. Epub 2009 Apr 12.
• [803] Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.J Cancer Res Clin Oncol. 2007 Nov;133(11):875-93. doi: 10.1007/s00432-007-0274-1. Epub 2007 Aug 2.
• [804] Tax oncoprotein trans-represses endogenous B-myb promoter activity in human T cells.AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1629-32. doi: 10.1089/08892220050193065.
• [805] Transcriptional properties of human NANOG1 and NANOG2 in acute leukemic cells.Nucleic Acids Res. 2010 Sep;38(16):5384-95. doi: 10.1093/nar/gkq307. Epub 2010 Apr 28.
• [806] Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.Blood. 2013 May 2;121(18):3714-7. doi: 10.1182/blood-2012-11-465641. Epub 2013 Feb 20.
• [807] The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A.Biochem Biophys Res Commun. 1999 Nov 2;264(3):871-7. doi: 10.1006/bbrc.1999.1605.
• [808] Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.Blood. 2007 Jan 1;109(1):323-30. doi: 10.1182/blood-2005-08-027979. Epub 2006 Aug 29.
• [809] Chromosome band 16q22-linked familial AML: exclusion of candidate genes, and possible disease risk modification by NQO1 polymorphisms.Genes Chromosomes Cancer. 2004 Nov;41(3):278-82. doi: 10.1002/gcc.20084.
• [810] Functional polymorphisms in the NBS1 gene and acute lymphoblastic leukemia susceptibility in a Chinese population.Eur J Haematol. 2011 Mar;86(3):199-205. doi: 10.1111/j.1600-0609.2010.01562.x. Epub 2011 Jan 25.
• [811] Establishment of a myeloid leukemia cell line, TRL-01, with MLL-ENL fusion gene.Cancer Genet Cytogenet. 2006 Aug;169(1):1-11. doi: 10.1016/j.cancergencyto.2005.09.008.
• [812] Superoxide-Generating Nox5 Is Functionally Required for the Human T-Cell Leukemia Virus Type 1-Induced Cell Transformation Phenotype.J Virol. 2015 Sep;89(17):9080-9. doi: 10.1128/JVI.00983-15. Epub 2015 Jun 24.
• [813] NRARP displays either pro- or anti-tumoral roles in T-cell acute lymphoblastic leukemia depending on Notch and Wnt signaling.Oncogene. 2020 Jan;39(5):975-986. doi: 10.1038/s41388-019-1042-9. Epub 2019 Oct 4.
• [814] A unique mutator phenotype reveals complementary oncogenic lesions leading to acute leukemia.JCI Insight. 2019 Dec 5;4(23):e131434. doi: 10.1172/jci.insight.131434.
• [815] The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.Exp Hematol. 2017 Nov;55:76-85.e3. doi: 10.1016/j.exphem.2017.07.009. Epub 2017 Jul 28.
• [816] PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet. 2012 Nov 1;21(21):4793-804.
• [817] The functional polymorphisms of LIS1 are associated with acute myeloid leukemia risk in a Han Chinese population.Leuk Res. 2017 Mar;54:7-11. doi: 10.1016/j.leukres.2016.12.007. Epub 2017 Jan 2.
• [818] Fluctuation of gene expression for poly(ADP-ribose) synthetase during hemin-induced erythroid differentiation of human leukemia K562 cells and its reversion process.Biochim Biophys Acta. 1991 Mar 26;1088(3):359-64. doi: 10.1016/0167-4781(91)90125-6.
• [819] PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.Int J Cancer. 2017 Jul 15;141(2):324-335. doi: 10.1002/ijc.30739. Epub 2017 May 8.
• [820] Promoter methylation-mediated inactivation of PCDH10 in acute lymphoblastic leukemia contributes to chemotherapy resistance.Genes Chromosomes Cancer. 2011 Dec;50(12):1043-53. doi: 10.1002/gcc.20922. Epub 2011 Aug 24.
• [821] Protein signaling and regulation of gene transcription in leukemia: role of the Casein Kinase II-Ikaros axis.J Investig Med. 2016 Mar;64(3):735-9. doi: 10.1136/jim-2016-000075. Epub 2016 Feb 9.
• [822] The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.Acta Biochim Pol. 2002;49(1):99-107.
• [823] The prohibitin protein complex promotes mitochondrial stabilization and cell survival in hematologic malignancies.Oncotarget. 2017 Jul 1;8(39):65445-65456. doi: 10.18632/oncotarget.18920. eCollection 2017 Sep 12.
• [824] Lack of the Polycomb-group gene rae28 causes maturation arrest at the early B-cell developmental stage.Exp Hematol. 2001 Jan;29(1):93-103. doi: 10.1016/s0301-472x(00)00620-2.
• [825] Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity.Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3837-42. doi: 10.1073/pnas.0712250105. Epub 2008 Mar 3.
• [826] The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.Cancer Res. 2012 May 1;72(9):2275-84. doi: 10.1158/0008-5472.CAN-11-3159. Epub 2012 Mar 9.
• [827] Regulatory Network and Prognostic Effect Investigation of PIP4K2A in Leukemia and Solid Cancers.Front Genet. 2019 Jan 15;9:721. doi: 10.3389/fgene.2018.00721. eCollection 2018.
• [828] Protein kinase D2: a versatile player in cancer biology.Oncogene. 2018 Mar;37(10):1263-1278. doi: 10.1038/s41388-017-0052-8. Epub 2017 Dec 20.
• [829] The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA.Apoptosis. 2014 Jan;19(1):201-9. doi: 10.1007/s10495-013-0910-y.
• [830] Characterization of a novel gene, STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors.Mol Carcinog. 2001 Sep;32(1):44-53. doi: 10.1002/mc.1063.
• [831] Human CAP10-Like Protein 46kDa Gene Promotes Malignancy in Colorectal Cancer.OMICS. 2017 May;21(5):266-274. doi: 10.1089/omi.2017.0037.
• [832] POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature.Leukemia. 2010 May;24(5):950-7. doi: 10.1038/leu.2010.61. Epub 2010 Apr 8.
• [833] Interferon-inducible gene maps to a chromosomal band associated with a (4;11) translocation in acute leukemia cells.Proc Natl Acad Sci U S A. 1987 May;84(9):2868-71. doi: 10.1073/pnas.84.9.2868.
• [834] Expression and distribution of PPP2R5C gene in leukemia.J Hematol Oncol. 2011 May 6;4:21. doi: 10.1186/1756-8722-4-21.
• [835] DNA methylation in ATRA-treated leukemia cell lines lacking a PML-RAR chromosome translocation.Anticancer Res. 2012 Nov;32(11):4715-22.
• [836] The B-lymphocyte maturation promoting transcription factor BLIMP1/PRDI-BF1 maps to D6S447 on human chromosome 6q21-q22.1 and the syntenic region of mouse chromosome 10.Genomics. 1996 Oct 1;37(1):24-8. doi: 10.1006/geno.1996.0516.
• [837] The Pluripotency Regulator PRDM14 Requires Hematopoietic Regulator CBFA2T3 to Initiate Leukemia in Mice.Mol Cancer Res. 2019 Jul;17(7):1468-1479. doi: 10.1158/1541-7786.MCR-18-1327. Epub 2019 Apr 23.
• [838] Nucleotide alteration of retinoblastoma protein-interacting zinc finger gene, RIZ, in human leukemia.Tohoku J Exp Med. 2002 Mar;196(3):193-201. doi: 10.1620/tjem.196.193.
• [839] Leukemogenic properties of NUP98-PMX1 are linked to NUP98 and homeodomain sequence functions but not to binding properties of PMX1 to serum response factor.Oncogene. 2008 Oct 9;27(46):6056-67. doi: 10.1038/onc.2008.210. Epub 2008 Jul 7.
• [840] AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.Blood. 2011 Dec 1;118(23):6132-40. doi: 10.1182/blood-2011-01-323147. Epub 2011 Oct 14.
• [841] GATA4 is highly expressed in childhood acute lymphoblastic leukemia, promotes cell proliferation and inhibits apoptosis by activating BCL2 and MDM2.Mol Med Rep. 2017 Nov;16(5):6290-6298. doi: 10.3892/mmr.2017.7369. Epub 2017 Aug 28.
• [842] From oncogene to tumor suppressor: the dual role of Myc in leukemia.Cell Cycle. 2012 May 1;11(9):1757-64. doi: 10.4161/cc.19883. Epub 2012 May 1.
• [843] Mechanisms involved in the induced differentiation of leukemia cells.Pharmacol Ther. 2003 Dec;100(3):257-90. doi: 10.1016/j.pharmthera.2003.09.002.
• [844] Vav1 increases Bcl-2 expression by selective activation of Rac2-Akt in leukemia T cells.Cell Signal. 2014 Oct;26(10):2202-9. doi: 10.1016/j.cellsig.2014.05.015. Epub 2014 May 29.
• [845] Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.Cell Rep. 2018 Jun 12;23(11):3127-3136. doi: 10.1016/j.celrep.2018.05.034.
• [846] RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks.J Exp Med. 2017 Mar 6;214(3):815-831. doi: 10.1084/jem.20161638. Epub 2017 Feb 8.
• [847] Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma. PLoS One. 2013 Nov 6;8(11):e79863. doi: 10.1371/journal.pone.0079863. eCollection 2013.
• [848] Rap1GAP alters leukemia cell differentiation, apoptosis and invasion invitro.Oncol Rep. 2012 Aug;28(2):622-8. doi: 10.3892/or.2012.1825. Epub 2012 May 18.
• [849] The distinct role of guanine nucleotide exchange factor Vav1 in Bcl-2 transcription and apoptosis inhibition in Jurkat leukemia T cells.Acta Pharmacol Sin. 2011 Jan;32(1):99-107. doi: 10.1038/aps.2010.185. Epub 2010 Dec 13.
• [850] Fusion of OTT to BSAC results in aberrant up-regulation of transcriptional activity.J Biol Chem. 2008 Sep 26;283(39):26820-8. doi: 10.1074/jbc.M802315200. Epub 2008 Jul 30.
• [851] Intestinal folate transport: identification of a cDNA involved in folate transport and the functional expression and distribution of its mRNA.Biochim Biophys Acta. 1996 Jun 11;1281(2):164-72. doi: 10.1016/0005-2736(96)00005-3.
• [852] Genomic c-Myc quadruplex DNA selectively kills leukemia.Mol Cancer Ther. 2012 Jan;11(1):66-76. doi: 10.1158/1535-7163.MCT-11-0515. Epub 2011 Nov 14.
• [853] Identification of RHOXF2 (PEPP2) as a cancer-promoting gene by expression cloning.Int J Oncol. 2012 Jan;40(1):93-8. doi: 10.3892/ijo.2011.1173. Epub 2011 Aug 19.
• [854] Mechanisms of acquired resistance to ERK1/2 pathway inhibitors.Oncogene. 2013 Mar 7;32(10):1207-15. doi: 10.1038/onc.2012.160. Epub 2012 May 7.
• [855] Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3901-6. doi: 10.1073/pnas.1301045110. Epub 2013 Feb 14.
• [856] Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5' region of MEL1.Genes Chromosomes Cancer. 2003 Mar;36(3):313-6. doi: 10.1002/gcc.10176.
• [857] Changing pattern of secondary cancers among patients with malignant thymoma in the USA.Future Oncol. 2018 Aug;14(19):1943-1951. doi: 10.2217/fon-2017-0626. Epub 2018 Aug 7.
• [858] The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.Leukemia. 2013 Jul;27(7):1461-8. doi: 10.1038/leu.2013.42. Epub 2013 Feb 13.
• [859] Persistent detection of a novel MLL-SACM1L rearrangement in the absence of leukemia.Leuk Res. 2010 Oct;34(10):1398-401. doi: 10.1016/j.leukres.2010.05.001.
• [860] The Study of SALL4 Gene and BMI-1 Gene Expression in Acute Myeloid Leukemia Patients.Lab Med. 2020 May 6;51(3):265-270. doi: 10.1093/labmed/lmz056.
• [861] Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.Nat Commun. 2019 Aug 2;10(1):3475. doi: 10.1038/s41467-019-11413-4.
• [862] High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome.Genes Chromosomes Cancer. 2012 Feb;51(2):196-206. doi: 10.1002/gcc.20944. Epub 2011 Nov 10.
• [863] Blocking the proliferation of human tumor cell lines by peptidase inhibitors from Bauhinia seeds.Planta Med. 2013 Mar;79(3-4):227-35. doi: 10.1055/s-0032-1328156. Epub 2013 Jan 23.
• [864] Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.Mol Cell Biol. 2004 Jul;24(13):5639-49. doi: 10.1128/MCB.24.13.5639-5649.2004.
• [865] Novel mutations in ataxia telangiectasia and AOA2 associated with prolonged survival.J Neurol Sci. 2013 Dec 15;335(1-2):134-8. doi: 10.1016/j.jns.2013.09.014. Epub 2013 Sep 17.
• [866] Methylation of SFRP5 is related to multidrug resistance in leukemia cells.Cancer Gene Ther. 2014 Feb;21(2):83-9. doi: 10.1038/cgt.2013.87. Epub 2014 Jan 17.
• [867] PCR testing for HCV in anti-HCV negative blood donors involved in the so called HCV +ve post-transfusion hepatitis.Transfus Sci. 2000 Jun;22(3):161-4. doi: 10.1016/s0955-3886(00)00043-6.
• [868] Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO.Haematologica. 2008 Nov;93(11):1728-33. doi: 10.3324/haematol.13044. Epub 2008 Sep 11.
• [869] Differential expression of a novel C-terminally truncated splice form of SMAD5 in hematopoietic stem cells and leukemia.Blood. 2000 Jun 15;95(12):3945-50.
• [870] Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5.PLoS One. 2014 Feb 3;9(2):e87448. doi: 10.1371/journal.pone.0087448. eCollection 2014.
• [871] Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytes. Nat Genet. 2017 May;49(5):742-752. doi: 10.1038/ng.3833. Epub 2017 Apr 3.
• [872] Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.Leuk Lymphoma. 2018 Oct;59(10):2423-2430. doi: 10.1080/10428194.2017.1387906. Epub 2017 Oct 18.
• [873] Epigenetic regulator Smchd1 functions as a tumor suppressor.Cancer Res. 2013 Mar 1;73(5):1591-9. doi: 10.1158/0008-5472.CAN-12-3019. Epub 2012 Dec 26.
• [874] PML a target of translocations in APL is a regulator of cellular senescence.Leukemia. 2002 Oct;16(10):1918-26. doi: 10.1038/sj.leu.2402722.
• [875] Cloning and characterization of the EAP30 subunit of the ELL complex that confers derepression of transcription by RNA polymerase II.J Biol Chem. 1999 Jul 30;274(31):21981-5. doi: 10.1074/jbc.274.31.21981.
• [876] Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia.Cell Res. 2018 Feb;28(2):172-186. doi: 10.1038/cr.2017.146. Epub 2017 Nov 17.
• [877] Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.Cancer Sci. 2019 Jun;110(6):1931-1946. doi: 10.1111/cas.14021. Epub 2019 May 3.
• [878] SON and Its Alternatively Spliced Isoforms Control MLL Complex-Mediated H3K4me3 and Transcription of Leukemia-Associated Genes.Mol Cell. 2016 Mar 17;61(6):859-73. doi: 10.1016/j.molcel.2016.02.024.
• [879] SOX6 blocks the proliferation of BCR-ABL1(+) and JAK2V617F(+) leukemic cells.Sci Rep. 2019 Mar 4;9(1):3388. doi: 10.1038/s41598-019-39926-4.
• [880] Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia.Blood. 2015 Jun 18;125(25):3928-36. doi: 10.1182/blood-2014-06-580993. Epub 2015 May 4.
• [881] The PML nuclear bodies: actors or extras?.Curr Opin Genet Dev. 1999 Jun;9(3):362-7. doi: 10.1016/s0959-437x(99)80054-9.
• [882] Identification of SPAG9 as a novel JAK2 fusion partner gene in pediatric acute lymphoblastic leukemia with t(9;17)(p24;q21).Genes Chromosomes Cancer. 2015 Jul;54(7):401-8. doi: 10.1002/gcc.22251. Epub 2015 May 7.
• [883] Combined high-resolution array-based comparative genomic hybridization and expression profiling of ETV6/RUNX1-positive acute lymphoblastic leukemias reveal a high incidence of cryptic Xq duplications and identify several putative target genes within the commonly gained region.Leukemia. 2007 Oct;21(10):2137-44. doi: 10.1038/sj.leu.2404879. Epub 2007 Aug 9.
• [884] The Spi1/PU.1 transcription factor accelerates replication fork progression by increasing PP1 phosphatase in leukemia.Oncotarget. 2017 Jun 6;8(23):37104-37114. doi: 10.18632/oncotarget.16183.
• [885] ETV6-RUNX1 interacts with a region in SPIB intron 1 to regulate gene expression in pre-B-cell acute lymphoblastic leukemia.Exp Hematol. 2019 May;73:50-63.e2. doi: 10.1016/j.exphem.2019.03.004. Epub 2019 Apr 12.
• [886] Sorcin, an important gene associated with multidrug-resistance in human leukemia cells.Leuk Res. 2006 Apr;30(4):469-76. doi: 10.1016/j.leukres.2005.08.024. Epub 2005 Oct 6.
• [887] STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia.Cell Rep. 2018 Sep 11;24(11):3045-3060.e5. doi: 10.1016/j.celrep.2018.08.030.
• [888] The Oncogenic Potential of SUV39H2: A Comprehensive and Perspective View.J Cancer. 2019 Jan 1;10(3):721-729. doi: 10.7150/jca.28254. eCollection 2019.
• [889] N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia.J Biol Chem. 2006 Sep 22;281(38):28122-30. doi: 10.1074/jbc.M512391200. Epub 2006 May 12.
• [890] Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1.PLoS One. 2017 May 18;12(5):e0175523. doi: 10.1371/journal.pone.0175523. eCollection 2017.
• [891] Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia.Haematologica. 2016 Aug;101(8):951-8. doi: 10.3324/haematol.2016.143875. Epub 2016 May 5.
• [892] Expression of transcobalamin II receptors by human leukemia K562 and HL-60 cells.Blood. 1990 Oct 1;76(7):1380-6.
• [893] The proto-oncogene HLF and the related basic leucine zipper protein TEF display highly similar DNA-binding and transcriptional regulatory properties.Blood. 1996 Jun 1;87(11):4607-17.
• [894] Adenoviral transduction of TESTIN gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction in vivo.Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):806-13.
• [895] A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.Blood. 2014 Apr 17;123(16):2530-9. doi: 10.1182/blood-2013-07-512194. Epub 2014 Mar 7.
• [896] Identification and characterization of a soluble suppressor factor(s) in the serum of AKR mice bearing lymphocytic leukemia.Cell Immunol. 1983 Nov;82(1):163-73. doi: 10.1016/0008-8749(83)90150-8.
• [897] Promoter analysis of TFPT (FB1), a molecular partner of TCF3 (E2A) in childhood acute lymphoblastic leukemia.Biochem Biophys Res Commun. 2001 Nov 16;288(5):1250-7. doi: 10.1006/bbrc.2001.5906.
• [898] Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells.Blood. 2001 Nov 1;98(9):2714-9. doi: 10.1182/blood.v98.9.2714.
• [899] Epigenetic regulation of putative tumor suppressor TGFBI in human leukemias.Chin Med J (Engl). 2014;127(9):1645-50.
• [900] The human NOTCH1, 2, and 3 genes are located at chromosome positions 9q34, 1p13-p11, and 19p13.2-p13.1 in regions of neoplasia-associated translocation.Genomics. 1994 Nov 15;24(2):253-8. doi: 10.1006/geno.1994.1613.
• [901] TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia.J Hematol Oncol. 2016 Nov 25;9(1):128. doi: 10.1186/s13045-016-0360-4.
• [902] Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia.Leukemia. 2015 Dec;29(12):2317-27. doi: 10.1038/leu.2015.162. Epub 2015 Jun 25.
• [903] Synthesis of New Derivatives of Benzofuran as Potential Anticancer Agents.Molecules. 2019 Apr 18;24(8):1529. doi: 10.3390/molecules24081529.
• [904] Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types.Int J Cancer. 2004 May 1;109(5):786-92. doi: 10.1002/ijc.20041.
• [905] TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice.Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16600-5. doi: 10.1073/pnas.0407541101. Epub 2004 Nov 15.
• [906] Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function.Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6200-5. doi: 10.1073/pnas.0609174104. Epub 2007 Mar 30.
• [907] Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):115-127.e15. doi: 10.1016/j.clml.2014.07.011. Epub 2014 Aug 12.
• [908] Quantitative analysis and modeling of glucocorticoid-controlled gene expression.Pharmacogenomics. 2010 Nov;11(11):1545-60. doi: 10.2217/pgs.10.125.
• [909] Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL).Leuk Res. 2006 Jul;30(7):883-9. doi: 10.1016/j.leukres.2005.11.012. Epub 2006 Jan 6.
• [910] Single nucleotide polymorphism of the JWA gene is associated with risk of leukemia: a case-control study in a Chinese population.J Toxicol Environ Health A. 2007 Jun;70(11):895-900. doi: 10.1080/15287390701285956.
• [911] Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.PLoS One. 2010 Jul 2;5(7):e11418. doi: 10.1371/journal.pone.0011418.
• [912] Acute myeloid leukemia with t(7;21)(q11.2;q22) expresses a novel, reversed-sequence RUNX1-DTX2 chimera.Int J Hematol. 2012 Aug;96(2):268-73. doi: 10.1007/s12185-012-1112-z. Epub 2012 Jun 4.
• [913] FCHSD2 predicts response to chemotherapy in acute myeloid leukemia patients.Leuk Res. 2012 Nov;36(11):1339-46. doi: 10.1016/j.leukres.2012.06.011. Epub 2012 Aug 16.
• [914] Posterior column ataxia with retinitis pigmentosa coexisting with sensory-autonomic neuropathy and leukemia due to the homozygous p.Pro221Ser FLVCR1 mutation.Am J Med Genet B Neuropsychiatr Genet. 2017 Oct;174(7):732-739. doi: 10.1002/ajmg.b.32570. Epub 2017 Aug 2.
• [915] The small leucine rich proteoglycan fibromodulin is overexpressed in human prostate epithelial cancer cell lines in culture and human prostate cancer tissue.Cancer Biomark. 2016;16(1):191-202. doi: 10.3233/CBM-150555.
• [916] GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome.Cancer Med. 2017 Jan;6(1):267-274. doi: 10.1002/cam4.984. Epub 2016 Nov 28.
• [917] EDAG-1 promotes proliferation and invasion of human thyroid cancer cells by activating MAPK/Erk and AKT signal pathways.Cancer Biol Ther. 2016 Apr 2;17(4):414-21. doi: 10.1080/15384047.2016.1156259. Epub 2016 Mar 2.
• [918] KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.Blood. 2011 Apr 7;117(14):3869-80. doi: 10.1182/blood-2010-10-312736. Epub 2011 Feb 10.
• [919] KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.Leuk Lymphoma. 2018 Jan;59(1):204-213. doi: 10.1080/10428194.2017.1324156. Epub 2017 May 25.
• [920] Design, synthesis and evaluation of novel sulfonamides as potential anticancer agents.Comput Biol Chem. 2018 Jun;74:294-303. doi: 10.1016/j.compbiolchem.2018.04.006. Epub 2018 Apr 10.
• [921] Leukemia-related protein 16 (LRP16) promotes tumor growth and metastasis in pancreatic cancer.Onco Targets Ther. 2018 Mar 5;11:1215-1222. doi: 10.2147/OTT.S157914. eCollection 2018.
• [922] Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.Oncogene. 2014 Apr 24;33(17):2169-78. doi: 10.1038/onc.2013.169. Epub 2013 Jun 3.
• [923] Relation of "lymphoid" phenotype and response to chemotherapy incorporating vincristine-prednisolone in the acute phase of Ph1 positive leukemia.Cancer. 1979 Feb;43(2):426-34. doi: 10.1002/1097-0142(197902)43:2<426::aid-cncr2820430204>3.0.co;2-h.
• [924] PRDM16 isoforms differentially regulate normal and leukemic hematopoiesis and inflammatory gene signature.J Clin Invest. 2018 Aug 1;128(8):3250-3264. doi: 10.1172/JCI99862. Epub 2018 Jul 23.
• [925] STAG2 loss-of-function mutation induces PD-L1 expression in U2OS cells.Ann Transl Med. 2019 Apr;7(7):127. doi: 10.21037/atm.2019.02.23.
• [926] Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia.Mol Cancer Ther. 2017 Jul;16(7):1401-1411. doi: 10.1158/1535-7163.MCT-17-0099. Epub 2017 Apr 26.
• [927] Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies.Cancer Res. 2008 Jun 1;68(11):4116-22. doi: 10.1158/0008-5472.CAN-08-0085.
• [928] TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia.Cancer Discov. 2017 Nov;7(11):1336-1353. doi: 10.1158/2159-8290.CD-17-0267. Epub 2017 Oct 3.